0001437749-20-022452.txt : 20201104 0001437749-20-022452.hdr.sgml : 20201104 20201104091609 ACCESSION NUMBER: 0001437749-20-022452 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 201285395 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-Q 1 nhtc20200930_10q.htm FORM 10-Q nhtc20200630_10q.htm
0000912061 Natural Health Trends Corp. false --12-31 Q3 2020 0.001 0.001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 50,000,000 50,000,000 12,979,414 12,979,414 1,556,875 1,556,875 0.20 0.20 0.20 0.24 14 1 0 0 0 0 0 0 5 0 5 1 1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See "Item 1A. Risk Factors" in this report and in our most recent Annual Report on Form 10-K. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. 00009120612020-01-012020-09-30 xbrli:shares 00009120612020-10-30 thunderdome:item iso4217:USD 00009120612020-09-30 00009120612019-12-31 iso4217:USDxbrli:shares 00009120612020-07-012020-09-30 00009120612019-07-012019-09-30 00009120612019-01-012019-09-30 0000912061us-gaap:PreferredStockMember2019-12-31 0000912061us-gaap:CommonStockMember2019-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000912061us-gaap:RetainedEarningsMember2019-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000912061us-gaap:TreasuryStockMember2019-12-31 0000912061us-gaap:PreferredStockMember2020-01-012020-03-31 0000912061us-gaap:CommonStockMember2020-01-012020-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 0000912061us-gaap:RetainedEarningsMember2020-01-012020-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-31 0000912061us-gaap:TreasuryStockMember2020-01-012020-03-31 00009120612020-01-012020-03-31 0000912061us-gaap:PreferredStockMember2020-03-31 0000912061us-gaap:CommonStockMember2020-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-03-31 0000912061us-gaap:RetainedEarningsMember2020-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31 0000912061us-gaap:TreasuryStockMember2020-03-31 00009120612020-03-31 0000912061us-gaap:PreferredStockMember2020-04-012020-06-30 0000912061us-gaap:CommonStockMember2020-04-012020-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-30 0000912061us-gaap:RetainedEarningsMember2020-04-012020-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-30 0000912061us-gaap:TreasuryStockMember2020-04-012020-06-30 00009120612020-04-012020-06-30 0000912061us-gaap:PreferredStockMember2020-06-30 0000912061us-gaap:CommonStockMember2020-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000912061us-gaap:RetainedEarningsMember2020-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000912061us-gaap:TreasuryStockMember2020-06-30 00009120612020-06-30 0000912061us-gaap:PreferredStockMember2020-07-012020-09-30 0000912061us-gaap:CommonStockMember2020-07-012020-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-30 0000912061us-gaap:RetainedEarningsMember2020-07-012020-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-30 0000912061us-gaap:TreasuryStockMember2020-07-012020-09-30 0000912061us-gaap:PreferredStockMember2020-09-30 0000912061us-gaap:CommonStockMember2020-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-09-30 0000912061us-gaap:RetainedEarningsMember2020-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30 0000912061us-gaap:TreasuryStockMember2020-09-30 0000912061us-gaap:PreferredStockMember2018-12-31 0000912061us-gaap:CommonStockMember2018-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2018-12-31 0000912061us-gaap:RetainedEarningsMember2018-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0000912061us-gaap:TreasuryStockMember2018-12-31 00009120612018-12-31 0000912061us-gaap:PreferredStockMember2019-01-012019-03-31 0000912061us-gaap:CommonStockMember2019-01-012019-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-31 0000912061us-gaap:RetainedEarningsMember2019-01-012019-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-31 0000912061us-gaap:TreasuryStockMember2019-01-012019-03-31 00009120612019-01-012019-03-31 0000912061us-gaap:PreferredStockMember2019-03-31 0000912061us-gaap:CommonStockMember2019-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-03-31 0000912061us-gaap:RetainedEarningsMember2019-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-31 0000912061us-gaap:TreasuryStockMember2019-03-31 00009120612019-03-31 0000912061us-gaap:PreferredStockMember2019-04-012019-06-30 0000912061us-gaap:CommonStockMember2019-04-012019-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-30 0000912061us-gaap:RetainedEarningsMember2019-04-012019-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-30 0000912061us-gaap:TreasuryStockMember2019-04-012019-06-30 00009120612019-04-012019-06-30 0000912061us-gaap:PreferredStockMember2019-06-30 0000912061us-gaap:CommonStockMember2019-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2019-06-30 0000912061us-gaap:RetainedEarningsMember2019-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000912061us-gaap:TreasuryStockMember2019-06-30 00009120612019-06-30 0000912061us-gaap:PreferredStockMember2019-07-012019-09-30 0000912061us-gaap:CommonStockMember2019-07-012019-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-30 0000912061us-gaap:RetainedEarningsMember2019-07-012019-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-30 0000912061us-gaap:TreasuryStockMember2019-07-012019-09-30 0000912061us-gaap:PreferredStockMember2019-09-30 0000912061us-gaap:CommonStockMember2019-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2019-09-30 0000912061us-gaap:RetainedEarningsMember2019-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-30 0000912061us-gaap:TreasuryStockMember2019-09-30 00009120612019-09-30 iso4217:CNY 0000912061country:CN2019-12-31 0000912061us-gaap:RestrictedStockMember2019-07-012019-09-30 0000912061us-gaap:RestrictedStockMember2019-01-012019-09-30 utr:D 0000912061srt:MinimumMember2020-01-012020-09-30 utr:Y 0000912061srt:MaximumMember2020-01-012020-09-30 xbrli:pure 0000912061us-gaap:ProductMember2020-07-012020-09-30 0000912061us-gaap:ProductMember2019-07-012019-09-30 0000912061us-gaap:ProductMember2020-01-012020-09-30 0000912061us-gaap:ProductMember2019-01-012019-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-07-012020-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2019-07-012019-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-01-012020-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2019-01-012019-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2019-07-012019-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2019-01-012019-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-30 0000912061nhtc:UnshippedProductMember2020-09-30 0000912061nhtc:UnshippedProductMember2019-12-31 0000912061nhtc:AutoShipAdvancesMember2020-09-30 0000912061nhtc:AutoShipAdvancesMember2019-12-31 0000912061us-gaap:ProductAndServiceOtherMember2020-09-30 0000912061us-gaap:ProductAndServiceOtherMember2019-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-09-30 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2020-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-31 utr:acre 0000912061country:HK2020-09-30 utr:sqft 0000912061nhtc:RollingHillsEstatesMember2020-09-30 0000912061country:HK2020-07-012020-07-01 0000912061nhtc:RichmondBritishColumbiaMember2020-09-30 0000912061nhtc:MetuchenNewJerseyMember2020-09-30 0000912061country:CN2020-09-30 0000912061us-gaap:DomesticCountryMember2020-09-30 0000912061us-gaap:StateAndLocalJurisdictionMember2020-09-30 0000912061us-gaap:ForeignCountryMember2020-09-30 0000912061nhtc:DividendsDeclaredFebruary102020Member2020-01-012020-09-30 0000912061nhtc:DividendsDeclaredMay42020Member2020-01-012020-09-30 0000912061nhtc:DividendsDeclaredAugust32020Member2020-01-012020-09-30 00009120612015-07-28 00009120612016-01-12 0000912061nhtc:BroadyTrustMember2019-05-16 0000912061srt:DirectorMember2019-05-16 0000912061nhtc:OpenMarketPurchasesMember2019-05-31 00009120612019-05-012019-05-31 00009120612019-08-012019-09-30 0000912061nhtc:EquityIncentivePlan2016Member2020-09-30 0000912061us-gaap:RestrictedStockMember2019-12-31 0000912061us-gaap:RestrictedStockMember2020-01-012020-09-30 0000912061us-gaap:RestrictedStockMember2020-09-30 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2019-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-30 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-30 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-09-30 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-30 0000912061srt:DirectorMember2020-03-20 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-07-012020-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2019-07-012019-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-01-012020-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2019-01-012019-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-03-202020-03-20 0000912061nhtc:ShipmentOfApparelProductsMembernhtc:AberdeenMember2019-01-012019-03-31 0000912061nhtc:AberdeenMembernhtc:SharngHoldingsMember2020-09-30 0000912061nhtc:AberdeenMembersrt:DirectorMember2020-09-30 0000912061nhtc:UnrelatedThirdPartyMembernhtc:AberdeenMember2020-09-30 0000912061nhtc:AberdeenMember2020-01-012020-09-30 0000912061nhtc:BroadyTrustMember2019-05-172019-05-17 0000912061nhtc:PrimaryReportingSegmentMember2020-07-012020-09-30 0000912061nhtc:PrimaryReportingSegmentMember2019-07-012019-09-30 0000912061nhtc:PrimaryReportingSegmentMember2020-01-012020-09-30 0000912061nhtc:PrimaryReportingSegmentMember2019-01-012019-09-30 0000912061country:CN2020-07-012020-09-30 0000912061country:CN2019-07-012019-09-30 0000912061country:CN2020-01-012020-09-30 0000912061country:CN2019-01-012019-09-30 0000912061nhtc:RussiaAndKazakhstanMember2020-07-012020-09-30 0000912061nhtc:RussiaAndKazakhstanMember2019-07-012019-09-30 0000912061nhtc:RussiaAndKazakhstanMember2020-01-012020-09-30 0000912061nhtc:RussiaAndKazakhstanMember2019-01-012019-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2019-07-012019-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2019-01-012019-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2019-07-012019-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2019-01-012019-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2019-07-012019-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2019-01-012019-09-30 0000912061us-gaap:OperatingSegmentsMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMember2019-07-012019-09-30 0000912061us-gaap:OperatingSegmentsMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMember2019-01-012019-09-30 0000912061us-gaap:IntersegmentEliminationMember2020-07-012020-09-30 0000912061us-gaap:IntersegmentEliminationMember2019-07-012019-09-30 0000912061us-gaap:IntersegmentEliminationMember2020-01-012020-09-30 0000912061us-gaap:IntersegmentEliminationMember2019-01-012019-09-30 0000912061country:US2020-07-012020-09-30 0000912061country:US2019-07-012019-09-30 0000912061country:US2020-01-012020-09-30 0000912061country:US2019-01-012019-09-30 0000912061country:CA2020-07-012020-09-30 0000912061country:CA2019-07-012019-09-30 0000912061country:CA2020-01-012020-09-30 0000912061country:CA2019-01-012019-09-30 0000912061country:PE2020-07-012020-09-30 0000912061country:PE2019-07-012019-09-30 0000912061country:PE2020-01-012020-09-30 0000912061country:PE2019-01-012019-09-30 0000912061country:HK2020-07-012020-09-30 0000912061country:HK2019-07-012019-09-30 0000912061country:HK2020-01-012020-09-30 0000912061country:HK2019-01-012019-09-30 0000912061country:TW2020-07-012020-09-30 0000912061country:TW2019-07-012019-09-30 0000912061country:TW2020-01-012020-09-30 0000912061country:TW2019-01-012019-09-30 0000912061country:KR2020-07-012020-09-30 0000912061country:KR2019-07-012019-09-30 0000912061country:KR2020-01-012020-09-30 0000912061country:KR2019-01-012019-09-30 0000912061srt:EuropeMember2020-07-012020-09-30 0000912061srt:EuropeMember2019-07-012019-09-30 0000912061srt:EuropeMember2020-01-012020-09-30 0000912061srt:EuropeMember2019-01-012019-09-30 0000912061nhtc:OtherForeignCountriesMember2020-07-012020-09-30 0000912061nhtc:OtherForeignCountriesMember2019-07-012019-09-30 0000912061nhtc:OtherForeignCountriesMember2020-01-012020-09-30 0000912061nhtc:OtherForeignCountriesMember2019-01-012019-09-30 0000912061us-gaap:SubsequentEventMember2020-11-022020-11-02
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to _______

 

Commission File Number: 001-36849

 

NATURAL HEALTH TRENDS CORP.

(Exact name of registrant as specified in its charter)

Delaware

59-2705336

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

Units 1205-07, 12F

Mira Place Tower A

132 Nathan Road

, Tsimshatsui

Kowloon, Hong Kong

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: +852-3107-0800

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NHTC

The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

   

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☑

 

At October 30, 2020, the number of shares outstanding of the registrant’s common stock was 11,422,539 shares.

 

 

 

 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.

 

Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.

 

For a summary of certain risks related to our business, see “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, which includes the following:

 

 

We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;

 

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;

 

Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong, and the negative impact on our operations and financial performance could continue or intensify;

 

Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;

 

Our recent loss of a significant number of members is adversely affecting our business, and if we cannot stabilize or increase the number of members our business could be further negatively impacted;

 

Epidemics, such as the 2020 coronavirus outbreak, or natural disasters, terrorist attacks or acts of war may seriously harm our business;

 

We experienced negative operating cash flows during the year ended December 31, 2019, and if this trend continues it could have a material adverse effect on our business and our stock price;

 

We are currently involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business;

 

Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business;

 

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;

 

The high level of competition in our industry could adversely affect our business;

 

Challenges by third parties to the legality of our business operations could harm our business;

 

An increase in the amount of compensation paid to members would reduce profitability;

 

Currency exchange rate fluctuations could lower our revenue and net income;

 

Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;

 

Transfer pricing regulations affect our business and results of operations;

 

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;

 

Failure of new products to gain member and market acceptance could harm our business;

 

New regulations governing the marketing and sale of nutritional supplements could harm our business;

 

Regulations governing the production and marketing of our personal care products could harm our business;

 

If we are found not to be in compliance with good manufacturing practices our operations could be harmed;

 

Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;

 

Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;

 

 

 

We are subject to risks relating to product concentration and lack of revenue diversification;

 

We rely on a limited number of independent third parties to manufacture and supply our products;

 

Growth may be impeded by the political and economic risks of entering and operating in foreign markets;

 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;

 

Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition;

 

We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results;

 

We may be unable to protect or use our intellectual property rights;

 

We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;

 

Failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act of 2002 could negatively impact our business and the market price of our stock;

 

We rely on and are subject to risks associated with our reliance upon information technology systems;

 

System disruptions or failures, cybersecurity risks, and compromises of data could harm our business;

 

Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business;

 

Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;

 

Our common stock is particularly subject to volatility because of the industry and markets in which we operate;

 

Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and

 

Future sales by us or our existing stockholders could depress the market price of our common stock.

 

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.

 

 
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

  

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data) 

 

  

September 30, 2020

  

December 31, 2019

 
  

(Unaudited)

     

ASSETS

        

Current assets:

        
Cash and cash equivalents $90,789  $96,035 
Inventories  4,259   6,404 
Other current assets  4,972   5,936 
Total current assets  100,020   108,375 
Property and equipment, net  581   735 
Operating lease right-of-use assets  4,200   3,135 
Restricted cash  517   3,390 
Deferred tax asset  1,069   2,039 
Other assets  701   823 
Total assets $107,088  $118,497 

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        
Accounts payable $887  $680 
Accrued commissions  3,046   2,931 
Other accrued expenses  1,786   2,387 
Deferred revenue  3,477   4,506 
Amounts held in eWallets  9,831   12,938 
Operating lease liabilities  1,217   1,655 
Other current liabilities  1,067   1,205 
Total current liabilities  21,311   26,302 
Income taxes payable  13,748   15,365 
Deferred tax liability  203   202 
Operating lease liabilities  3,150   1,564 
Total liabilities  38,412   43,433 

Commitments and contingencies (Note 7)

          

Stockholders’ equity:

        

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

      
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2020 and December 31, 2019  13   13 
Additional paid-in capital  86,102   86,102 
Retained earnings  9,358   16,117 
Accumulated other comprehensive loss  (893)  (1,264)
Treasury stock, at cost; 1,556,875 shares at September 30, 2020 and December 31, 2019  (25,904)  (25,904)
Total stockholders’ equity  68,676   75,064 
Total liabilities and stockholders’ equity $107,088  $118,497 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP. 

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except per share data)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Net sales

  $ 14,124     $ 17,023     $ 45,476     $ 59,779  

Cost of sales

    3,635       4,371       12,966       15,002  

Gross profit

    10,489       12,652       32,510       44,777  

Operating expenses:

                               

Commissions expense

    5,620       7,362       19,336       28,258  

Selling, general and administrative expenses

    4,201       6,354       13,771       20,296  

Total operating expenses

    9,821       13,716       33,107       48,554  

Income (loss) from operations

    668       (1,064 )     (597 )     (3,777 )
Other income, net     385       323       603       1,128  

Income (loss) before income taxes

    1,053       (741 )     6       (2,649 )

Income tax provision (benefit)

    418       502       (90 )     120  

Net income (loss)

  $ 635     $ (1,243 )   $ 96     $ (2,769 )
Net income (loss) per common share:                                

Basic

  $ 0.06     $ (0.12 )   $ 0.01     $ (0.25 )

Diluted

  $ 0.06     $ (0.12 )   $ 0.01     $ (0.25 )
Weighted-average common shares outstanding:                                
Basic     10,678       10,623       10,581       11,010  

Diluted

    11,424       10,623       11,424       11,010  

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

(In thousands)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Net income (loss)

  $ 635     $ (1,243 )   $ 96     $ (2,769 )

Other comprehensive income (loss), net of tax:

                               

Foreign currency translation adjustment

    493       (584 )     355       (537 )

Unrealized gains (losses) on available-for-sale securities

    (2 )     12       16       23  

Comprehensive income (loss)

  $ 1,126     $ (1,815 )   $ 467     $ (3,283 )

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(In Thousands, Except Share Data)

 

Nine months ended September 30, 2020

 

                          

Accumulated

             
                  

Additional

      

Other

             
  

Preferred Stock

  

Common Stock

  

Paid-In

  

Retained

  

Comprehensive

  

Treasury Stock

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Earnings

  

Loss

  

Shares

  

Amount

  

Total

 
                                         

BALANCE, December 31, 2019

    $   12,979,414  $13  $86,102  $16,117  $(1,264)  (1,556,875) $(25,904) $75,064 

Net loss

                 (573)           (573)

Dividends declared, $0.20/share

                 (2,285)           (2,285)

Foreign currency translation adjustments

                    (222)        (222)

Unrealized losses on available-for-sale securities

                    (87)        (87)

BALANCE, March 31, 2020

        12,979,414   13   86,102   13,259   (1,573)  (1,556,875)  (25,904)  71,897 
Net income                 34            34 
Dividends declared, $0.20/share                 (2,285)           (2,285)
Foreign currency translation adjustments                    84         84 
Unrealized gains on available-for-sale securities                    105         105 
BALANCE, June 30, 2020        12,979,414   13   86,102   11,008   (1,384)  (1,556,875)  (25,904)  69,835 
Net income                 635            635 
Dividends declared, $0.20/share                 (2,285)           (2,285)
Foreign currency translation adjustments                    493         493 
Unrealized losses on available-for-sale securities                    (2)        (2)
BALANCE, September 30, 2020    $   12,979,414  $13  $86,102  $9,358  $(893)  (1,556,875) $(25,904) $68,676 

 

 

Nine months ended September 30, 2019

 

                          

Accumulated

             
                  

Additional

      

Other

             
  

Preferred Stock

  

Common Stock

  

Paid-In

  

Retained

  

Comprehensive

  

Treasury Stock

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Earnings

  

Loss

  

Shares

  

Amount

  

Total

 

BALANCE, December 31, 2018

    $   12,979,414  $13  $86,415  $44,431  $(1,250)  (1,603,322) $(39,748) $89,861 

Net loss

                 (1,923)           (1,923)

Common stock issued

              (166)        22,603   543   377 

Dividends declared, $0.24/share

                 (2,736)           (2,736)

Foreign currency translation adjustments

                    259         259 

Unrealized gains on available-for-sale securities

                    17         17 

BALANCE, March 31, 2019

        12,979,414   13   86,249   39,772   (974)  (1,580,719)  (39,205)  85,855 

Net income

                 397            397 

Repurchase of common stock

                       (612,729)  (6,682)  (6,682)

Foreign currency translation adjustments

                    (212)        (212)

Unrealized losses on available-for-sale securities

                    (6)        (6)
BALANCE, June 30, 2019        12,979,414   13   86,249   40,169   (1,192)  (2,193,448)  (45,887)  79,352 
Net loss                 (1,243)           (1,243)
Repurchase of common stock                       (383,127)  (2,882)  (2,882)
Common stock issued              (147)  (15,359)     1,117,485   23,418   7,912 
Foreign currency translation adjustments                    (584)        (584)
Unrealized gains on available-for-sale securities                    12         12 

BALANCE, September 30, 2019

    $   12,979,414  $13  $86,102  $23,567  $(1,764)  (1,459,090) $(25,351) $82,567 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

 

   

Nine Months Ended September 30,

 
   

2020

   

2019

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               
Net income (loss)   $ 96     $ (2,769 )

Adjustments to reconcile net income (loss) to net cash used in operating activities:

               
Depreciation and amortization     301       290  
Noncash lease expense     1,199       1,336  
Deferred income taxes     979       (3 )

Changes in assets and liabilities:

               
Inventories     2,193       4,104  
Other current assets     923       (1,674 )
Other assets     120       2  
Accounts payable     206       (1,002 )
Accrued commissions     136       (8,683 )
Other accrued expenses     (598 )     (1,779 )
Deferred revenue     (1,045 )     (3,485 )
Amounts held in eWallets     (3,163 )     (1,508 )
Operating lease liabilities     (1,120 )     (1,392 )
Income taxes payable     (1,617 )     (1,617 )
Other current liabilities     (140 )     (235 )

Long-term incentive

          (333 )
Net cash used in operating activities     (1,530 )     (18,748 )

CASH FLOWS FROM INVESTING ACTIVITIES:

               
Purchases of property and equipment     (147 )     (181 )
Net cash used in investing activities     (147 )     (181 )

CASH FLOWS FROM FINANCING ACTIVITIES:

               
Repurchase of common stock           (9,564 )
Dividends paid     (6,855 )     (2,736 )
Net cash used in financing activities     (6,855 )     (12,300 )
Effect of exchange rates on cash, cash equivalents and restricted cash     413       (428 )
Net decrease in cash, cash equivalents and restricted cash     (8,119 )     (31,657 )
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period     99,425       135,651  
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period   $ 91,306     $ 103,994  

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:

               

Issuance of treasury stock for employee awards, net

  $     $ 8,289  
Right-of-use assets obtained in exchange for operating lease liabilities   $ 2,724     $ 5,058  

 

 

See accompanying notes to consolidated financial statements.

 

 

NATURAL HEALTH TRENDS CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

 

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

 

Nature of Operations 

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2019 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 9, 2020.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in March 2020 in connection with the withdrawal of its application.

 

Net Income (Loss) Per Common Share

 

Diluted net income (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $635   10,678  $0.06  $(1,243)  10,623  $(0.12)

Effect of dilutive securities:

                        

Non-vested restricted stock

     746               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $635   11,424  $0.06  $(1,243)  10,623  $(0.12)

 

  

Nine Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $96   10,581  $0.01  $(2,769)  11,010  $(0.25)

Effect of dilutive securities:

                        

Non-vested restricted stock

     843               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $96   11,424  $0.01  $(2,769)  11,010  $(0.25)

 

In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were not included for the three and nine months ended September 30, 2019, respectively.

 

6

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company’s consolidated financial statement.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

 

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 10% of sales.  Sales returns were 1% and 2% of sales for the nine months ended September 30, 2020 and 2019, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 3 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from June 30, 2020 to September 30, 2020 is primarily due to an increase of $812,000 in the value of unshipped product orders and unredeemed vouchers. See Note 3 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. See Note 10 for revenue by market information.

 

7

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Product sales

 $12,023  $15,732  $41,234  $56,355 

Administrative fees, freight and other

  2,316   1,468   4,854   4,713 

Less: sales returns

  (215)  (177)  (612)  (1,289)

Total net sales

 $14,124  $17,023  $45,476  $59,779 

 

During June 2020, the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue during the three months ended September 30, 2020.

 

Concentration

 

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2020 and 2019. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

8

 

 

 

3. BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

   

September 30, 2020

   

December 31, 2019

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 22,408     $ 13,720  

Cash equivalents

    68,381       82,315  
      90,789       96,035  

Restricted cash

    517       3,390  
    $ 91,306     $ 99,425  

Inventories:

               

Finished goods

  $ 3,844     $ 6,142  

Raw materials

    836       1,249  

Reserve for obsolescence

    (421 )     (987 )
    $ 4,259     $ 6,404  

Other accrued expenses:

               

Sales returns

  $ 207     $ 373  

Employee-related expense

    941       1,258  

Warehousing, inventory-related and other

    638       756  
    $ 1,786     $ 2,387  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 1,397     $ 2,390  

Auto ship advances

    1,971       1,985  

Other

    109       131  
    $ 3,477     $ 4,506  

 

 

4. FAIR VALUE MEASUREMENTS

 

As of September 30, 2020, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2020 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

9

 

Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):

 

       

September 30, 2020

   

December 31, 2019

 
    Fair Value Level1  

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

   

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

 

Money market funds

 

Level 1

  $ 56,547     $     $ 56,547     $ 11,659     $     $ 11,659  

Time deposits

 

Level 2

    5,000             5,000       13,544             13,544  

Municipal debt securities

 

Level 2

    2,104             2,104       347             347  

Corporate debt securities

 

Level 2

    4,732       (2 )     4,730       56,784       (19 )     56,765  

Total investments

      $ 68,383     $ (2 )   $ 68,381     $ 82,334     $ (19 )   $ 82,315  

 


 

1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

5. LEASES

 

The Company leases 9,600 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030.  Effective July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in 10% monthly lease cost savings and a lease extension through June 2023.  To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2021, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Operating leases

  $ 377     $ 512     $ 1,292     $ 1,544  

Short-term leases

    72       73       237       201  

Total lease cost

  $ 449     $ 585     $ 1,529     $ 1,745  

 

Cash paid for amounts included in the measurement of operating leases liabilities was $342,000 and $459,000 for the three months ended  September 30, 2020 and 2019, respectively, and $1.2 million and $1.5 million for the nine months ended  September 30, 2020 and 2019, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2020 were as follows:

 

Weighted-average remaining lease term (in years)

    5.5  

Weighted-average discount rate

    3.5 %

 

10

 

As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2020 were as follows (in thousands):

 

Remainder of 2020

  $ 373  

2021

    1,245  

2022

    1,095  

2023

    582  

2024

    261  

Thereafter

    1,251  

Total lease payments

  $ 4,807  

Less: imputed interest

    (440 )

Present value of lease liabilities

  $ 4,367  

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

 

6. INCOME TAXES

 

The effective income tax rate for the three and nine months ended September 30, 2020 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on March 27, 2020. The CARES Act makes broad changes to the Internal Revenue Code of 1986, as amended, including, but not limited to, the ability to carry net operating losses generated in tax years 2018, 2019 or 2020 back to the each of the five tax years preceding the tax year of such loss.

 

As of September 30, 2020, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2020, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of September 30, 2020, the Company no longer has U.S. federal net operating losses due to its filing in August 2020 to carry back $3.6 million of losses generated in the tax year ended December 31, 2019 to offset taxable income from the tax year ended December 31, 2016. The Company has U.S. state net operating loss carryforwards of $2.4 million that begin expiring in 2040. At September 30, 2020, the Company has foreign net operating loss carryforwards of approximately $2.9 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of September 30, 2020, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of September 30, 2020 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2020.

 

11

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. The audit was expanded to also include the 2017 and 2018 tax years. For purposes of this audit, fiscal years since 2007 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2015.

 

 

7. COMMITMENTS AND CONTINGENCIES

 

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On January 17, 2020, after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On February 14, 2020, plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On April 9, 2020, plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.

 

The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

 

 

8. STOCKHOLDERS’ EQUITY

 

Dividends

 

The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2020 (in thousands, except per share data):

 

Declaration Date

 

Per Share

   

Amount

 

Record Date

 

Payment Date

February 10, 2020

  $ 0.20     $ 2,285  

February 25, 2020

 

March 6, 2020

May 4, 2020

    0.20       2,285  

May 19, 2020

 

May 29, 2020

August 3, 2020     0.20       2,285   August 18, 2020   August 28, 2020
    $ 0.60     $ 6,855        

 

The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

 

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady 2012 Irrevocable Trust (the "Broady Trust") on a basis roughly proportional to his family’s ownership interest (see Note 9). During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

 

On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs.

 

As of September 30, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2020, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

12

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

   

Shares

    Wtd. Avg. Price at Date of Issuance  

Nonvested at December 31, 2019

    957,682     $ 7.34  

Vested

    (293,583 )   $ 7.53  

Nonvested at September 30, 2020

    664,099     $ 7.25  

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for the nine months of 2020 were as follows (in thousands):

 

    Foreign Currency Translation Adjustment     Unrealized Gains (Losses) on Available-For-Sale Investments    

Total

 

Balance, December 31, 2019

  $ (1,245 )   $ (19 )   $ (1,264 )
Other comprehensive income     355       16       371  
Balance, September 30, 2020   $ (890 )   $ (3 )   $ (893 )

 

 

9. RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. Such royalties were $14,000 and $19,000 for the three months ended September 30, 2020 and 2019, respectively, and $64,000 and $75,000 for the nine months ended September 30, 2020 and 2019, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. An amendment to the agreement effective March 20, 2020 extends the term of the agreement for an additional five years to March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the three months ended March 31, 2019. Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

 

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note 8.

 

13

 

 

 

10.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales:

                

Primary Reporting Segment

 $13,294  $16,254  $42,718  $56,979 
China  640   525   2,156   2,138 

Russia and Kazakhstan

  190   244   602   662 

Total net sales

 $14,124  $17,023  $45,476  $59,779 
                 

Income (loss) from operations:

                

Primary Reporting Segment

 $2,715  $2,974  $6,038  $7,506 

China

  134   (795)  64   (1,530)

Russia and Kazakhstan

  (59)  (82)  (37)  (138)

Total income from operations for reportable segments

  2,790   2,097   6,065   5,838 

Unallocated corporate expenses

  (2,122)  (3,161)  (6,662)  (9,615)

Other income, net

  385   323   603   1,128 

Income (loss) before income taxes

 $1,053  $(741) $6  $(2,649)

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales from external customers:

                

United States

 $338  $551  $1,202  $1,607 

Canada

  132   313   536   808 

Peru

  357   581   954   1,938 

Hong Kong1

  11,132   13,575   36,238   48,465 

China

  640   525   2,156   2,138 
Taiwan  771   649   2,261   2,340 

South Korea

  52   98   220   288 

Russia and Kazakhstan

  190   244   602   662 

Europe

  259   343   747   1,017 

Other foreign countries

  253   144   560   516 

Total net sales

 $14,124  $17,023  $45,476  $59,779 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

14

 

 

 

11. SUBSEQUENT EVENT

 

On November 2, 2020, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 27, 2020 to stockholders of record on November 17, 2020. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

15

 
 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Business Overview

 

We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

 

As of September 30, 2020, we were conducting business through 53,300 active members, compared to 54,370 three months ago and 68,150 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe.

 

We generate approximately 94% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 79% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. We have identified certain matters of potential noncompliance and are working on a continuing basis to satisfactorily address such matters. For further information regarding some of the risks associated with the conduct of our business in China and Hong Kong, see generally in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, and more specifically under the captions “Because our Hong Kong operations account for a substantial portion of our overall business...”, “Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...”, and “Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.

 

China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon the submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. If we are ultimately able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

 

On January 8, 2019, the Chinese government announced a 100-day campaign focused on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, is reviewing its regulatory oversight of the industry, and is prohibiting companies from conducting large distributor meetings. Since it was implemented, the campaign and associated negative media coverage have had a significant adverse impact on our business, as consumers have widely curtailed their purchases within the affected industries. We, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China. We did this because we have learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions as the provincial and local governments formulate and implement their interpretive guidance and rule-making. Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment for health product companies operating in China continues to be challenging, which has recently been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market.

 

In late 2019 or early 2020 an outbreak of the coronavirus (COVID-19) was first identified in Wuhan, China. The coronavirus subsequently spread within China and in many countries around the world, and on March 11, 2020 the World Health Organization declared the coronavirus outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. We conduct significant business in or near Wuhan and in 2019 generated approximately 81% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control the coronavirus, while the governments of other countries in which we operate are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but we are taking steps to adapt some of our marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the outbreak. We also determined to cancel both of our major member events planned for 2020, as protecting the health and safety of our members, employees, and customers remains paramount. The severity of the impact on us of the pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results for the first three fiscal quarters of 2020, and we expect that our financial results for the foreseeable future will be adversely affected. These disruptions have also adversely affected the operations of some of our third party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions. We will continue to assess the operational and financial impact of the coronavirus pandemic for the remainder of the year. See “Item 1A. Risk Factors - Epidemics, such as the 2020 coronavirus outbreak, or natural disasters, terrorists attacks or acts of war…” in our most recent Annual Report on Form 10-K.

 

Recent political and social developments in Hong Kong are also adversely affecting our Hong Kong operations.

 

 

Although the recently enacted tariffs and the trade disputes between the United States and China have not materially impacted our business, to date, they may have negatively impacted the value of the Chinese yuan, which has in turn negatively affected our Hong Kong revenues because the prices at which our Chinese members can purchase our products have effectively increased. In the event that political and trade tensions involving the United States, China and Hong Kong continue or intensify, our business could be negatively impacted in the future. For more information, see “Item 1A. Risk Factors - The China legislature's recent passage of a national security law in Hong Kong...” in this Quarterly Report on Form 10-Q, and “Item 1A. Risk Factors - Recently enacted tariffs, other potential changes to tariff and import/export regulations, and ongoing trade disputes between the United States and other jurisdictions, particularly China…” in our most recent Annual Report on Form 10-K.

 

Our Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for the first nine months of 2020 were substantially lower than the comparable period in 2019, and it’s likely that we will experience continued lower net sales on a year-over-year basis for the foreseeable future. The substantial decline in net sales during the first nine months of 2020 resulted in a loss from operations for the nine-month period ended September 30, 2020, as well as negative cash flows and a decreasing cash balance. We anticipate that our financial performance will be adversely impacted for the foreseeable future.

 

 

Statement of Operations Presentation

 

We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.

 

Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.

 

Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

 

 

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

 

 

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first nine months of 2020 and 2019, represented 43% and 47%, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.

 

Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.

 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates. The resulting translation adjustments are recorded directly into stockholders’ equity.

 

Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate. Most of our product purchases from third-party manufacturers are transacted in U.S. dollars. Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar.

 

 

Results of Operations 

 

The following table sets forth our operating results as a percentage of net sales for the periods indicated.

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Net sales

    100.0 %     100.0 %     100.0 %     100.0 %

Cost of sales

    25.7       25.7       28.5       25.1  

Gross profit

    74.3       74.3       71.5       74.9  

Operating expenses:

                               

Commissions expense

    39.8       43.2       42.5       47.3  

Selling, general and administrative expenses

    29.7       37.3       30.3       34.0  

Total operating expenses

    69.5       80.5       72.8       81.3  

Income (loss) from operations

    4.8       (6.2 )     (1.3 )     (6.4 )

Other income, net

    2.7       1.9       1.3       1.9  

Income (loss) before income taxes

    7.5       (4.3 )     0.0       (4.5 )

Income tax provision (benefit)

    3.0       2.9       (0.2 )     0.2  

Net income (loss)

    4.5 %     (7.2 )%     0.2 %     (4.7 )%

 

 

Net Sales

 

The following table sets forth revenue by market for the periods indicated (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Americas1

  $ 827       5.9 %   $ 1,445       8.5 %   $ 2,692       5.9 %   $ 4,353       7.3 %

Hong Kong2

    11,132       78.8       13,575       79.7       36,238       79.7       48,465       81.0  
China     640       4.5       525       3.1       2,156       4.8       2,138       3.6  
Taiwan     771       5.5       649       3.8       2,261       5.0       2,340       3.9  
South Korea     52       0.4       98       0.6       220       0.5       288       0.5  
Japan     70       0.5       47       0.3       184       0.4       141       0.2  

Singapore

    19       0.1       13       0.1       55       0.1       43       0.1  

Malaysia

    111       0.8       51       0.3       198       0.4       170       0.3  
Russia and Kazakhstan     190       1.3       244       1.4       602       1.3       662       1.1  
Europe     259       1.8       343       2.0       747       1.6       1,017       1.7  

India

    53       0.4       33       0.2       123       0.3       162       0.3  

Total

  $ 14,124       100.0 %   $ 17,023       100.0 %   $ 45,476       100.0 %   $ 59,779       100.0 %

 

1 United States, Canada, Mexico and Peru

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

Net sales were $14.1 million for the three months ended September 30, 2020 compared with $17.0 million for the comparable period a year ago, a decrease of $2.9 million, or 17%. Hong Kong net sales, substantially all of which were derived from the sale of products shipped to members residing in China, decreased $2.4 million, or 18%, over the comparable period a year ago. This decrease in Hong Kong net sales was mitigated by increased administrative fees of $1.2 million resulting from the modification of our fee structure associated with certain electronic (eWallet) accounts held by our Hong Kong members.  The overall decrease in our Hong Kong net sales primarily resulted from the impact of the coronavirus outbreak in China, and the related powerful measures implemented by the Chinese government to control the virus, including the required closure of some businesses and restrictions on public gatherings and travel. We believe that the decrease in our net sales can also be attributed to the continuing impact of China’s 100-day campaign and the related look-back review. Due to both of these factors, the operating environment for our business in China remains restrictive. Outside of our Hong Kong business, net sales decreased $456,000, or 13%, over the comparable three-month period a year ago due primarily to the spread of the coronavirus pandemic and efforts to control it in a number of countries around the world.

 

Net sales were $45.5 million for the nine months ended September 30, 2020 compared with $59.8 million for the comparable period a year ago, a decrease of $14.3 million, or 24%, due to substantially the same factors that adversely affected net sales for the three months ended September 30, 2020.

 

As of September 30, 2020, deferred revenue was $3.5 million, which primarily consisted of $1.4 million pertaining to unshipped product orders and unredeemed product vouchers, as well as $2.0 million in auto ship advances.

 

Gross Profit

 

Gross profit was 74.3% of net sales for each of the three month periods ended September 30, 2020 and 2019, and 71.5% of net sales for the nine months ended September 30, 2020 compared with 74.9% of net sales for the nine months ended September 30, 2019. The gross profit margin percentage was consistent for the three month periods as higher logistics costs and product promotions incurred during the most recent quarter were offset by, as referenced above, the additional administrative fees recognized during the most recent quarter.  The gross profit margin percentage decrease for the nine month period ended September 30, 2020 was primarily attributable to higher logistics costs and product promotions throughout the current year period.

 

Commissions

 

Commissions were 39.8% of net sales for the three months ended September 30, 2020, compared with 43.2% of net sales for the three month period ended September 30, 2019, and 42.5% of net sales for the nine months ended September 30, 2020, compared with 47.3% for the comparable period a year ago. Excluding the additional administrative fee revenue recognized during the most recent quarter referred to above, commissions as a percentage of net sales were roughly consistent with the same period in the prior year.  The decrease in commissions as a percentage of net sales of the nine month period ended September 30, 2020 largely resulted from lower estimated costs for on-going incentive programs during the current year period.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $4.2 million for the three months ended September 30, 2020 compared with $6.4 million in the same period a year ago. For the nine months ended September 30, 2020, selling, general and administrative expenses were $13.8 million compared with $20.3 million for the comparable period a year ago. The decrease in selling, general and administrative expenses during each of the three- and nine-month periods as compared to the comparable periods in the prior year is primarily due to lower employee-related expenses and professional fees.  The decrease in the nine-month period is also due to a reduction in event costs as we did not hold a first-half 2020 major event due to the coronavirus outbreak.

 

 

Income Taxes

 

An income tax provision of $418,000 and $502,000 was recognized during the three month periods ended September 30, 2020 and 2019, respectively. An income tax benefit of $90,000 and an income tax provision of $120,000 was recognized during the nine month periods ended September 30, 2020 and 2019, respectively. The tax benefit during 2020 primarily results from a $512,000 deferred tax asset adjustment necessary to reflect the net operating losses arising from the 2019 tax year, which is due to the CARES Act enacted in March 2020 (described below under “– Critical Accounting Policies and Estimates – Income Taxes”) and which were carried back in August 2020 to offset taxable income in tax year 2016.

 

 

Liquidity and Capital Resources

 

At September 30, 2020, our cash and cash equivalents totaled $90.8 million. Total cash and cash equivalents decreased by $5.2 million from December 31, 2019 to September 30, 2020, primarily due to the dividends paid and the net cash used in operating activities during the first nine months of 2020, offset by the refund received in March 2020 in connection with the withdrawal of our Chinese direct selling license application. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2020, we had $68.4 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $13.4 million held in banks located within China subject to foreign currency controls.

 

As of September 30, 2020, the ratio of current assets to current liabilities was 4.69 to 1.00 and we had $78.7 million of working capital. Working capital as of September 30, 2020 decreased $3.4 million compared to our working capital as of December 31, 2019.

 

Cash used in operations was $1.5 million for the first nine months of 2020 compared with $18.7 million in the comparable period of 2019. The improvement in operating cash flows resulted primarily from a smaller operating loss incurred during 2020 and a decrease in accrued commission payments.

 

Cash flows used in investing activities totaled $147,000 and $181,000 during the first nine months of 2020 and 2019, respectively.

 

Cash flows used in financing activities during the first nine months of 2020 included the following dividend payments (in thousands, except per share amounts):

 

Declaration Date

 

Per Share

   

Amount

 

Record Date

 

Payment Date

February 10, 2020

  $ 0.20     $ 2,285  

February 25, 2020

 

March 6, 2020

May 4, 2020

    0.20       2,285  

May 19, 2020

 

May 29, 2020

August 3, 2020     0.20       2,285   August 18, 2020   August 28, 2020
    $ 0.60     $ 6,855        

 

Cash flows used in financing activities during the first nine months of 2019 included the repurchase of common stock totaling $9.6 million and dividend payments totaling $2.7 million.

 

Subsequent to September 30, 2020, on November 2, 2020, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 27, 2020 to stockholders of record on November 17, 2020. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and are made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of September 30, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.

 

We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

 

 

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a prospective China direct selling license application.

 

Critical Accounting Policies and Estimates 

 

A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 9, 2020. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.

 

Revenue Recognition. All revenue is recognized when the performance obligations under a contract, including product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product orders and unredeemed product vouchers are recorded as deferred revenue. Such amounts totaled $1.4 million and $2.4 million at September 30, 2020 and December 31, 2019, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

 

Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $2.0 million at September 30, 2020 and December 31, 2019.

 

Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.

 

Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $3.0 million and $2.9 million at September 30, 2020 and December 31, 2019, respectively.

 

 

Income Taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of September 30, 2020, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. The Tax Act, enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of September 30, 2020, we have not recorded a state deferred tax liability for earnings to be repatriated in the future because all earnings as of September 30, 2020 have already been repatriated. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2020.

 

The U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted on March 27, 2020. The CARES Act was enacted to provide tax relief to companies impacted by the COVID-19 pandemic. In addition to other broad changes, the CARES Act allows for a 5-year carryback period for net operating losses arising in tax years beginning after 2017 and before 2021, effectively taking advantage of differences in tax rate as a result of enactment of the Tax Act. We booked a tax benefit of $512,000 during 2020 due to the net operating loss generated in the taxable year ended December 31, 2019.

 

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. The Company’s effective tax rate projected for the year ending December 31, 2020 differs from the year ended December 31, 2019 primarily as a result of the CARES Act.

 

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable under smaller reporting company disclosure rules.

 

Item 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2020. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2020.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

 

 

 

PART II — OTHER INFORMATION

 

 

Item 1. LEGAL PROCEEDINGS

 

Reference is made to Part II, Item 1 of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 for disclosure of a legal proceeding that has since been concluded.

 

Item 1A. RISK FACTORS

 

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2019, except that we are now adding the following risk factor:

 

The China legislature’s recent passage of a national security law in Hong Kong may escalate political and trade tensions involving the U.S., China and Hong Kong, which could harm our business and adversely affect our financial performance. 

 

On June 30, 2020, China’s legislature passed a national security law that changes the way Hong Kong has been governed since the territory was handed over by England to China in 1997. This law criminalizes secessionist activities, subversion, terrorism, and collusion with a foreign country or with external elements to endanger national security in Hong Kong. The U.S. State Department has announced that the U.S. no longer considers Hong Kong to have significant autonomy from China, and the U.S. administration is taking action to end many of the U.S. government’s special trade and economic relations with Hong Kong. Further, on July 14, 2020 the U.S. enacted the Hong Kong Autonomy Act, authorizing the U.S. administration to impose sanctions against individuals and entities determined to materially contribute to the erosion of Hong Kong's autonomy, as well as to punish financial institutions that facilitate certain significant transactions. These and other recent actions may represent an escalation in political and trade tensions involving the U.S, China and Hong Kong, which could harm our business. A continued deterioration in these political or economic relations or other future unforeseen problems could disrupt our China and Hong Kong operations (including our Hong Kong office and employees), adversely affect the distribution of our products, reduce our net sales, increase the cost of conducting our operations, or result in retaliatory actions against U.S. interests, any of which could have a material adverse effect on our results of operations, financial condition and business.

 

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

Item 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

Item 5. OTHER INFORMATION

 

None.

 

Item 6. EXHIBITS

 

Exhibit

Number

 

 

Exhibit Description

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

 

Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation

101.DEF

 

Inline XBRL Taxonomy Extension Definition

101.LAB

 

Inline XBRL Taxonomy Extension Labels

101.PRE

 

Inline XBRL Taxonomy Extension Presentation

104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

NATURAL HEALTH TRENDS CORP.

 

 

 

 

Date: November 4, 2020

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

Exhibit Description

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

 

Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation

101.DEF

 

Inline XBRL Taxonomy Extension Definition

101.LAB

 

Inline XBRL Taxonomy Extension Labels

101.PRE

 

Inline XBRL Taxonomy Extension Presentation

104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

26
EX-31.1 2 ex_201344.htm EXHIBIT 31.1 ex_191212.htm

EXHIBIT 31.1

 

CERTIFICATION

 

I, Chris T. Sharng, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2020

/s/ Chris T. Sharng

 

 

Chris T. Sharng

 

 

President

 

 

(Principal Executive Officer)

 

 

 
EX-31.2 3 ex_201345.htm EXHIBIT 31.2 ex_191213.htm

EXHIBIT 31.2

 

CERTIFICATION

 

I, Timothy S. Davidson, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2020

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 
EX-32.1 4 ex_201346.htm EXHIBIT 32.1 ex_191527.htm

EXHIBIT 32.1

 

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 4, 2020

/s/ Chris T. Sharng

 

 

Chris T. Sharng

 

 

President

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

Date: November 4, 2020

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 
EX-101.SCH 5 nhtc-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Revenue link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Leases link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Segment Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 2 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 5 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 10 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 2 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 5 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 6 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 8 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Stockholders' Equity - Dividend Activity (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 8 - Stockholders' Equity - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 9 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 10 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 10 - Segment Information - Operating Information by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 10 - Segment Information - Net Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 11 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 nhtc-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nhtc-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nhtc-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies 2021 Note 1 - Nature of Operations, Basis of Presentation and Consolidation 2022 Note 2 - Revenue Note 3 - Balance Sheet Components Note 4 - Fair Value Measurements Note 5 - Leases Note 8 - Stockholders' Equity Note 10 - Segment Information Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details) Income Tax Disclosure [Text Block] Note 2 - Revenue - Net Sales by Product and Service (Details) Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Unrealized gains (losses) on available-for-sale securities Note 4 - Fair Value Measurements - Investments (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Note 5 - Leases - Lease Cost (Details) Other assets Note 5 - Leases - Maturity of Lease Liabilities (Details) Remainder of 2020 us-gaap_LiabilitiesCurrent Total current liabilities Note 8 - Stockholders' Equity - Dividend Activity (Details) Note 8 - Stockholders' Equity - Restricted Stock Activity (Details) Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Other current liabilities Note 10 - Segment Information - Operating Information by Geographic Area (Details) Earnings Per Share, Policy [Policy Text Block] Note 10 - Segment Information - Net Sales by Geographic Area (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Operating expenses: Vested, wtd. avg. price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Nonvested at December 31, 2019, wtd. avg. price (in dollars per share) Nonvested at June 30, 2020, wtd. avg. price (in dollars per share) Foreign currency translation adjustment us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Nonvested at December 31, 2019 (in shares) Nonvested at September 30, 2020 (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested (in shares) Depreciation and amortization Corporate Debt Securities [Member] Nonvested Restricted Stock Shares Activity [Table Text Block] us-gaap_AssetsCurrent Total current assets Stockholders' Equity Note Disclosure [Text Block] Treasury stock, shares (in shares) Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2020 and December 31, 2019 Adjustments to reconcile net income (loss) to net cash used in operating activities: Common stock, authorized (in shares) Common stock, issued (in shares) Deferred revenue Common stock, par value (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Other accrued expenses us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Statistical Measurement [Domain] us-gaap_OperatingLeasePayments Operating Lease, Payments Maximum [Member] Minimum [Member] Lessee, Operating Leases [Text Block] Accounts payable Ownership [Domain] Product and Service [Axis] Other current assets Product and Service [Domain] Statistical Measurement [Axis] Employee-related expense Ownership [Axis] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Other accrued expenses Preferred stock, issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Geographical [Axis] Geographical [Domain] Preferred stock, authorized (in shares) Europe [Member] Inventories Inventories Accrued commissions us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Issuance of treasury stock for employee awards, net Preferred stock, par value (in dollars per share) Raw materials us-gaap_InventoryValuationReserves Reserve for obsolescence Revenue from External Customers by Products and Services [Table Text Block] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Non-vested restricted stock, shares (in shares) Finished goods SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Fair Value Hierarchy and NAV [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Product and Service, Other [Member] Fair Value Hierarchy and NAV [Axis] Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Product [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] us-gaap_Assets Total assets Inventories: Plan Name [Axis] Plan Name [Domain] CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) available to common stockholders us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Net income (loss) available to common stockholders plus assumed conversions Statement [Line Items] us-gaap_NumberOfReportableSegments Number of Reportable Segments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Additional paid-in capital Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Deferred tax asset AOCI Attributable to Parent [Member] Stockholders’ equity: Other income, net Segment Reporting Disclosure [Text Block] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Amounts held in eWallets Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current. us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents, Total Current assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net income (loss) Net income (loss) us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash Restricted Stock [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 7) Director [Member] Noncash lease expense Represents the amount of lessee's noncash lease expense during the period. Deferred income taxes Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange. Effect of exchange rates on cash, cash equivalents and restricted cash us-gaap_OperatingIncomeLoss Income (loss) from operations Income (loss) from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent Revenue from Contract with Customers, Historical Sales Returns, Percent Represents the percentage of historical sales returns. nhtc_RevenueFromContractWithCustomersSalesReturnsPercent Revenue from Contract with Customers, Sales Returns, Percent Represents the percentage of sales returns. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_GrossProfit Gross profit nhtc_IncreaseDecreaseInAccruedSalesCommissions Accrued commissions Amount of increase (decrease) in accrued sales commissions. Cost of sales Counterparty Name [Axis] nhtc_IncreaseDecreaseInOperatingLeaseLiabilities Operating lease liabilities Amount of increase (decrease) in operating lease liabilities. Counterparty Name [Domain] nhtc_IncreaseDecreaseInCapitalizedContractCostLiability Amounts held in eWallets Amount of increase (decrease) in capitalized contract cost liability. nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm Revenue from Contract with Customer, Sales Returns Policy Term (Day) Represents the sales returns policy term. Deferred tax liability Consolidation Items [Domain] nhtc_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. nhtc_NumberOfMajorMarkets Number of Major Markets Represents the number of major markets accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Bank Time Deposits [Member] Consolidation Items [Axis] us-gaap_Dividends Dividends declared nhtc_RevenueFromContractWithCustomerSalesReturns Less: sales returns Represents the amount of sales returns during the period. Dividends Dividends paid Unshipped Product [Member] Information pertaining to unshipped product. Auto ship advances [Member] Information pertaining to auto ship advances. Sales returns Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns. Schedule of Additional Balance Sheet Components [Table Text Block] Tabular disclosure of additional balance sheet components. CASH FLOWS FROM INVESTING ACTIVITIES: us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase of common stock Warehousing, inventory-related and other Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense. Fair value Long-term incentive Retained Earnings [Member] us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty Related Party Transaction, Other Revenues from Transactions with Related Party Net sales Treasury Stock [Member] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Intersegment Eliminations [Member] Additional Paid-in Capital [Member] Share Repurchase Program [Domain] CANADA Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Related Party Transactions Disclosure [Text Block] Preferred Stock [Member] us-gaap_IncreaseDecreaseInAccruedLiabilities Other accrued expenses Income tax provision (benefit) Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] CHINA nhtc_LesseeNumberOfBranches Lessee, Number of Branches Represents the lessees' number of branches. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Rolling Hills Estates [Member] Information pertaining to Rolling Hills Estates. Richmond, British Columbia [Member] Information pertaining to Richmond, British Columbia. Metuchen, New Jersey [Member] Information pertaining to Metuchen, New Jersey. Income (loss) before income taxes Income (loss) before income taxes us-gaap_OperatingExpenses Total operating expenses nhtc_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] nhtc_CommonStockPercentageOfBeneficialStockOutstanding Common Stock, Percentage of Beneficial Stock Outstanding Represents the percentage of beneficial stock outstanding. Cash Cash equivalents BHS [Member] Information pertaining to BHS. Cash and cash equivalents Cash and cash equivalents State and Local Jurisdiction [Member] Equity Incentive Plan 2016 [Member] Information pertaining to the 2016 Equity Incentive Plan. us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities Income Tax Authority [Axis] nhtc_NumberOfProductOrders Number of Product Orders Represents the number of product orders. Income Tax Authority [Domain] Aberdeen [Member] Information pertaining to Aberdeen. Domestic Tax Authority [Member] Shipment of Apparel Products [Member] Information pertaining to shipment of apparel products. Foreign Tax Authority [Member] Royalty Agreement and License [Member] Information pertaining to the Royalty Agreement and License. nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement Related Party Transaction, Additional Extension Period of Agreement (Year) Represents the additional extension period of the agreement in related party transaction. nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement Related Party Transaction, Automatic Renewal Period of Agreement (Year) Represents the automatic renewal period of the agreement in related party transaction. Revenue from Contract with Customer [Text Block] nhtc_NumberOfDaysTerminationNotice Number of Days Termination Notice (Day) Represents the number of days for termination notice. Primary Reporting Segment [Member] Information pertaining to the primary reporting segment. Russia and Kazakhstan [Member] Information pertaining to Russia and Kazakhstan. Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Sharng Holdings [Member] Information pertaining to Sharng Holdings. Document Quarterly Report us-gaap_RoyaltyExpense Royalty Expense Unrelated Third Party [Member] Information pertaining to the unrelated third party. Amendment Flag Entity Incorporation, State or Country Code HONG KONG Accounting Policies [Abstract] Other comprehensive income (loss), net of tax: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income (loss) Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Other Foreign Countries [Member] Information pertaining to other foreign countries. New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared (in dollars per share) Dividends per share (in dollars per share) us-gaap_TreasuryStockSharesAcquired Treasury Stock, Shares, Acquired (in shares) Repurchase of common stock (in shares) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue us-gaap_SharesOutstanding BALANCE (in shares) BALANCE (in shares) Security Exchange Name Preferred stock, outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date us-gaap_LeaseCost Total lease cost Weighted-average discount rate Document Fiscal Period Focus Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term leases Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities Weighted-average remaining lease term (in years) (Year) Entity File Number KOREA, REPUBLIC OF Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Other accrued expenses: Document Information [Table] Entity Filer Category Entity Current Reporting Status Segments [Axis] Segments [Domain] Weighted-average common shares outstanding: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Net income available to common stockholders plus assumed conversions, shares (in shares) Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Administrative Fees, Freight and Other [Member] Information related to administrative fees, freight and other. Entity Registrant Name Dividends Declared August 3, 2020 [Member] Information related to the dividends declared August 3, 2020. Net income (loss) per common share: Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] us-gaap_MinorityInterestOwnershipPercentageByParent Noncontrolling Interest, Ownership Percentage by Parent Entity Address, Address Line One Statement of Financial Position [Abstract] Diluted (in dollars per share) Net income available to common stockholders plus assumed conversions, per share (in dollars per share) Basic (in shares) us-gaap_TreasuryStockValueAcquiredCostMethod Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Country Basic (in dollars per share) Net income available to common stockholders, per share (in dollars per share) Concentration Risk Type [Axis] Concentration Risk Type [Domain] Deferred revenue: us-gaap_TreasuryStockValue Treasury stock, at cost; 1,556,875 shares at September 30, 2020 and December 31, 2019 Statement of Cash Flows [Abstract] PERU Entity Common Stock, Shares Outstanding Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Statement of Stockholders' Equity [Abstract] Available-for-sale Securities [Table Text Block] Other comprehensive income Income Statement [Abstract] Municipal Bonds [Member] Revenue Benchmark [Member] us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Local Phone Number us-gaap_TableTextBlock Notes Tables Related Party [Axis] Related Party [Domain] us-gaap_AreaOfLand Area of Land (Acre) Open Market Purchases [Member] Information pertaining to the open market purchases. Broady Trust [Member] Information pertaining to the Broady Trust. Selling, general and administrative expenses Dividends Declared February 10, 2020 [Member] Information pertaining to the dividends declared February 10, 2020. Dividends Declared May 4, 2020 [Member] Information pertaining to the dividends declared May 4, 2020. Commissions expense nhtc_PercentOfIncreaseInMonthlyLeaseCostSavings Percent of Increase in Monthly Lease Cost Savings Represents the percentage of increase in monthly lease cost savings. CASH FLOWS FROM FINANCING ACTIVITIES: Thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction Represents the ratio of number of shares authorized to be repurchased in private transaction. TAIWAN, PROVINCE OF CHINA nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired Common stock issued Amount of decrease in additional paid in capital (APIC) resulting from treasury stock acquired. Common stock issued (in shares) Represents the number of treasury shares reissued. Common stock issued Represents the value of treasury shares reissued. us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Dividends [Axis] Dividends [Domain] Retained earnings Accumulated other comprehensive loss Money Market Funds [Member] Changes in assets and liabilities: Cash, cash equivalents and restricted cash: us-gaap_StockholdersEquity Total stockholders’ equity Balance, December 31, 2019 Balance, September 30, 2020 Income taxes payable us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Operating lease liabilities Class of Stock [Axis] Restricted cash Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Present value of lease liabilities Subsequent Event Type [Axis] Operating lease liabilities Subsequent Event Type [Domain] Schedule of Dividends Payable [Table Text Block] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Gross unrealized losses Subsequent Events [Text Block] Operating Segments [Member] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Adjusted cost 2023 2024 EX-101.PRE 9 nhtc-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 nhtc20200930_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2020-01-01 2020-09-30 0000912061 2020-10-30 0000912061 2020-09-30 0000912061 2019-12-31 0000912061 2020-07-01 2020-09-30 0000912061 2019-07-01 2019-09-30 0000912061 2019-01-01 2019-09-30 0000912061 us-gaap:PreferredStockMember 2019-12-31 0000912061 us-gaap:CommonStockMember 2019-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000912061 us-gaap:TreasuryStockMember 2019-12-31 0000912061 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000912061 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000912061 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000912061 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000912061 2020-01-01 2020-03-31 0000912061 us-gaap:PreferredStockMember 2020-03-31 0000912061 us-gaap:CommonStockMember 2020-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000912061 us-gaap:RetainedEarningsMember 2020-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000912061 us-gaap:TreasuryStockMember 2020-03-31 0000912061 2020-03-31 0000912061 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000912061 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000912061 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000912061 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000912061 2020-04-01 2020-06-30 0000912061 us-gaap:PreferredStockMember 2020-06-30 0000912061 us-gaap:CommonStockMember 2020-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000912061 us-gaap:RetainedEarningsMember 2020-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000912061 us-gaap:TreasuryStockMember 2020-06-30 0000912061 2020-06-30 0000912061 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000912061 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000912061 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:PreferredStockMember 2020-09-30 0000912061 us-gaap:CommonStockMember 2020-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000912061 us-gaap:RetainedEarningsMember 2020-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000912061 us-gaap:TreasuryStockMember 2020-09-30 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 2018-12-31 0000912061 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0000912061 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000912061 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000912061 2019-01-01 2019-03-31 0000912061 us-gaap:PreferredStockMember 2019-03-31 0000912061 us-gaap:CommonStockMember 2019-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000912061 us-gaap:RetainedEarningsMember 2019-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000912061 us-gaap:TreasuryStockMember 2019-03-31 0000912061 2019-03-31 0000912061 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0000912061 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000912061 2019-04-01 2019-06-30 0000912061 us-gaap:PreferredStockMember 2019-06-30 0000912061 us-gaap:CommonStockMember 2019-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000912061 us-gaap:RetainedEarningsMember 2019-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000912061 us-gaap:TreasuryStockMember 2019-06-30 0000912061 2019-06-30 0000912061 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000912061 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:PreferredStockMember 2019-09-30 0000912061 us-gaap:CommonStockMember 2019-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000912061 us-gaap:RetainedEarningsMember 2019-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000912061 us-gaap:TreasuryStockMember 2019-09-30 0000912061 2019-09-30 0000912061 country:CN 2019-12-31 0000912061 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000912061 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000912061 srt:MinimumMember 2020-01-01 2020-09-30 0000912061 srt:MaximumMember 2020-01-01 2020-09-30 0000912061 us-gaap:ProductMember 2020-07-01 2020-09-30 0000912061 us-gaap:ProductMember 2019-07-01 2019-09-30 0000912061 us-gaap:ProductMember 2020-01-01 2020-09-30 0000912061 us-gaap:ProductMember 2019-01-01 2019-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-07-01 2020-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2019-07-01 2019-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-01-01 2020-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000912061 nhtc:UnshippedProductMember 2020-09-30 0000912061 nhtc:UnshippedProductMember 2019-12-31 0000912061 nhtc:AutoShipAdvancesMember 2020-09-30 0000912061 nhtc:AutoShipAdvancesMember 2019-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2020-09-30 0000912061 us-gaap:ProductAndServiceOtherMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-09-30 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2020-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2020-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000912061 country:HK 2020-09-30 0000912061 nhtc:RollingHillsEstatesMember 2020-09-30 0000912061 country:HK 2020-07-01 2020-07-01 0000912061 nhtc:RichmondBritishColumbiaMember 2020-09-30 0000912061 nhtc:MetuchenNewJerseyMember 2020-09-30 0000912061 country:CN 2020-09-30 0000912061 us-gaap:DomesticCountryMember 2020-09-30 0000912061 us-gaap:StateAndLocalJurisdictionMember 2020-09-30 0000912061 us-gaap:ForeignCountryMember 2020-09-30 0000912061 nhtc:DividendsDeclaredFebruary102020Member 2020-01-01 2020-09-30 0000912061 nhtc:DividendsDeclaredMay42020Member 2020-01-01 2020-09-30 0000912061 nhtc:DividendsDeclaredAugust32020Member 2020-01-01 2020-09-30 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 nhtc:BroadyTrustMember 2019-05-16 0000912061 srt:DirectorMember 2019-05-16 0000912061 nhtc:OpenMarketPurchasesMember 2019-05-31 0000912061 2019-05-01 2019-05-31 0000912061 2019-08-01 2019-09-30 0000912061 nhtc:EquityIncentivePlan2016Member 2020-09-30 0000912061 us-gaap:RestrictedStockMember 2019-12-31 0000912061 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000912061 us-gaap:RestrictedStockMember 2020-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0000912061 srt:DirectorMember 2020-03-20 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-07-01 2020-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2019-07-01 2019-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-01-01 2020-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2019-01-01 2019-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-03-20 2020-03-20 0000912061 nhtc:ShipmentOfApparelProductsMember nhtc:AberdeenMember 2019-01-01 2019-03-31 0000912061 nhtc:AberdeenMember nhtc:SharngHoldingsMember 2020-09-30 0000912061 nhtc:AberdeenMember srt:DirectorMember 2020-09-30 0000912061 nhtc:UnrelatedThirdPartyMember nhtc:AberdeenMember 2020-09-30 0000912061 nhtc:AberdeenMember 2020-01-01 2020-09-30 0000912061 nhtc:BroadyTrustMember 2019-05-17 2019-05-17 0000912061 nhtc:PrimaryReportingSegmentMember 2020-07-01 2020-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2019-07-01 2019-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2019-01-01 2019-09-30 0000912061 country:CN 2020-07-01 2020-09-30 0000912061 country:CN 2019-07-01 2019-09-30 0000912061 country:CN 2020-01-01 2020-09-30 0000912061 country:CN 2019-01-01 2019-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2020-07-01 2020-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2019-07-01 2019-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2019-01-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2019-07-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2019-01-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2019-07-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2019-01-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2019-07-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2019-01-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000912061 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000912061 country:US 2020-07-01 2020-09-30 0000912061 country:US 2019-07-01 2019-09-30 0000912061 country:US 2020-01-01 2020-09-30 0000912061 country:US 2019-01-01 2019-09-30 0000912061 country:CA 2020-07-01 2020-09-30 0000912061 country:CA 2019-07-01 2019-09-30 0000912061 country:CA 2020-01-01 2020-09-30 0000912061 country:CA 2019-01-01 2019-09-30 0000912061 country:PE 2020-07-01 2020-09-30 0000912061 country:PE 2019-07-01 2019-09-30 0000912061 country:PE 2020-01-01 2020-09-30 0000912061 country:PE 2019-01-01 2019-09-30 0000912061 country:HK 2020-07-01 2020-09-30 0000912061 country:HK 2019-07-01 2019-09-30 0000912061 country:HK 2020-01-01 2020-09-30 0000912061 country:HK 2019-01-01 2019-09-30 0000912061 country:TW 2020-07-01 2020-09-30 0000912061 country:TW 2019-07-01 2019-09-30 0000912061 country:TW 2020-01-01 2020-09-30 0000912061 country:TW 2019-01-01 2019-09-30 0000912061 country:KR 2020-07-01 2020-09-30 0000912061 country:KR 2019-07-01 2019-09-30 0000912061 country:KR 2020-01-01 2020-09-30 0000912061 country:KR 2019-01-01 2019-09-30 0000912061 srt:EuropeMember 2020-07-01 2020-09-30 0000912061 srt:EuropeMember 2019-07-01 2019-09-30 0000912061 srt:EuropeMember 2020-01-01 2020-09-30 0000912061 srt:EuropeMember 2019-01-01 2019-09-30 0000912061 nhtc:OtherForeignCountriesMember 2020-07-01 2020-09-30 0000912061 nhtc:OtherForeignCountriesMember 2019-07-01 2019-09-30 0000912061 nhtc:OtherForeignCountriesMember 2020-01-01 2020-09-30 0000912061 nhtc:OtherForeignCountriesMember 2019-01-01 2019-09-30 0000912061 us-gaap:SubsequentEventMember 2020-11-02 2020-11-02 shares thunderdome:item iso4217:USD iso4217:USD shares iso4217:CNY utr:D utr:Y pure utr:acre utr:sqft 0000912061 Natural Health Trends Corp. false --12-31 Q3 2020 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 50000000 50000000 12979414 12979414 1556875 1556875 0.20 0.20 0.20 0.24 P14D P1Y 0 0 0 0 0 0 P5Y 0 P5Y P1Y 1 10-Q true 2020-09-30 false 001-36849 DE 59-2705336 Units 1205-07, 12F Mira Place Tower A 132 Nathan Road Kowloon HK 852 3107-0800 Common Stock, par value $0.001 per share NHTC NASDAQ Yes Yes Non-accelerated Filer true false false 11422539 90789000 96035000 4259000 6404000 4972000 5936000 100020000 108375000 581000 735000 4200000 3135000 517000 3390000 1069000 2039000 701000 823000 107088000 118497000 887000 680000 3046000 2931000 1786000 2387000 3477000 4506000 9831000 12938000 1217000 1655000 1067000 1205000 21311000 26302000 13748000 15365000 203000 202000 3150000 1564000 38412000 43433000 0 0 13000 13000 86102000 86102000 9358000 16117000 -893000 -1264000 25904000 25904000 68676000 75064000 107088000 118497000 14124000 17023000 45476000 59779000 3635000 4371000 12966000 15002000 10489000 12652000 32510000 44777000 5620000 7362000 19336000 28258000 4201000 6354000 13771000 20296000 9821000 13716000 33107000 48554000 668000 -1064000 -597000 -3777000 385000 323000 603000 1128000 1053000 -741000 6000 -2649000 418000 502000 -90000 120000 635000 -1243000 96000 -2769000 0.06 -0.12 0.01 -0.25 0.06 -0.12 0.01 -0.25 10678000 10623000 10581000 11010000 11424000 10623000 11424000 11010000 635000 -1243000 96000 -2769000 493000 -584000 355000 -537000 -2000 12000 16000 23000 1126000 -1815000 467000 -3283000 0 0 12979414 13000 86102000 16117000 -1264000 -1556875 -25904000 75064000 0 0 0 -573000 0 0 -573000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 -222000 0 -222000 0 0 0 0 -87000 0 -87000 0 0 12979414 13000 86102000 13259000 -1573000 -1556875 -25904000 71897000 0 0 0 34000 0 0 34000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 84000 0 84000 0 0 0 0 105000 0 105000 0 0 12979414 13000 86102000 11008000 -1384000 -1556875 -25904000 69835000 0 0 0 635000 0 0 635000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 493000 0 493000 0 0 0 0 -2000 0 -2000 0 0 12979414 13000 86102000 9358000 -893000 -1556875 -25904000 68676000 0 0 12979414 13000 86415000 44431000 -1250000 -1603322 -39748000 89861000 0 0 0 -1923000 0 0 -1923000 0 0 0 0 166000 0 0 22603 543000 377000 -0 -0 -0 2736000 -0 -0 2736000 0 0 0 0 259000 0 259000 0 0 0 0 17000 0 17000 0 0 12979414 13000 86249000 39772000 -974000 -1580719 -39205000 85855000 0 0 0 397000 0 0 397000 -0 -0 -0 -0 -0 -0 -0 612729 6682000 6682000 0 0 0 0 -212000 0 -212000 0 0 0 0 -6000 0 -6000 0 0 12979414 13000 86249000 40169000 -1192000 -2193448 -45887000 79352000 0 0 0 -1243000 0 0 -1243000 -0 -0 -0 -0 -0 -0 -0 383127 2882000 2882000 0 0 0 0 147000 -15359000 0 1117485 23418000 7912000 0 0 0 0 -584000 0 -584000 0 0 0 0 12000 0 12000 0 0 12979414 13000 86102000 23567000 -1764000 -1459090 -25351000 82567000 96000 -2769000 301000 290000 1199000 1336000 979000 -3000 -2193000 -4104000 -923000 1674000 -120000 -2000 206000 -1002000 136000 -8683000 -598000 -1779000 -1045000 -3485000 -3163000 -1508000 -1120000 -1392000 -1617000 -1617000 -140000 -235000 0 -333000 -1530000 -18748000 147000 181000 -147000 -181000 -0 9564000 6855000 2736000 -6855000 -12300000 413000 -428000 -8119000 -31657000 99425000 135651000 91306000 103994000 0 8289000 2724000 5058000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Nature of Operations</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Natural Health Trends Corp., a Delaware corporation (whether or <em style="font: inherit;">not</em> including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Basis of Presentation</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form <em style="font: inherit;">10</em>-Q and Rule <em style="font: inherit;">10</em>-<em style="font: inherit;">01</em> of Regulation S-<em style="font: inherit;">X.</em> As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are <em style="font: inherit;">not</em> necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s <em style="font: inherit;">2019</em> Annual Report on Form <em style="font: inherit;">10</em>-K filed with the United States Securities and Exchange Commission (SEC) on <em style="font: inherit;"> March 9, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Cash</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27.35pt;">In <em style="font: inherit;"> June 2015, </em>the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at <em style="font: inherit;"> December 31, 2019</em>) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in <em style="font: inherit;"> March 2020 </em>in connection with the withdrawal of its application.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income (Loss) Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">Diluted net income (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27.35pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27.35pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were <em style="font: inherit;">not</em> included for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2019, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>. The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">13,</em> <i>Fair Value Measurement</i> <i>(Topic <em style="font: inherit;">820</em>): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.</i> This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU is effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>and early adoption is permitted. The adoption of this standard did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes</i> <i>(Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes.</i> This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2020, </em>and early adoption is permitted. The Company elected to early adopt the new standard during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> Such adoption did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statement.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Basis of Presentation</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form <em style="font: inherit;">10</em>-Q and Rule <em style="font: inherit;">10</em>-<em style="font: inherit;">01</em> of Regulation S-<em style="font: inherit;">X.</em> As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are <em style="font: inherit;">not</em> necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s <em style="font: inherit;">2019</em> Annual Report on Form <em style="font: inherit;">10</em>-K filed with the United States Securities and Exchange Commission (SEC) on <em style="font: inherit;"> March 9, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Cash</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27.35pt;">In <em style="font: inherit;"> June 2015, </em>the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at <em style="font: inherit;"> December 31, 2019</em>) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in <em style="font: inherit;"> March 2020 </em>in connection with the withdrawal of its application.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 20000000 2900000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income (Loss) Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">Diluted net income (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27.35pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27.35pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were <em style="font: inherit;">not</em> included for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2019, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,623</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,769</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 635000 10678000 0.06 -1243000 10623000 -0.12 746000 0 635000 11424000 0.06 -1243000 10623000 -0.12 96000 10581000 0.01 -2769000 11010000 -0.25 843000 0 96000 11424000 0.01 -2769000 11010000 -0.25 672231 263289 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>. The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">13,</em> <i>Fair Value Measurement</i> <i>(Topic <em style="font: inherit;">820</em>): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.</i> This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU is effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>and early adoption is permitted. The adoption of this standard did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes</i> <i>(Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes.</i> This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2020, </em>and early adoption is permitted. The Company elected to early adopt the new standard during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> Such adoption did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statement.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> REVENUE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do <em style="font: inherit;">not</em> contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from <span style="-sec-ix-hidden:c66149967">14</span> days to <span style="-sec-ix-hidden:c66149968">one</span> year, and their historical return rates, which range from 1% to 10% of sales.  Sales returns were 1% and 2% of sales for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2019</em>, respectively.  <em style="font: inherit;">No</em> material changes in estimates have been recognized during the periods presented. See Note <em style="font: inherit;">3</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Deferred Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from <em style="font: inherit;"> June 30, 2020 </em>to <em style="font: inherit;"> September 30, 2020</em> is primarily due to an increase of $812,000 in the value of unshipped product orders and unredeemed vouchers. See Note <em style="font: inherit;">3</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Disaggregation of Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a <em style="font: inherit;">third</em>-party service provider. See Note <em style="font: inherit;">10</em> for revenue by market information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s net sales by product and service are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,732</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,355</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,316</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">During <em style="font: inherit;"> June 2020, </em>the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Concentration</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">No single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total net sales. Sales are made to the Company’s members and no single customer accounted for <em style="font: inherit;">10%</em> or more of net sales for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020</em> and <em style="font: inherit;">2019</em>. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Arrangements with Multiple Performance Obligations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s contracts with customers <em style="font: inherit;"> may </em>include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Practical Expedients</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company generally expenses sales commissions when incurred because the amortization period would have been <em style="font: inherit;">one</em> year or less. These costs are recorded in commissions expense.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company does <em style="font: inherit;">not</em> provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.01 0.10 0.01 0.02 812000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,732</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,355</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,316</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,713</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12023000 15732000 41234000 56355000 2316000 1468000 4854000 4713000 215000 177000 612000 1289000 14124000 17023000 45476000 59779000 0 0 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em> BALANCE SHEET COMPONENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of certain balance sheet amounts are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">September 30, 2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">December 31, 2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,720</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">82,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,789</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,035</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">91,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99,425</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,844</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,142</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">836</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reserve for obsolescence</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(421</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,259</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,404</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sales returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employee-related expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">941</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,258</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warehousing, inventory-related and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">638</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,786</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unshipped product and unredeemed product vouchers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Auto ship advances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,985</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">131</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,477</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,506</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">September 30, 2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">December 31, 2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,408</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,720</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">82,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90,789</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,035</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">517</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">91,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99,425</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,844</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,142</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">836</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reserve for obsolescence</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(421</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,259</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,404</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sales returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">207</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employee-related expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">941</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,258</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warehousing, inventory-related and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">638</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,786</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unshipped product and unredeemed product vouchers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,397</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Auto ship advances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,985</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">131</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,477</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,506</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 22408000 13720000 68381000 82315000 90789000 96035000 517000 3390000 91306000 99425000 3844000 6142000 836000 1249000 421000 987000 4259000 6404000 207000 373000 941000 1258000 638000 756000 1786000 2387000 1397000 2390000 1971000 1985000 109000 131000 3477000 4506000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em> FAIR VALUE MEASUREMENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As of <em style="font: inherit;"> September 30, 2020</em>, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> September 30, 2020</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">September 30, 2020</em></em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2019</em></em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%; border-bottom: thin solid rgb(0, 0, 0);">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Gross Unrealized Losses</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Gross Unrealized Losses</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td> <td style="width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Municipal debt securities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,732</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,730</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,383</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <hr/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup><sup style="vertical-align:top;line-height:120%;font-size:pt"><i> </i></sup><i>FASB Topic <em style="font: inherit;">820,</em> Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">1:</em> Quoted market prices in active markets for identical assets or liabilities.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">2:</em> Observable market-based inputs or unobservable inputs that are corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">3:</em> Unobservable inputs that are <em style="font: inherit;">not</em> corroborated by market data.</i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">September 30, 2020</em></em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2019</em></em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%; border-bottom: thin solid rgb(0, 0, 0);">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Gross Unrealized Losses</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Gross Unrealized Losses</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td> <td style="width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Municipal debt securities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level <sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,732</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,730</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,784</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,383</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,381</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,334</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 56547000 -0 56547000 11659000 -0 11659000 5000000 -0 5000000 13544000 -0 13544000 2104000 -0 2104000 347000 -0 347000 4732000 2000 4730000 56784000 19000 56765000 68383000 2000 68381000 82334000 19000 82315000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5</em></b><b>. LEASES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company leases 9,600 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In <em style="font: inherit;"> June 2020, </em>the Company extended the Rolling Hills Estates office lease for an additional <span style="-sec-ix-hidden:c66150132">five</span> years with a term now expiring in <em style="font: inherit;"> September 2030.  </em>Effective <em style="font: inherit;"> July 1, 2020, </em>the Company modified the terms of its largest Hong Kong office lease resulting in 10% monthly lease cost savings and a lease extension through <em style="font: inherit;"> June 2023.  </em>To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in <em style="font: inherit;"> November 2025, </em><em style="font: inherit;"> February 2021, </em>and <em style="font: inherit;"> November 2022, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with <em style="font: inherit;">third</em> parties for fulfillment and distribution operations in all of its international markets. <em style="font: inherit;">None</em> of the Company’s <em style="font: inherit;">third</em> party logistics contracts contain a lease as the Company does <em style="font: inherit;">not</em> have the right to access the warehouses or move its inventories at will.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of lease cost for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020</em> and <em style="font: inherit;">2019</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">377</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">512</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,292</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">201</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">449</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">585</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,529</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,745</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Cash paid for amounts included in the measurement of operating leases liabilities was $342,000 and $459,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2020</em> and <em style="font: inherit;">2019</em>, respectively, and $1.2 million and $1.5 million for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020</em> and <em style="font: inherit;">2019</em>, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The weighted-average remaining lease term and discount rate related to operating leases as of <em style="font: inherit;"> September 30, 2020</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As most of our leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The annual scheduled lease payments of our operating lease liabilities as of <em style="font: inherit;"> September 30, 2020</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Remainder of 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,245</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,807</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(440</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,367</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For all asset classes, the Company elected <em style="font: inherit;">not</em> to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of <em style="font: inherit;">12</em> months or less. Additionally, for all asset classes, the Company choose <em style="font: inherit;">not</em> to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.</p> 9600 4900 0.10 1600 2000 8 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">377</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">512</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,292</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">201</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">449</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">585</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,529</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,745</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody> </table> 377000 512000 1292000 1544000 72000 73000 237000 201000 449000 585000 1529000 1745000 342000 459000 1200000 1500000 P5Y6M 0.035 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Remainder of 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,245</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,095</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">582</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,807</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(440</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,367</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 373000 1245000 1095000 582000 261000 1251000 4807000 440000 4367000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6</em></b><b>. INCOME TAXES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">The effective income tax rate for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020</em> includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on <em style="font: inherit;"> March 27, 2020. </em>The CARES Act makes broad changes to the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended, including, but <em style="font: inherit;">not</em> limited to, the ability to carry net operating losses generated in tax years <em style="font: inherit;">2018</em>, <em style="font: inherit;">2019</em> or <em style="font: inherit;">2020</em> back to the each of the <em style="font: inherit;">five</em> tax years preceding the tax year of such loss.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">As of <em style="font: inherit;"> September 30, 2020</em>, the Company does <span style="-sec-ix-hidden:c66150199">not</span> have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than <em style="font: inherit;">not</em> to realize the tax benefits of their deferred assets. As of <em style="font: inherit;"> September 30, 2020</em>, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than <em style="font: inherit;">not</em> that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">As of <em style="font: inherit;"> September 30, 2020</em>, the Company <em style="font: inherit;">no</em> longer has U.S. federal net operating losses due to its filing in <em style="font: inherit;"> August 2020 </em>to carry back $3.6 million of losses generated in the tax year ended <em style="font: inherit;"> December 31, 2019 </em>to offset taxable income from the tax year ended <em style="font: inherit;"> December 31, 2016. </em>The Company has U.S. state net operating loss carryforwards of $2.4 million that begin expiring in <em style="font: inherit;">2040.</em> At <em style="font: inherit;"> September 30, 2020</em>, the Company has foreign net operating loss carryforwards of approximately $2.9 million in various jurisdictions with various expirations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is <em style="font: inherit;">no</em> longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are <em style="font: inherit;">not</em> deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of <em style="font: inherit;"> September 30, 2020</em>, the Company has <em style="font: inherit;">not</em> recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of <em style="font: inherit;"> September 30, 2020</em> have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in <em style="font: inherit;">2017,</em> repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to <em style="font: inherit;">no</em> impact on federal tax expense. All undistributed earnings in excess of <em style="font: inherit;">50%</em> of current earnings on an annual basis are intended to be reinvested indefinitely as of <em style="font: inherit;"> September 30, 2020</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2018,</em> the Company was notified that it was selected for audit of the <em style="font: inherit;">2016</em> tax year by the U.S. Internal Revenue Service. The audit was expanded to also include the <em style="font: inherit;">2017</em> and <em style="font: inherit;">2018</em> tax years. For purposes of this audit, fiscal years since <em style="font: inherit;">2007</em> are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. <em style="font: inherit;">No</em> adjustments have been proposed at this time. The Company is <em style="font: inherit;">no</em> longer subject to state income tax examinations for years prior to <em style="font: inherit;">2015.</em></p> 3600000 2400000 2900000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7</em></b><b>. COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> January 8, 2019, </em>the Company and its <em style="font: inherit;">two</em> executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned <i>Kauffman v. Natural Health Trends Corp.</i>, Case <em style="font: inherit;">No.</em> <em style="font: inherit;">2:19</em>-cv-<em style="font: inherit;">00163.</em> On <em style="font: inherit;"> May 3, 2019, </em>the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On <em style="font: inherit;"> June 3, 2019, </em>lead plaintiff filed an amended complaint. On <em style="font: inherit;"> January 17, 2020, </em>after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On <em style="font: inherit;"> February 14, 2020, </em>plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On <em style="font: inherit;"> April 9, 2020, </em>plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">8.</em> STOCKHOLDERS’ EQUITY</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Dividends</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;">The following table summarizes the Company’s cash dividend activity for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020</em> (in thousands, except per share data):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Declaration Date</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 14px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 223px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 22.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Record Date</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Payment Date</em></p> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">February 10, 2020</p> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">February 25, 2020</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 6, 2020</em></p> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">May 4, 2020</p> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">May 19, 2020</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">May 29, 2020</em></p> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">August 3, 2020</td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">August 18, 2020</em></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 581px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">August 28, 2020</em></td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,855</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 581px;"><em style="font: inherit;"> </em></td> </tr> </tbody> </table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Stock Repurchases</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> January 12, 2016, </em>the Board of Directors authorized an increase to the Company’s stock repurchase program <em style="font: inherit;">first</em> approved on <em style="font: inherit;"> July 28, 2015 </em>from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company <em style="font: inherit;"> may </em>enter into <em style="font: inherit;">one</em> or more plans that are compliant with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does <em style="font: inherit;">not</em> require the Company to acquire a specific number of shares, and <em style="font: inherit;"> may </em>be suspended from time to time or discontinued.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> May 16, 2019, </em>the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady <em style="font: inherit;">2012</em> Irrevocable Trust (the "Broady Trust") on a basis roughly proportional to his family’s ownership interest (see Note <em style="font: inherit;">9</em>). During <em style="font: inherit;"> May 2019, </em>the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> of the Exchange Act. The open market repurchases were completed on <em style="font: inherit;"> May 31, 2019. </em>The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> August 6, 2019, </em>the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During <em style="font: inherit;"> August </em>and <em style="font: inherit;"> September 2019, </em>the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As of <em style="font: inherit;"> September 30, 2020</em>, $21.9 million of the <em style="font: inherit;">$70.0</em> million stock repurchase program approved on <em style="font: inherit;"> July 28, 2015 </em>and increased on <em style="font: inherit;"> January 12, 2016 </em>remained available for future purchases, inclusive of related estimated income tax.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Stock</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">At the Company’s annual meeting of stockholders held on <em style="font: inherit;"> April 7, 2016, </em>the Company’s stockholders approved the Natural Health Trends Corp. <em style="font: inherit;">2016</em> Equity Incentive Plan (the <em style="font: inherit;">“2016</em> Plan”) to replace its <em style="font: inherit;">2007</em> Equity Incentive Plan. The <em style="font: inherit;">2016</em> Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) <em style="font: inherit;"> may </em>be issued pursuant to awards granted. At <em style="font: inherit;"> September 30, 2020</em>, 1,219,583 shares remained available for issuance under the <em style="font: inherit;">2016</em> Plan.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The following table summarizes the Company’s restricted stock activity under the <em style="font: inherit;">2016</em> Plan:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(293,583</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.53</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at September 30, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">664,099</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.25</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Accumulated Other Comprehensive Loss</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The changes in accumulated other comprehensive loss by component for the <em style="font: inherit;">nine</em> months of <em style="font: inherit;">2020</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Foreign Currency Translation Adjustment</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2019</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,245</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">Other comprehensive income</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">355</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">371</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">Balance, September 30, 2020</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(890</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Declaration Date</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 14px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 223px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 22.6%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Record Date</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Payment Date</em></p> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">February 10, 2020</p> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">February 25, 2020</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 6, 2020</em></p> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">May 4, 2020</p> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">May 19, 2020</em></p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 13px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 581px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">May 29, 2020</em></p> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">August 3, 2020</td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">0.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,285</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">August 18, 2020</em></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 581px; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><em style="font: inherit;">August 28, 2020</em></td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 202.594px;"> </td> <td style="width: 14px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,855</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 13px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 581px;"><em style="font: inherit;"> </em></td> </tr> </tbody> </table> 0.20 2285000 0.20 2285000 0.20 2285000 0.60 6855000 15000000.0 70000000.0 8000000.0 0.05 4700000 612729 6700000 383127 2900000 21900000 2500000 1219583 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(293,583</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.53</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at September 30, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">664,099</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.25</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 957682 7.34 293583 7.53 664099 7.25 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Foreign Currency Translation Adjustment</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2019</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,245</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,264</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">Other comprehensive income</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">355</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">371</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">Balance, September 30, 2020</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(890</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">(893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">)</td> </tr> </tbody> </table> -1245000 -19000 -1264000 355000 16000 371000 -890000 -3000 -893000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em> RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. Such royalties were $14,000 and $19,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2020</em> and <em style="font: inherit;">2019</em>, respectively, and $64,000 and $75,000 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2019</em>, respectively. The Company is <em style="font: inherit;">not</em> required to purchase any product under the agreement, and the agreement <em style="font: inherit;"> may </em>be terminated under certain circumstances with <em style="font: inherit;">no</em> notice. An amendment to the agreement effective <em style="font: inherit;"> March 20, 2020 </em>extends the term of the agreement for an additional <span style="-sec-ix-hidden:c66150315">five</span> years to <em style="font: inherit;"> March 31, 2025, </em>after which it shall be automatically renewed for successive <span style="-sec-ix-hidden:c66150316">one</span>-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2019. </em>Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated <em style="font: inherit;">third</em> party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section <em style="font: inherit;">402</em> of the Sarbanes-Oxley Act of <em style="font: inherit;">2002.</em> The Company, through advice from its legal counsel, concluded that there is <em style="font: inherit;">not</em> a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section <em style="font: inherit;">402.</em> This relationship between the Company and Aberdeen ceased following the completion of this transaction.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> May 17, 2019, </em>the Company entered into a Stock Repurchase Agreement with The George K. Broady <em style="font: inherit;">2012</em> Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> under the Securities Exchange Act of <em style="font: inherit;">1934,</em> provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on <em style="font: inherit;"> May 16, 2019. </em>The Company’s purchases from the Broady Trust concluded on <em style="font: inherit;"> May 31, 2019, </em>were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note <em style="font: inherit;">8.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.05 14000 19000 64000 75000 P90D 1 7100 0.40 0.40 0.20 420 0.4105 178324 1900000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em>    SEGMENT INFORMATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a <em style="font: inherit;">third</em>-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a <span style="-sec-ix-hidden:c66150347">single</span> reporting segment (the “Primary Reporting Segment”).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and <em style="font: inherit;">not</em> by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are <em style="font: inherit;">not</em> presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s operating information by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-indent: 9pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,974</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total income from operations for reportable segments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unallocated corporate expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">323</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">603</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s net sales by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">808</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">357</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,575</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,238</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">Taiwan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">South Korea</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 0pt auto 0pt 0pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup> <i>Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item <em style="font: inherit;">1A.</em> Risk Factors” in this report and in our most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0px; margin: 0px; text-indent: 9pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,974</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total income from operations for reportable segments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,790</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,097</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,065</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unallocated corporate expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">323</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">603</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 13294000 16254000 42718000 56979000 640000 525000 2156000 2138000 190000 244000 602000 662000 14124000 17023000 45476000 59779000 2715000 2974000 6038000 7506000 134000 -795000 64000 -1530000 -59000 -82000 -37000 -138000 2790000 2097000 6065000 5838000 -2122000 -3161000 -6662000 -9615000 385000 323000 603000 1128000 1053000 -741000 6000 -2649000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,607</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">808</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">357</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">581</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">954</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,575</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,238</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,465</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">640</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">Taiwan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0">2,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">South Korea</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">220</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">747</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,023</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 338000 551000 1202000 1607000 132000 313000 536000 808000 357000 581000 954000 1938000 11132000 13575000 36238000 48465000 640000 525000 2156000 2138000 771000 649000 2261000 2340000 52000 98000 220000 288000 190000 244000 602000 662000 259000 343000 747000 1017000 253000 144000 560000 516000 14124000 17023000 45476000 59779000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">11.</em> SUBSEQUENT EVENT</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> November 2, 2020, </em>the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on <em style="font: inherit;"> November 27, 2020 </em>to stockholders of record on <em style="font: inherit;"> November 17, 2020. </em>The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> 0.20 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See "Item 1A. Risk Factors" in this report and in our most recent Annual Report on Form 10-K. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2020
Oct. 30, 2020
Document Information [Line Items]    
Entity Central Index Key 0000912061  
Entity Registrant Name Natural Health Trends Corp.  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-36849  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 59-2705336  
Entity Address, Address Line One Units 1205-07, 12F Mira Place Tower A 132 Nathan Road  
Entity Address, City or Town Kowloon  
Entity Address, Country HK  
City Area Code 852  
Local Phone Number 3107-0800  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol NHTC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   11,422,539
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 90,789 $ 96,035
Inventories 4,259 6,404
Other current assets 4,972 5,936
Total current assets 100,020 108,375
Property and equipment, net 581 735
Operating lease right-of-use assets 4,200 3,135
Restricted cash 517 3,390
Deferred tax asset 1,069 2,039
Other assets 701 823
Total assets 107,088 118,497
Current liabilities:    
Accounts payable 887 680
Accrued commissions 3,046 2,931
Other accrued expenses 1,786 2,387
Deferred revenue 3,477 4,506
Amounts held in eWallets 9,831 12,938
Operating lease liabilities 1,217 1,655
Other current liabilities 1,067 1,205
Total current liabilities 21,311 26,302
Income taxes payable 13,748 15,365
Deferred tax liability 203 202
Operating lease liabilities 3,150 1,564
Total liabilities 38,412 43,433
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2020 and December 31, 2019 13 13
Additional paid-in capital 86,102 86,102
Retained earnings 9,358 16,117
Accumulated other comprehensive loss (893) (1,264)
Treasury stock, at cost; 1,556,875 shares at September 30, 2020 and December 31, 2019 (25,904) (25,904)
Total stockholders’ equity 68,676 75,064
Total liabilities and stockholders’ equity $ 107,088 $ 118,497
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 50,000,000 50,000,000
Common stock, issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,556,875 1,556,875
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net sales $ 14,124 $ 17,023 $ 45,476 $ 59,779
Cost of sales 3,635 4,371 12,966 15,002
Gross profit 10,489 12,652 32,510 44,777
Operating expenses:        
Commissions expense 5,620 7,362 19,336 28,258
Selling, general and administrative expenses 4,201 6,354 13,771 20,296
Total operating expenses 9,821 13,716 33,107 48,554
Income (loss) from operations 668 (1,064) (597) (3,777)
Other income, net 385 323 603 1,128
Income (loss) before income taxes 1,053 (741) 6 (2,649)
Income tax provision (benefit) 418 502 (90) 120
Net income (loss) $ 635 $ (1,243) $ 96 $ (2,769)
Net income (loss) per common share:        
Basic (in dollars per share) $ 0.06 $ (0.12) $ 0.01 $ (0.25)
Diluted (in dollars per share) $ 0.06 $ (0.12) $ 0.01 $ (0.25)
Weighted-average common shares outstanding:        
Basic (in shares) 10,678 10,623 10,581 11,010
Diluted (in shares) 11,424 10,623 11,424 11,010
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net income (loss) $ 635 $ (1,243) $ 96 $ (2,769)
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment 493 (584) 355 (537)
Unrealized gains (losses) on available-for-sale securities (2) 12 16 23
Comprehensive income (loss) $ 1,126 $ (1,815) $ 467 $ (3,283)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
BALANCE (in shares) at Dec. 31, 2018 0 12,979,414       (1,603,322)  
Balance, December 31, 2019 at Dec. 31, 2018 $ 0 $ 13 $ 86,415 $ 44,431 $ (1,250) $ (39,748) $ 89,861
Net income (loss) 0 0 0 (1,923) 0 0 (1,923)
Dividends declared 0 0 0 (2,736) 0 0 (2,736)
Foreign currency translation adjustment 0 0 0 0 259 0 259
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 17 $ 0 17
Common stock issued (in shares) 0 0       22,603  
Common stock issued $ 0 $ 0   0 0 $ 543 377
Common stock issued     (166)        
BALANCE (in shares) at Mar. 31, 2019 0 12,979,414       (1,580,719)  
Balance, September 30, 2020 at Mar. 31, 2019 $ 0 $ 13 86,249 39,772 (974) $ (39,205) 85,855
BALANCE (in shares) at Dec. 31, 2018 0 12,979,414       (1,603,322)  
Balance, December 31, 2019 at Dec. 31, 2018 $ 0 $ 13 86,415 44,431 (1,250) $ (39,748) 89,861
Net income (loss)             (2,769)
Foreign currency translation adjustment             (537)
Unrealized gains (losses) on available-for-sale securities             23
BALANCE (in shares) at Sep. 30, 2019 0 12,979,414       (1,459,090)  
Balance, September 30, 2020 at Sep. 30, 2019 $ 0 $ 13 86,102 23,567 (1,764) $ (25,351) 82,567
BALANCE (in shares) at Mar. 31, 2019 0 12,979,414       (1,580,719)  
Balance, December 31, 2019 at Mar. 31, 2019 $ 0 $ 13 86,249 39,772 (974) $ (39,205) 85,855
Net income (loss) 0 0 0 397 0 0 397
Foreign currency translation adjustment 0 0 0 0 (212) 0 (212)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (6) $ 0 (6)
Repurchase of common stock (in shares) 0 0       (612,729)  
Repurchase of common stock $ 0 $ 0 0 0 0 $ (6,682) (6,682)
BALANCE (in shares) at Jun. 30, 2019 0 12,979,414       (2,193,448)  
Balance, September 30, 2020 at Jun. 30, 2019 $ 0 $ 13 86,249 40,169 (1,192) $ (45,887) 79,352
Net income (loss) 0 0 0 (1,243) 0 0 (1,243)
Foreign currency translation adjustment 0 0 0 0 (584) 0 (584)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 12 $ 0 12
Common stock issued (in shares) 0 0       1,117,485  
Common stock issued $ 0 $ 0   (15,359) 0 $ 23,418 7,912
Common stock issued     (147)        
Repurchase of common stock (in shares) 0 0       (383,127)  
Repurchase of common stock $ 0 $ 0 0 0 0 $ (2,882) (2,882)
BALANCE (in shares) at Sep. 30, 2019 0 12,979,414       (1,459,090)  
Balance, September 30, 2020 at Sep. 30, 2019 $ 0 $ 13 86,102 23,567 (1,764) $ (25,351) 82,567
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance, December 31, 2019 at Dec. 31, 2019 $ 0 $ 13 86,102 16,117 (1,264) $ (25,904) 75,064
Net income (loss) 0 0 0 (573) 0 0 (573)
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustment 0 0 0 0 (222) 0 (222)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (87) $ 0 (87)
BALANCE (in shares) at Mar. 31, 2020 0 12,979,414       (1,556,875)  
Balance, September 30, 2020 at Mar. 31, 2020 $ 0 $ 13 86,102 13,259 (1,573) $ (25,904) 71,897
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance, December 31, 2019 at Dec. 31, 2019 $ 0 $ 13 86,102 16,117 (1,264) $ (25,904) 75,064
Net income (loss)             96
Foreign currency translation adjustment             355
Unrealized gains (losses) on available-for-sale securities             16
BALANCE (in shares) at Sep. 30, 2020 0 12,979,414       (1,556,875)  
Balance, September 30, 2020 at Sep. 30, 2020 $ 0 $ 13 86,102 9,358 (893) $ (25,904) 68,676
BALANCE (in shares) at Mar. 31, 2020 0 12,979,414       (1,556,875)  
Balance, December 31, 2019 at Mar. 31, 2020 $ 0 $ 13 86,102 13,259 (1,573) $ (25,904) 71,897
Net income (loss) 0 0 0 34 0 0 34
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustment 0 0 0 0 84 0 84
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 105 $ 0 105
BALANCE (in shares) at Jun. 30, 2020 0 12,979,414       (1,556,875)  
Balance, September 30, 2020 at Jun. 30, 2020 $ 0 $ 13 86,102 11,008 (1,384) $ (25,904) 69,835
Net income (loss) 0 0 0 635 0 0 635
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustment 0 0 0 0 493 0 493
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (2) $ 0 (2)
BALANCE (in shares) at Sep. 30, 2020 0 12,979,414       (1,556,875)  
Balance, September 30, 2020 at Sep. 30, 2020 $ 0 $ 13 $ 86,102 $ 9,358 $ (893) $ (25,904) $ 68,676
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Mar. 31, 2019
Dividends declared, per share (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.24
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 96 $ (2,769)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 301 290
Noncash lease expense 1,199 1,336
Deferred income taxes 979 (3)
Changes in assets and liabilities:    
Inventories 2,193 4,104
Other current assets 923 (1,674)
Other assets 120 2
Accounts payable 206 (1,002)
Accrued commissions 136 (8,683)
Other accrued expenses (598) (1,779)
Deferred revenue (1,045) (3,485)
Amounts held in eWallets (3,163) (1,508)
Operating lease liabilities (1,120) (1,392)
Income taxes payable (1,617) (1,617)
Other current liabilities (140) (235)
Long-term incentive 0 (333)
Net cash used in operating activities (1,530) (18,748)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (147) (181)
Net cash used in investing activities (147) (181)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repurchase of common stock 0 (9,564)
Dividends paid (6,855) (2,736)
Net cash used in financing activities (6,855) (12,300)
Effect of exchange rates on cash, cash equivalents and restricted cash 413 (428)
Net decrease in cash, cash equivalents and restricted cash (8,119) (31,657)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 99,425 135,651
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 91,306 103,994
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Issuance of treasury stock for employee awards, net 0 8,289
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,724 $ 5,058
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

 

Nature of Operations 

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2019 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 9, 2020.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in March 2020 in connection with the withdrawal of its application.

 

Net Income (Loss) Per Common Share

 

Diluted net income (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $635   10,678  $0.06  $(1,243)  10,623  $(0.12)

Effect of dilutive securities:

                        

Non-vested restricted stock

     746               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $635   11,424  $0.06  $(1,243)  10,623  $(0.12)

 

  

Nine Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $96   10,581  $0.01  $(2,769)  11,010  $(0.25)

Effect of dilutive securities:

                        

Non-vested restricted stock

     843               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $96   11,424  $0.01  $(2,769)  11,010  $(0.25)

 

In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were not included for the three and nine months ended September 30, 2019, respectively.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company’s consolidated financial statement.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 10% of sales.  Sales returns were 1% and 2% of sales for the nine months ended September 30, 2020 and 2019, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 3 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from June 30, 2020 to September 30, 2020 is primarily due to an increase of $812,000 in the value of unshipped product orders and unredeemed vouchers. See Note 3 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. See Note 10 for revenue by market information.

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Product sales

 $12,023  $15,732  $41,234  $56,355 

Administrative fees, freight and other

  2,316   1,468   4,854   4,713 

Less: sales returns

  (215)  (177)  (612)  (1,289)

Total net sales

 $14,124  $17,023  $45,476  $59,779 

 

During June 2020, the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue during the three months ended September 30, 2020.

 

Concentration

 

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2020 and 2019. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Balance Sheet Components
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

3. BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

   

September 30, 2020

   

December 31, 2019

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 22,408     $ 13,720  

Cash equivalents

    68,381       82,315  
      90,789       96,035  

Restricted cash

    517       3,390  
    $ 91,306     $ 99,425  

Inventories:

               

Finished goods

  $ 3,844     $ 6,142  

Raw materials

    836       1,249  

Reserve for obsolescence

    (421 )     (987 )
    $ 4,259     $ 6,404  

Other accrued expenses:

               

Sales returns

  $ 207     $ 373  

Employee-related expense

    941       1,258  

Warehousing, inventory-related and other

    638       756  
    $ 1,786     $ 2,387  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 1,397     $ 2,390  

Auto ship advances

    1,971       1,985  

Other

    109       131  
    $ 3,477     $ 4,506  

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Fair Value Measurements
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4. FAIR VALUE MEASUREMENTS

 

As of September 30, 2020, cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2020 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):

 

       

September 30, 2020

   

December 31, 2019

 
    Fair Value Level1  

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

   

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

 

Money market funds

 

Level 1

  $ 56,547     $     $ 56,547     $ 11,659     $     $ 11,659  

Time deposits

 

Level 2

    5,000             5,000       13,544             13,544  

Municipal debt securities

 

Level 2

    2,104             2,104       347             347  

Corporate debt securities

 

Level 2

    4,732       (2 )     4,730       56,784       (19 )     56,765  

Total investments

      $ 68,383     $ (2 )   $ 68,381     $ 82,334     $ (19 )   $ 82,315  

 


 

1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Leases
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

5. LEASES

 

The Company leases 9,600 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030.  Effective July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in 10% monthly lease cost savings and a lease extension through June 2023.  To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2021, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Operating leases

  $ 377     $ 512     $ 1,292     $ 1,544  

Short-term leases

    72       73       237       201  

Total lease cost

  $ 449     $ 585     $ 1,529     $ 1,745  

 

Cash paid for amounts included in the measurement of operating leases liabilities was $342,000 and $459,000 for the three months ended  September 30, 2020 and 2019, respectively, and $1.2 million and $1.5 million for the nine months ended  September 30, 2020 and 2019, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2020 were as follows:

 

Weighted-average remaining lease term (in years)

    5.5  

Weighted-average discount rate

    3.5 %

 

As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2020 were as follows (in thousands):

 

Remainder of 2020

  $ 373  

2021

    1,245  

2022

    1,095  

2023

    582  

2024

    261  

Thereafter

    1,251  

Total lease payments

  $ 4,807  

Less: imputed interest

    (440 )

Present value of lease liabilities

  $ 4,367  

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Income Taxes
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

6. INCOME TAXES

 

The effective income tax rate for the three and nine months ended September 30, 2020 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on March 27, 2020. The CARES Act makes broad changes to the Internal Revenue Code of 1986, as amended, including, but not limited to, the ability to carry net operating losses generated in tax years 2018, 2019 or 2020 back to the each of the five tax years preceding the tax year of such loss.

 

As of September 30, 2020, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2020, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of September 30, 2020, the Company no longer has U.S. federal net operating losses due to its filing in August 2020 to carry back $3.6 million of losses generated in the tax year ended December 31, 2019 to offset taxable income from the tax year ended December 31, 2016. The Company has U.S. state net operating loss carryforwards of $2.4 million that begin expiring in 2040. At September 30, 2020, the Company has foreign net operating loss carryforwards of approximately $2.9 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of September 30, 2020, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of September 30, 2020 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2020.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. The audit was expanded to also include the 2017 and 2018 tax years. For purposes of this audit, fiscal years since 2007 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2015.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Commitments and Contingencies
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

7. COMMITMENTS AND CONTINGENCIES

 

On January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. On May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On June 3, 2019, lead plaintiff filed an amended complaint. On January 17, 2020, after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On February 14, 2020, plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On April 9, 2020, plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.

 

The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

8. STOCKHOLDERS’ EQUITY

 

Dividends

 

The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2020 (in thousands, except per share data):

 

Declaration Date

 

Per Share

   

Amount

 

Record Date

 

Payment Date

February 10, 2020

  $ 0.20     $ 2,285  

February 25, 2020

 

March 6, 2020

May 4, 2020

    0.20       2,285  

May 19, 2020

 

May 29, 2020

August 3, 2020     0.20       2,285   August 18, 2020   August 28, 2020
    $ 0.60     $ 6,855        

 

The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

 

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady 2012 Irrevocable Trust (the "Broady Trust") on a basis roughly proportional to his family’s ownership interest (see Note 9). During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. The open market repurchases were completed on May 31, 2019. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

 

On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs.

 

As of September 30, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2020, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

   

Shares

    Wtd. Avg. Price at Date of Issuance  

Nonvested at December 31, 2019

    957,682     $ 7.34  

Vested

    (293,583 )   $ 7.53  

Nonvested at September 30, 2020

    664,099     $ 7.25  

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for the nine months of 2020 were as follows (in thousands):

 

    Foreign Currency Translation Adjustment     Unrealized Gains (Losses) on Available-For-Sale Investments    

Total

 

Balance, December 31, 2019

  $ (1,245 )   $ (19 )   $ (1,264 )
Other comprehensive income     355       16       371  
Balance, September 30, 2020   $ (890 )   $ (3 )   $ (893 )
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Related Party Transactions
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

9. RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. Such royalties were $14,000 and $19,000 for the three months ended September 30, 2020 and 2019, respectively, and $64,000 and $75,000 for the nine months ended September 30, 2020 and 2019, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. An amendment to the agreement effective March 20, 2020 extends the term of the agreement for an additional five years to March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the three months ended March 31, 2019. Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

 

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in conjunction with the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note 8.

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

10.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales:

                

Primary Reporting Segment

 $13,294  $16,254  $42,718  $56,979 
China  640   525   2,156   2,138 

Russia and Kazakhstan

  190   244   602   662 

Total net sales

 $14,124  $17,023  $45,476  $59,779 
                 

Income (loss) from operations:

                

Primary Reporting Segment

 $2,715  $2,974  $6,038  $7,506 

China

  134   (795)  64   (1,530)

Russia and Kazakhstan

  (59)  (82)  (37)  (138)

Total income from operations for reportable segments

  2,790   2,097   6,065   5,838 

Unallocated corporate expenses

  (2,122)  (3,161)  (6,662)  (9,615)

Other income, net

  385   323   603   1,128 

Income (loss) before income taxes

 $1,053  $(741) $6  $(2,649)

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales from external customers:

                

United States

 $338  $551  $1,202  $1,607 

Canada

  132   313   536   808 

Peru

  357   581   954   1,938 

Hong Kong1

  11,132   13,575   36,238   48,465 

China

  640   525   2,156   2,138 
Taiwan  771   649   2,261   2,340 

South Korea

  52   98   220   288 

Russia and Kazakhstan

  190   244   602   662 

Europe

  259   343   747   1,017 

Other foreign countries

  253   144   560   516 

Total net sales

 $14,124  $17,023  $45,476  $59,779 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Subsequent Events
9 Months Ended
Sep. 30, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]

11. SUBSEQUENT EVENT

 

On November 2, 2020, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 27, 2020 to stockholders of record on November 17, 2020. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2019 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 9, 2020.

 

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in March 2020 in connection with the withdrawal of its application.

 

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) Per Common Share

 

Diluted net income (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following tables illustrate the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $635   10,678  $0.06  $(1,243)  10,623  $(0.12)

Effect of dilutive securities:

                        

Non-vested restricted stock

     746               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $635   11,424  $0.06  $(1,243)  10,623  $(0.12)

 

  

Nine Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $96   10,581  $0.01  $(2,769)  11,010  $(0.25)

Effect of dilutive securities:

                        

Non-vested restricted stock

     843               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $96   11,424  $0.01  $(2,769)  11,010  $(0.25)

 

In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 672,231 and 263,289 shares were not included for the three and nine months ended September 30, 2019, respectively.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company’s consolidated financial statement.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Three Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $635   10,678  $0.06  $(1,243)  10,623  $(0.12)

Effect of dilutive securities:

                        

Non-vested restricted stock

     746               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $635   11,424  $0.06  $(1,243)  10,623  $(0.12)
  

Nine Months Ended September 30,

 
  

2020

  

2019

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Loss (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $96   10,581  $0.01  $(2,769)  11,010  $(0.25)

Effect of dilutive securities:

                        

Non-vested restricted stock

     843               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $96   11,424  $0.01  $(2,769)  11,010  $(0.25)
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Revenue from External Customers by Products and Services [Table Text Block]
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Product sales

 $12,023  $15,732  $41,234  $56,355 

Administrative fees, freight and other

  2,316   1,468   4,854   4,713 

Less: sales returns

  (215)  (177)  (612)  (1,289)

Total net sales

 $14,124  $17,023  $45,476  $59,779 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Schedule of Additional Balance Sheet Components [Table Text Block]
   

September 30, 2020

   

December 31, 2019

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 22,408     $ 13,720  

Cash equivalents

    68,381       82,315  
      90,789       96,035  

Restricted cash

    517       3,390  
    $ 91,306     $ 99,425  

Inventories:

               

Finished goods

  $ 3,844     $ 6,142  

Raw materials

    836       1,249  

Reserve for obsolescence

    (421 )     (987 )
    $ 4,259     $ 6,404  

Other accrued expenses:

               

Sales returns

  $ 207     $ 373  

Employee-related expense

    941       1,258  

Warehousing, inventory-related and other

    638       756  
    $ 1,786     $ 2,387  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 1,397     $ 2,390  

Auto ship advances

    1,971       1,985  

Other

    109       131  
    $ 3,477     $ 4,506  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Available-for-sale Securities [Table Text Block]
       

September 30, 2020

   

December 31, 2019

 
    Fair Value Level1  

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

   

Adjusted Cost

    Gross Unrealized Losses    

Fair Value

 

Money market funds

 

Level 1

  $ 56,547     $     $ 56,547     $ 11,659     $     $ 11,659  

Time deposits

 

Level 2

    5,000             5,000       13,544             13,544  

Municipal debt securities

 

Level 2

    2,104             2,104       347             347  

Corporate debt securities

 

Level 2

    4,732       (2 )     4,730       56,784       (19 )     56,765  

Total investments

      $ 68,383     $ (2 )   $ 68,381     $ 82,334     $ (19 )   $ 82,315  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Leases (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Lease, Cost [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Operating leases

  $ 377     $ 512     $ 1,292     $ 1,544  

Short-term leases

    72       73       237       201  

Total lease cost

  $ 449     $ 585     $ 1,529     $ 1,745  

Weighted-average remaining lease term (in years)

    5.5  

Weighted-average discount rate

    3.5 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Remainder of 2020

  $ 373  

2021

    1,245  

2022

    1,095  

2023

    582  

2024

    261  

Thereafter

    1,251  

Total lease payments

  $ 4,807  

Less: imputed interest

    (440 )

Present value of lease liabilities

  $ 4,367  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Schedule of Dividends Payable [Table Text Block]

Declaration Date

 

Per Share

   

Amount

 

Record Date

 

Payment Date

February 10, 2020

  $ 0.20     $ 2,285  

February 25, 2020

 

March 6, 2020

May 4, 2020

    0.20       2,285  

May 19, 2020

 

May 29, 2020

August 3, 2020     0.20       2,285   August 18, 2020   August 28, 2020
    $ 0.60     $ 6,855        
Nonvested Restricted Stock Shares Activity [Table Text Block]
   

Shares

    Wtd. Avg. Price at Date of Issuance  

Nonvested at December 31, 2019

    957,682     $ 7.34  

Vested

    (293,583 )   $ 7.53  

Nonvested at September 30, 2020

    664,099     $ 7.25  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
    Foreign Currency Translation Adjustment     Unrealized Gains (Losses) on Available-For-Sale Investments    

Total

 

Balance, December 31, 2019

  $ (1,245 )   $ (19 )   $ (1,264 )
Other comprehensive income     355       16       371  
Balance, September 30, 2020   $ (890 )   $ (3 )   $ (893 )
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information (Tables)
9 Months Ended
Sep. 30, 2020
Notes Tables  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales:

                

Primary Reporting Segment

 $13,294  $16,254  $42,718  $56,979 
China  640   525   2,156   2,138 

Russia and Kazakhstan

  190   244   602   662 

Total net sales

 $14,124  $17,023  $45,476  $59,779 
                 

Income (loss) from operations:

                

Primary Reporting Segment

 $2,715  $2,974  $6,038  $7,506 

China

  134   (795)  64   (1,530)

Russia and Kazakhstan

  (59)  (82)  (37)  (138)

Total income from operations for reportable segments

  2,790   2,097   6,065   5,838 

Unallocated corporate expenses

  (2,122)  (3,161)  (6,662)  (9,615)

Other income, net

  385   323   603   1,128 

Income (loss) before income taxes

 $1,053  $(741) $6  $(2,649)
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales from external customers:

                

United States

 $338  $551  $1,202  $1,607 

Canada

  132   313   536   808 

Peru

  357   581   954   1,938 

Hong Kong1

  11,132   13,575   36,238   48,465 

China

  640   525   2,156   2,138 
Taiwan  771   649   2,261   2,340 

South Korea

  52   98   220   288 

Russia and Kazakhstan

  190   244   602   662 

Europe

  259   343   747   1,017 

Other foreign countries

  253   144   560   516 

Total net sales

 $14,124  $17,023  $45,476  $59,779 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual)
¥ in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2019
shares
Sep. 30, 2019
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2019
CNY (¥)
Restricted Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 672,231 263,289    
CHINA        
Restricted Cash and Cash Equivalents, Total     $ 2.9 ¥ 20
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net income (loss) available to common stockholders $ 635 $ (1,243) $ 96 $ (2,769)
Basic (in shares) 10,678 10,623 10,581 11,010
Net income available to common stockholders, per share (in dollars per share) $ 0.06 $ (0.12) $ 0.01 $ (0.25)
Non-vested restricted stock, shares (in shares) 746 0 843 0
Net income (loss) available to common stockholders plus assumed conversions $ 635 $ (1,243) $ 96 $ (2,769)
Net income available to common stockholders plus assumed conversions, shares (in shares) 11,424 10,623 11,424 11,010
Net income available to common stockholders plus assumed conversions, per share (in dollars per share) $ 0.06 $ (0.12) $ 0.01 $ (0.25)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue (Details Textual)
3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from Contract with Customers, Sales Returns, Percent     1.00% 2.00%
Contract with Customer, Liability, Revenue Recognized $ 812,000      
Geographic Concentration Risk [Member] | Revenue Benchmark [Member]        
Number of Major Markets 0 0 0 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]        
Number of Major Customers 0 0 0 0
Minimum [Member]        
Revenue from Contract with Customer, Sales Returns Policy Term (Day)     14 days  
Revenue from Contract with Customers, Historical Sales Returns, Percent     1.00%  
Maximum [Member]        
Revenue from Contract with Customer, Sales Returns Policy Term (Day)     1 year  
Revenue from Contract with Customers, Historical Sales Returns, Percent     10.00%  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Revenue - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net sales $ 14,124 $ 17,023 $ 45,476 $ 59,779
Less: sales returns (215) (177) (612) (1,289)
Product [Member]        
Net sales 12,023 15,732 41,234 56,355
Administrative Fees, Freight and Other [Member]        
Net sales $ 2,316 $ 1,468 $ 4,854 $ 4,713
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Cash, cash equivalents and restricted cash:        
Cash $ 22,408 $ 13,720    
Cash equivalents 68,381 82,315    
Cash and cash equivalents 90,789 96,035    
Restricted cash 517 3,390    
Cash, cash equivalents and restricted cash 91,306 99,425 $ 103,994 $ 135,651
Inventories:        
Finished goods 3,844 6,142    
Raw materials 836 1,249    
Reserve for obsolescence (421) (987)    
Inventories 4,259 6,404    
Other accrued expenses:        
Sales returns 207 373    
Employee-related expense 941 1,258    
Warehousing, inventory-related and other 638 756    
Other accrued expenses 1,786 2,387    
Deferred revenue:        
Deferred revenue 3,477 4,506    
Unshipped Product [Member]        
Deferred revenue:        
Deferred revenue 1,397 2,390    
Auto ship advances [Member]        
Deferred revenue:        
Deferred revenue 1,971 1,985    
Product and Service, Other [Member]        
Deferred revenue:        
Deferred revenue $ 109 $ 131    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Adjusted cost [1] $ 68,383 $ 82,334
Gross unrealized losses [1] (2) (19)
Fair value [1] 68,381 82,315
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Adjusted cost [1] 56,547 11,659
Gross unrealized losses [1] 0 0
Fair value [1] 56,547 11,659
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 5,000 13,544
Gross unrealized losses [1] 0 0
Fair value [1] 5,000 13,544
Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 2,104 347
Gross unrealized losses [1] 0 0
Fair value [1] 2,104 347
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 4,732 56,784
Gross unrealized losses [1] (2) (19)
Fair value [1] $ 4,730 $ 56,765
[1] FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data.
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Leases (Details Textual)
3 Months Ended 9 Months Ended
Jul. 01, 2020
Sep. 30, 2020
USD ($)
a
ft²
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
a
ft²
Sep. 30, 2019
USD ($)
Operating Lease, Payments | $   $ 342,000 $ 459,000 $ 1,200,000 $ 1,500,000
HONG KONG          
Area of Land (Acre) | a   9,600   9,600  
Percent of Increase in Monthly Lease Cost Savings 10.00%        
Rolling Hills Estates [Member]          
Area of Land (Acre)   4,900   4,900  
Lessee, Operating Lease, Renewal Term (Year)   5 years   5 years  
Richmond, British Columbia [Member]          
Area of Land (Acre)   1,600   1,600  
Metuchen, New Jersey [Member]          
Area of Land (Acre)   2,000   2,000  
CHINA          
Lessee, Number of Branches   8   8  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating leases $ 377 $ 512 $ 1,292 $ 1,544
Short-term leases 72 73 237 201
Total lease cost $ 449 $ 585 $ 1,529 $ 1,745
Weighted-average remaining lease term (in years) (Year) 5 years 6 months   5 years 6 months  
Weighted-average discount rate 3.50%   3.50%  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Leases - Maturity of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Remainder of 2020 $ 373
2021 1,245
2022 1,095
2023 582
2024 261
Thereafter 1,251
Total lease payments 4,807
Less: imputed interest (440)
Present value of lease liabilities $ 4,367
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Income Taxes (Details Textual)
$ in Thousands
Sep. 30, 2020
USD ($)
Deferred Tax Assets, Valuation Allowance, Total $ 0
Domestic Tax Authority [Member]  
Operating Loss Carryforwards, Total 3,600
State and Local Jurisdiction [Member]  
Operating Loss Carryforwards, Subject to Expiration 2,400
Foreign Tax Authority [Member]  
Operating Loss Carryforwards, Subject to Expiration $ 2,900
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended
May 31, 2019
Sep. 30, 2019
Sep. 30, 2019
Jun. 30, 2019
Sep. 30, 2020
Mar. 20, 2020
May 16, 2019
Jan. 12, 2016
Jul. 28, 2015
Stock Repurchase Program, Authorized Amount               $ 70,000 $ 15,000
Treasury Stock, Shares, Acquired (in shares) 612,729 383,127              
Treasury Stock, Value, Acquired, Cost Method $ 6,700 $ 2,900 $ 2,882 $ 6,682          
Stock Repurchase Program, Remaining Authorized Repurchase Amount         $ 21,900        
Equity Incentive Plan 2016 [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)         2,500,000        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)         1,219,583        
Director [Member]                  
Common Stock, Percentage of Beneficial Stock Outstanding           5.00% 5.00%    
Broady Trust [Member]                  
Stock Repurchase Program, Authorized Amount             $ 8,000    
Open Market Purchases [Member]                  
Stock Repurchase Program, Authorized Amount $ 4,700                
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity - Dividend Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dividends per share (in dollars per share) $ 0.60  
Dividends $ 6,855 $ 2,736
Dividends Declared February 10, 2020 [Member]    
Dividends per share (in dollars per share) $ 0.20  
Dividends $ 2,285  
Dividends Declared May 4, 2020 [Member]    
Dividends per share (in dollars per share) $ 0.20  
Dividends $ 2,285  
Dividends Declared August 3, 2020 [Member]    
Dividends per share (in dollars per share) $ 0.20  
Dividends $ 2,285  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock [Member]
9 Months Ended
Sep. 30, 2020
$ / shares
shares
Nonvested at December 31, 2019 (in shares) | shares 957,682
Nonvested at December 31, 2019, wtd. avg. price (in dollars per share) | $ / shares $ 7.34
Vested (in shares) | shares (293,583)
Vested, wtd. avg. price (in dollars per share) | $ / shares $ 7.53
Nonvested at September 30, 2020 (in shares) | shares 664,099
Nonvested at June 30, 2020, wtd. avg. price (in dollars per share) | $ / shares $ 7.25
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Balance, December 31, 2019 $ 75,064
Balance, September 30, 2020 68,676
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Balance, December 31, 2019 (1,245)
Other comprehensive income 355
Balance, September 30, 2020 (890)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]  
Balance, December 31, 2019 (19)
Other comprehensive income 16
Balance, September 30, 2020 (3)
AOCI Attributable to Parent [Member]  
Balance, December 31, 2019 (1,264)
Other comprehensive income 371
Balance, September 30, 2020 $ (893)
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Related Party Transactions (Details Textual)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Mar. 20, 2020
May 17, 2019
USD ($)
shares
May 31, 2019
USD ($)
shares
Sep. 30, 2019
USD ($)
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
May 16, 2019
Treasury Stock, Shares, Acquired (in shares) | shares     612,729 383,127              
Treasury Stock, Value, Acquired, Cost Method     $ 6,700,000 $ 2,900,000   $ 2,882,000 $ 6,682,000        
Aberdeen [Member] | Unrelated Third Party [Member]                      
Noncontrolling Interest, Ownership Percentage by Parent         20.00%       20.00%    
Broady Trust [Member]                      
Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction   0.4105                  
Treasury Stock, Shares, Acquired (in shares) | shares   178,324                  
Treasury Stock, Value, Acquired, Cost Method   $ 1,900,000                  
Director [Member]                      
Common Stock, Percentage of Beneficial Stock Outstanding 5.00%                   5.00%
Director [Member] | Aberdeen [Member]                      
Noncontrolling Interest, Ownership Percentage by Parent         40.00%       40.00%    
BHS [Member] | Royalty Agreement and License [Member]                      
Royalty Expense         $ 14,000 $ 19,000     $ 64,000 $ 75,000  
Related Party Transaction, Additional Extension Period of Agreement (Year) 5 years                    
Related Party Transaction, Automatic Renewal Period of Agreement (Year) 1 year                    
Number of Days Termination Notice (Day) 90 days                    
Aberdeen [Member]                      
Related Party Transaction, Other Revenues from Transactions with Related Party                 $ 420    
Aberdeen [Member] | Shipment of Apparel Products [Member]                      
Number of Product Orders               1      
Related Party Transaction, Amounts of Transaction               $ 7,100      
Sharng Holdings [Member] | Aberdeen [Member]                      
Noncontrolling Interest, Ownership Percentage by Parent         40.00%       40.00%    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information (Details Textual)
9 Months Ended
Sep. 30, 2020
Number of Reportable Segments 1
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information - Operating Information by Geographic Area (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net sales $ 14,124 $ 17,023 $ 45,476 $ 59,779
Income (loss) from operations 668 (1,064) (597) (3,777)
Other income, net 385 323 603 1,128
Income (loss) before income taxes 1,053 (741) 6 (2,649)
Operating Segments [Member]        
Income (loss) from operations 2,790 2,097 6,065 5,838
Intersegment Eliminations [Member]        
Income (loss) from operations (2,122) (3,161) (6,662) (9,615)
CHINA        
Net sales 640 525 2,156 2,138
CHINA | Operating Segments [Member]        
Income (loss) from operations 134 (795) 64 (1,530)
Russia and Kazakhstan [Member]        
Net sales 190 244 602 662
Russia and Kazakhstan [Member] | Operating Segments [Member]        
Income (loss) from operations (59) (82) (37) (138)
Primary Reporting Segment [Member]        
Net sales 13,294 16,254 42,718 56,979
Primary Reporting Segment [Member] | Operating Segments [Member]        
Income (loss) from operations $ 2,715 $ 2,974 $ 6,038 $ 7,506
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information - Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net sales $ 14,124 $ 17,023 $ 45,476 $ 59,779
UNITED STATES        
Net sales 338 551 1,202 1,607
CANADA        
Net sales 132 313 536 808
PERU        
Net sales 357 581 954 1,938
HONG KONG        
Net sales [1] 11,132 13,575 36,238 48,465
CHINA        
Net sales 640 525 2,156 2,138
TAIWAN, PROVINCE OF CHINA        
Net sales 771 649 2,261 2,340
KOREA, REPUBLIC OF        
Net sales 52 98 220 288
Russia and Kazakhstan [Member]        
Net sales 190 244 602 662
Europe [Member]        
Net sales 259 343 747 1,017
Other Foreign Countries [Member]        
Net sales $ 253 $ 144 $ 560 $ 516
[1] Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See "Item 1A. Risk Factors" in this report and in our most recent Annual Report on Form 10-K.
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Subsequent Events (Details Textual) - $ / shares
3 Months Ended
Nov. 02, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Mar. 31, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 0.20 $ 0.20 $ 0.20 $ 0.24
Subsequent Event [Member]          
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20        
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 243 280 1 true 61 0 false 10 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation Note 1 - Nature of Operations, Basis of Presentation and Consolidation Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Revenue Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue Note 2 - Revenue Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components Note 3 - Balance Sheet Components Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Leases Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases Note 5 - Leases Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes Note 6 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity Note 8 - Stockholders' Equity Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions Note 9 - Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Segment Information Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information Note 10 - Segment Information Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Subsequent Events Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events Note 11 - Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies 20 false false R21.htm 020 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation 21 false false R22.htm 021 - Disclosure - Note 2 - Revenue (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables Note 2 - Revenue (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue 22 false false R23.htm 022 - Disclosure - Note 3 - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables Note 3 - Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components 23 false false R24.htm 023 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements 24 false false R25.htm 024 - Disclosure - Note 5 - Leases (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables Note 5 - Leases (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases 25 false false R26.htm 025 - Disclosure - Note 8 - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables Note 8 - Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity 26 false false R27.htm 026 - Disclosure - Note 10 - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables Note 10 - Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information 27 false false R28.htm 027 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables 28 false false R29.htm 028 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details) Details 29 false false R30.htm 029 - Disclosure - Note 2 - Revenue (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual Note 2 - Revenue (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables 30 false false R31.htm 030 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details Note 2 - Revenue - Net Sales by Product and Service (Details) Details 31 false false R32.htm 031 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Details 32 false false R33.htm 032 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details Note 4 - Fair Value Measurements - Investments (Details) Details 33 false false R34.htm 033 - Disclosure - Note 5 - Leases (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual Note 5 - Leases (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables 34 false false R35.htm 034 - Disclosure - Note 5 - Leases - Lease Cost (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details Note 5 - Leases - Lease Cost (Details) Details 35 false false R36.htm 035 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details Note 5 - Leases - Maturity of Lease Liabilities (Details) Details 36 false false R37.htm 036 - Disclosure - Note 6 - Income Taxes (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual Note 6 - Income Taxes (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes 37 false false R38.htm 037 - Disclosure - Note 8 - Stockholders' Equity (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual Note 8 - Stockholders' Equity (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables 38 false false R39.htm 038 - Disclosure - Note 8 - Stockholders' Equity - Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details Note 8 - Stockholders' Equity - Dividend Activity (Details) Details 39 false false R40.htm 039 - Disclosure - Note 8 - Stockholders' Equity - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details Note 8 - Stockholders' Equity - Restricted Stock Activity (Details) Details 40 false false R41.htm 040 - Disclosure - Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Details 41 false false R42.htm 041 - Disclosure - Note 9 - Related Party Transactions (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual Note 9 - Related Party Transactions (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions 42 false false R43.htm 042 - Disclosure - Note 10 - Segment Information (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual Note 10 - Segment Information (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables 43 false false R44.htm 043 - Disclosure - Note 10 - Segment Information - Operating Information by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details Note 10 - Segment Information - Operating Information by Geographic Area (Details) Details 44 false false R45.htm 044 - Disclosure - Note 10 - Segment Information - Net Sales by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details Note 10 - Segment Information - Net Sales by Geographic Area (Details) Details 45 false false R46.htm 045 - Disclosure - Note 11 - Subsequent Events (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual Note 11 - Subsequent Events (Details Textual) Details http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events 46 false false All Reports Book All Reports nhtc20200930_10q.htm ex_201344.htm ex_201345.htm ex_201346.htm nhtc-20200930.xsd nhtc-20200930_cal.xml nhtc-20200930_def.xml nhtc-20200930_lab.xml nhtc-20200930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20200930_10q.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 243, "dts": { "calculationLink": { "local": [ "nhtc-20200930_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nhtc20200930_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "nhtc-20200930.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 366, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 25, "http://www.naturalhealthtrendscorp.com/20200930": 10, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 41 }, "keyCustom": 28, "keyStandard": 252, "memberCustom": 21, "memberStandard": 37, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Revenue", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "shortName": "Note 2 - Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "shortName": "Note 3 - Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Fair Value Measurements", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Leases", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "shortName": "Note 5 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "shortName": "Note 6 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "shortName": "Note 7 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "shortName": "Note 8 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "shortName": "Note 9 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "shortName": "Note 10 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Subsequent Events", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "shortName": "Note 11 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 2 - Revenue (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "shortName": "Note 2 - Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 3 - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "shortName": "Note 3 - Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 5 - Leases (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "shortName": "Note 5 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables", "shortName": "Note 8 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 10 - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "shortName": "Note 10 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2019-07-01_2019-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2019-07-01_2019-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 2 - Revenue (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual", "shortName": "Note 2 - Revenue (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "shortName": "Note 2 - Revenue - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "lang": null, "name": "nhtc:RevenueFromContractWithCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "shortName": "Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details", "shortName": "Note 4 - Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 5 - Leases (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual", "shortName": "Note 5 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 5 - Leases - Lease Cost (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details", "shortName": "Note 5 - Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "shortName": "Note 5 - Leases - Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 6 - Income Taxes (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual", "shortName": "Note 6 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2020-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2016-01-12", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "shortName": "Note 8 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2016-01-12", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 8 - Stockholders' Equity - Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details", "shortName": "Note 8 - Stockholders' Equity - Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 8 - Stockholders' Equity - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details", "shortName": "Note 8 - Stockholders' Equity - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "shortName": "Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2019-05-01_2019-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 9 - Related Party Transactions (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual", "shortName": "Note 9 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2019-05-17_2019-05-17_RelatedPartyTransactionAxis-BroadyTrustMember", "decimals": "INF", "lang": null, "name": "nhtc:StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 10 - Segment Information (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual", "shortName": "Note 10 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 10 - Segment Information - Operating Information by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "shortName": "Note 10 - Segment Information - Operating Information by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30_ConsolidationItemsAxis-OperatingSegmentsMember", "decimals": "-4", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 10 - Segment Information - Net Sales by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "shortName": "Note 10 - Segment Information - Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-11-02_2020-11-02_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 11 - Subsequent Events (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual", "shortName": "Note 11 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-11-02_2020-11-02_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "shortName": "Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-07-01_2020-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation", "role": "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20200930_10q.htm", "contextRef": "d_2020-01-01_2020-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KOREA, REPUBLIC OF" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "PERU" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TAIWAN, PROVINCE OF CHINA" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nhtc_AberdeenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Aberdeen.", "label": "Aberdeen [Member]" } } }, "localname": "AberdeenMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns.", "label": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense.", "label": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from treasury stock acquired.", "label": "nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired", "negatedLabel": "Common stock issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_AdministrativeFeesFreightAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to administrative fees, freight and other.", "label": "Administrative Fees, Freight and Other [Member]" } } }, "localname": "AdministrativeFeesFreightAndOtherMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to auto ship advances.", "label": "Auto ship advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_BHSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to BHS.", "label": "BHS [Member]" } } }, "localname": "BHSMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_BroadyTrustMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the Broady Trust.", "label": "Broady Trust [Member]" } } }, "localname": "BroadyTrustMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_CommonStockPercentageOfBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of beneficial stock outstanding.", "label": "nhtc_CommonStockPercentageOfBeneficialStockOutstanding", "terseLabel": "Common Stock, Percentage of Beneficial Stock Outstanding" } } }, "localname": "CommonStockPercentageOfBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_DividendsDeclaredAugust32020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to the dividends declared August 3, 2020.", "label": "Dividends Declared August 3, 2020 [Member]" } } }, "localname": "DividendsDeclaredAugust32020Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_DividendsDeclaredFebruary102020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the dividends declared February 10, 2020.", "label": "Dividends Declared February 10, 2020 [Member]" } } }, "localname": "DividendsDeclaredFebruary102020Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_DividendsDeclaredMay42020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the dividends declared May 4, 2020.", "label": "Dividends Declared May 4, 2020 [Member]" } } }, "localname": "DividendsDeclaredMay42020Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the 2016 Equity Incentive Plan.", "label": "Equity Incentive Plan 2016 [Member]" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_IncreaseDecreaseInAccruedSalesCommissions": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued sales commissions.", "label": "nhtc_IncreaseDecreaseInAccruedSalesCommissions", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedSalesCommissions", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in capitalized contract cost liability.", "label": "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of lessee's noncash lease expense during the period.", "label": "Noncash lease expense" } } }, "localname": "LesseeNoncashLeaseExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNumberOfBranches": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the lessees' number of branches.", "label": "nhtc_LesseeNumberOfBranches", "terseLabel": "Lessee, Number of Branches" } } }, "localname": "LesseeNumberOfBranches", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nhtc_MetuchenNewJerseyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Metuchen, New Jersey.", "label": "Metuchen, New Jersey [Member]" } } }, "localname": "MetuchenNewJerseyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of days for termination notice.", "label": "nhtc_NumberOfDaysTerminationNotice", "terseLabel": "Number of Days Termination Notice (Day)" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "nhtc_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfMajorMarkets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of major markets accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "nhtc_NumberOfMajorMarkets", "terseLabel": "Number of Major Markets" } } }, "localname": "NumberOfMajorMarkets", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfProductOrders": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of product orders.", "label": "nhtc_NumberOfProductOrders", "terseLabel": "Number of Product Orders" } } }, "localname": "NumberOfProductOrders", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_OpenMarketPurchasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the open market purchases.", "label": "Open Market Purchases [Member]" } } }, "localname": "OpenMarketPurchasesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "nhtc_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to other foreign countries.", "label": "Other Foreign Countries [Member]" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_PercentOfIncreaseInMonthlyLeaseCostSavings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of increase in monthly lease cost savings.", "label": "nhtc_PercentOfIncreaseInMonthlyLeaseCostSavings", "terseLabel": "Percent of Increase in Monthly Lease Cost Savings" } } }, "localname": "PercentOfIncreaseInMonthlyLeaseCostSavings", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_PrimaryReportingSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the primary reporting segment.", "label": "Primary Reporting Segment [Member]" } } }, "localname": "PrimaryReportingSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the additional extension period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement", "terseLabel": "Related Party Transaction, Additional Extension Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the automatic renewal period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "terseLabel": "Related Party Transaction, Automatic Renewal Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of sales returns during the period.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturns", "negatedLabel": "Less: sales returns" } } }, "localname": "RevenueFromContractWithCustomerSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the sales returns policy term.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "terseLabel": "Revenue from Contract with Customer, Sales Returns Policy Term (Day)" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of historical sales returns.", "label": "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Historical Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of sales returns.", "label": "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RichmondBritishColumbiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Richmond, British Columbia.", "label": "Richmond, British Columbia [Member]" } } }, "localname": "RichmondBritishColumbiaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RollingHillsEstatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Rolling Hills Estates.", "label": "Rolling Hills Estates [Member]" } } }, "localname": "RollingHillsEstatesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyAgreementAndLicenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the Royalty Agreement and License.", "label": "Royalty Agreement and License [Member]" } } }, "localname": "RoyaltyAgreementAndLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RussiaAndKazakhstanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Russia and Kazakhstan.", "label": "Russia and Kazakhstan [Member]" } } }, "localname": "RussiaAndKazakhstanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of additional balance sheet components.", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_SharngHoldingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to Sharng Holdings.", "label": "Sharng Holdings [Member]" } } }, "localname": "SharngHoldingsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_ShipmentOfApparelProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to shipment of apparel products.", "label": "Shipment of Apparel Products [Member]" } } }, "localname": "ShipmentOfApparelProductsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the ratio of number of shares authorized to be repurchased in private transaction.", "label": "nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "terseLabel": "Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction" } } }, "localname": "StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "pureItemType" }, "nhtc_TreasuryStockSharesReissued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of treasury shares reissued.", "label": "Common stock issued (in shares)" } } }, "localname": "TreasuryStockSharesReissued", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "nhtc_TreasuryStockValueOfSharesReissued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the value of treasury shares reissued.", "label": "Common stock issued" } } }, "localname": "TreasuryStockValueOfSharesReissued", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_UnrelatedThirdPartyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the unrelated third party.", "label": "Unrelated Third Party [Member]" } } }, "localname": "UnrelatedThirdPartyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to unshipped product.", "label": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share, Basic and Diluted (Details)" } } }, "localname": "statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation" } } }, "localname": "statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-10-segment-information-net-sales-by-geographic-area-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Segment Information - Net Sales by Geographic Area (Details)" } } }, "localname": "statement-statement-note-10-segment-information-net-sales-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-10-segment-information-operating-information-by-geographic-area-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Segment Information - Operating Information by Geographic Area (Details)" } } }, "localname": "statement-statement-note-10-segment-information-operating-information-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-10-segment-information-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Segment Information" } } }, "localname": "statement-statement-note-10-segment-information-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-2-revenue-net-sales-by-product-and-service-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Revenue - Net Sales by Product and Service (Details)" } } }, "localname": "statement-statement-note-2-revenue-net-sales-by-product-and-service-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-2-revenue-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Revenue" } } }, "localname": "statement-statement-note-2-revenue-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)" } } }, "localname": "statement-statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-balance-sheet-components-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 3 - Balance Sheet Components" } } }, "localname": "statement-statement-note-3-balance-sheet-components-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-fair-value-measurements-investments-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Fair Value Measurements - Investments (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-investments-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-lease-cost-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Leases - Lease Cost (Details)" } } }, "localname": "statement-statement-note-5-leases-lease-cost-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-maturity-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Leases - Maturity of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-5-leases-maturity-of-lease-liabilities-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Leases" } } }, "localname": "statement-statement-note-5-leases-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)" } } }, "localname": "statement-statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockholders-equity-dividend-activity-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Stockholders' Equity - Dividend Activity (Details)" } } }, "localname": "statement-statement-note-8-stockholders-equity-dividend-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockholders-equity-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Stockholders' Equity - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-8-stockholders-equity-restricted-stock-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Stockholders' Equity" } } }, "localname": "statement-statement-note-8-stockholders-equity-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.naturalhealthtrendscorp.com/20200930", "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r127", "r139", "r140", "r141", "r142", "r143", "r145", "r149" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r127", "r139", "r140", "r141", "r142", "r143", "r145", "r149" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r39", "r84" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r210", "r211", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r343", "r346" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r210", "r211", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r343", "r346" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r151", "r193", "r197", "r302", "r342", "r344" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r151", "r193", "r197", "r302", "r342", "r344" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r200", "r210", "r211", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r343", "r346" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r200", "r210", "r211", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r343", "r346" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r152", "r153", "r193", "r198", "r345", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r152", "r153", "r193", "r198", "r345", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r9", "r10", "r29" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r16", "r318", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other accrued expenses:" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Other accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r9", "r10", "r29" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r43", "r44", "r45", "r49", "r50" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r47", "r48", "r49", "r332", "r351", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r50", "r87", "r88", "r89", "r248", "r347", "r348" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r41", "r49", "r50", "r248", "r261", "r262", "r263", "r264", "r266" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r223" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r220", "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of land held.", "label": "us-gaap_AreaOfLand", "terseLabel": "Area of Land (Acre)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r135", "r141", "r147", "r163", "r244", "r249", "r255", "r317", "r329" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r38", "r82", "r163", "r244", "r249", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r160", "r165" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Adjusted cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r159", "r161", "r165", "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r213", "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r86", "r121" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r25", "r355", "r356" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r25", "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r75", "r80", "r316" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r74", "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r258" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r175", "r321", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Dividends per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared, per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2020 and December 31, 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56", "r59", "r324", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r119", "r120", "r155", "r253", "r254" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r119", "r120", "r155", "r253", "r254", "r354" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r119", "r120", "r155", "r253", "r254", "r354" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r119", "r120", "r155", "r253", "r254" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r80", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred revenue:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r182", "r183", "r194" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r195" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r201", "r209", "r353" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r63", "r302" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r117", "r155" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r224", "r225" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r224", "r225" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r130" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r178", "r328" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r92", "r93", "r94", "r95", "r96", "r100", "r103", "r109", "r110", "r111", "r114", "r115", "r325", "r339" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": 0.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)", "terseLabel": "Net income available to common stockholders, per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net income (loss) per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted-average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r92", "r93", "r94", "r95", "r96", "r103", "r109", "r110", "r111", "r114", "r115", "r325", "r339" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)", "terseLabel": "Net income available to common stockholders plus assumed conversions, per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r80", "r112", "r113" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r258" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r87", "r88", "r89", "r91", "r97", "r99", "r116", "r164", "r177", "r178", "r220", "r221", "r222", "r233", "r234", "r260", "r261", "r262", "r263", "r264", "r266", "r347", "r348", "r349" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r251", "r292", "r293", "r294" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r201", "r202", "r207", "r209", "r251", "r292" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r201", "r202", "r207", "r209", "r251", "r293" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r292", "r293", "r294" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r62", "r82", "r135", "r140", "r143", "r146", "r149", "r163", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r57", "r135", "r140", "r143", "r146", "r149", "r315", "r322", "r327", "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (loss) before income taxes", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r227", "r229", "r231", "r235", "r237", "r239", "r240", "r241" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r98", "r99", "r133", "r226", "r236", "r238", "r341" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r104", "r105", "r106", "r111" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Non-vested restricted stock, shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r127", "r139", "r140", "r141", "r142", "r143", "r145", "r149" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r34" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r36", "r85", "r166" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r278", "r280" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r279" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r82", "r142", "r163", "r245", "r249", "r250", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r82", "r163", "r255", "r319", "r334" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30", "r82", "r163", "r245", "r249", "r250", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r73" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r51", "r54", "r58", "r73", "r82", "r90", "r92", "r93", "r94", "r95", "r98", "r99", "r107", "r135", "r140", "r143", "r146", "r149", "r163", "r255", "r323", "r337" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r92", "r93", "r94", "r95", "r100", "r101", "r108", "r111", "r135", "r140", "r143", "r146", "r149" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income (loss) available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r102", "r108", "r111" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Net income (loss) available to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r140", "r143", "r146", "r149" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "terseLabel": "Income (loss) from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r272", "r280" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r269" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r270", "r274" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r268" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r277", "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r276", "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143", "r149" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r29" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r42", "r47", "r256", "r257", "r259" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r52", "r55", "r242", "r243", "r247" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r29" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r67" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r213", "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r168", "r335" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r140", "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r208", "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r284", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r208", "r284", "r285", "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Other Revenues from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r208", "r284", "r286", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r282", "r283", "r285", "r287", "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r12", "r74", "r79", "r316", "r331" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_RestrictedCashAndCashEquivalents", "terseLabel": "Restricted Cash and Cash Equivalents, Total" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r7", "r15", "r79", "r373" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r178", "r223", "r333", "r350", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r87", "r88", "r89", "r91", "r97", "r99", "r164", "r220", "r221", "r222", "r233", "r234", "r347", "r349" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r126", "r127", "r139", "r144", "r145", "r151", "r152", "r155", "r192", "r193", "r302" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r196", "r199" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r275", "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "us-gaap_RoyaltyExpense", "terseLabel": "Royalty Expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r65" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r119", "r155" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r265", "r266" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r61", "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r122", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r149", "r155", "r342" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r122", "r124", "r125", "r135", "r138", "r143", "r147", "r148", "r149", "r150", "r151", "r154", "r155", "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Nonvested at September 30, 2020 (in shares)", "periodStartLabel": "Nonvested at December 31, 2019 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Nonvested at June 30, 2020, wtd. avg. price (in dollars per share)", "periodStartLabel": "Nonvested at December 31, 2019, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r212", "r215" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "BALANCE (in shares)", "periodStartLabel": "BALANCE (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r273", "r280" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r122", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r149", "r155", "r167", "r169", "r170", "r171", "r342" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r33", "r87", "r88", "r89", "r91", "r97", "r99", "r116", "r164", "r177", "r178", "r220", "r221", "r222", "r233", "r234", "r260", "r261", "r262", "r263", "r264", "r266", "r347", "r348", "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r116", "r302" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r82", "r158", "r163", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance, September 30, 2020", "periodStartLabel": "Balance, December 31, 2019", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r178", "r181" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r267", "r290" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r267", "r290" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r267", "r290" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r289", "r291" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-11-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-10-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r32", "r179" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r32", "r179" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r18", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "us-gaap_TreasuryStockSharesAcquired", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Treasury Stock, Shares, Acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r179", "r180" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 1,556,875 shares at September 30, 2020 and December 31, 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r177", "r178", "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Repurchase of common stock", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-8-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-9-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r102", "r111" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Net income available to common stockholders plus assumed conversions, shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r100", "r111" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20200930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20200930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-basic-and-diluted-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r383": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r384": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r385": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r386": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r387": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r388": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" } }, "version": "2.1" } ZIP 64 0001437749-20-022452-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-022452-xbrl.zip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

TW">#A=@H@VQG#S4,GT.&LA=%AU/G@^E[9'47 M3#_E>TF,4'7ROJ)%&W'\C_>*^/W^ERXD#HP@/G]'EGQ=+T^G%!7/$ F,F&L@ MK/IN/J,^+9 GU.ET^I%+>7%/LIPD5;M6R, +P>G-Y'0A-K*$Z_5Q'F5*BD!= M6B#N:[J2LP\S3$OK2TZ6MG$_*19%&BBBQ<8@B9CKFKF="P(B[N9;RI4?/M$D M\%5^WS-ITF*-DA;]D+>UT#=2;'^N20DW[CORC!I'V+"9&.12"HMYSHK=_ X) M4>#7(.TS&%;<2BJ2T0A/LZ@Q@L_6\>>0?2J+3V7QJ2Q=5:FKMD4(P!9P@7NE M(4L:V15CA\?G.;6 $@06C2+K"D(^@\-GO(V8.7]4@%.)X3.BR>OB01FFZH'L9=G"J'+9YCND>4O$_#9-&/-IEE=E7>' M%H2*"UL,"C# >_J, )\1X#,"?$: SP@8NSDV4*>%-\>:'@ TWI:H+KVUEDXO,I6S8+LZEMOJ7M+W5OJ1VNI:P0U M,1:)SB"C-^ AFYPS_HS:$^4XT:5Q=,'T,YON+8:G*9[@*.2_AU$D M=7/2*]+ZPW7]C.JZK]TG:]9&V,U[]!>+JA MZG9%B\;OI._0/Q-G(\6TJ5_1BY#FHIC![>(%C6!8;P M>_7/SA?T;6?Q4)+R7Z/2:6*R#NL.TS_#>X1H!*:F]4C)]S&&8<08QF7EM*>^KS/L*7+!C-YB]Y]7G2'G7T8L;!#2*!C$WXER!!L O:681NK*N M>*H-\6G-T';EW*D9?D8VKROG4,T@:F8VV\][#8JN*""3@"P0+1[,@DVSX<,/5L,/[;]678"BJXG4JV9V/W+G@7I'=!>A?D+A*239"TK%Y9MUK?!52<9,Q1/0-4UMV> M+:FFR)N%]LU"V1L"67CJUVO)6"O@^PW'Z'I;FNFN)/.*2Y5+/NEH&B;G.X1?<(1TA]@ZOIYWN#S!I\W^.RK(#4%H+?=O.WF;3=ONWG; MS9-*17!5L;JTKX%ST"0P6LXG[WYYLVW\1![?.8; M?#E[>\[;<]Z>\_:$WH<)ND=13KE@TBO1OG)33^1ZH] ;A=XH]$:A-PKU1B%(_W-E M8D#@:*@S6K>9?^:[)*=J1A+^1EB _LPYQ?4,:,A0]JQI.'7>M+9O6D/>%LC. MAK_V/O7U+R1]0BQ#\;8TV[T@LSB8S$ZC##]!S=8F0]D\CGD:1?D\3_C+BF^R M&:(B_X.B&4H9?D+7*5_/Z!-AZB3CED>U"<<%?TVQD&:WX=*,96U/[YWPW@GO MG;"O5K:P47E7A7=5>%>%=U5X5X7)Z5&@AN3*)-%#T]QF &,U\/+:)M.H!=O" MNKOGY&W T+3X&V]/4MET@EX_!B^_3"KI#$4DC MG.""G)O)QFM\2\D$9T)TB%(&]R7I[(%L+SM L/&.%^]XL:_LM;%= M>,^+][QXSXOWO'C/B]YD[D(9=64>F3@<.E9,[3LCFMV*$*,LQ D+,LY>'B:F MWHM.'C[:VYF4_#3PCQ0WA=%EJ;.N_MA75U\]-=\ MX7.+2QB MK52%_4L:3N="!$@LUU;&MGFQ?$,&SI;5 U3,CAZ?.!08OX1S5+FX3;O9E4'9?)6D[H\WZMSIF'Z4K$ M2 \<.R9]:@BD[B;L"LAR;Z*!&C]VEQAX%D428*5 M!]_U2)(4JXIO^_?=\S4@IGB9PG&'V1]G*(UFL:G"M-I;1$[B-,5_H5C.F<$@-D.I M:^H.WH4RJ KLU3\[6\^O&4/@?A:"KZ6^4LR9+RA3LJ%LZX/=/MCM@]T^V-TT MS':H:Q.-OCMVKDWT+E)#OW$8GVH=6P62TM!P!2EUS%YBS8X]GJH4'@K'PMBC MG6J^Y;Z>L;]O>(@3;-"Z HGA3F)HGHQ]P32:. JOCL.S1[O/ DQ#5Z:-J9IF MXLQP/^VDO42Y..T'6+L3T>,$KTW(C"7VX"!K)_S0 MG7P?'&#@]!,P)C\ZB(DT.\AZ.N#F%JYFV8"Z8>PE \(H:?L1)PBX+^Y%9$_I\K98]LGRM%O[ [:HFC)V'E"XGA'X+:=;]_C\'3%Q4,2-)+ Z)H3]S M+B$;NO^-QK07!:A!I@\&]!8,.*,DC)+;G$8S<:!3CI^V<3_':2XPY?L.H=+JUM4-^G$]+S#SQ#4+8Q5>$?N!]99>)=_4XZQ#>H<5J4[JE(FUXKEA,^@Y#84(I MX"!=?,3/9L2O*V*Y5GTX?3?BK+PA[43*!:BWW1AX%8EW2$QL;D5L:=VVJ<,S M9$";,#R(I-R<+@OJ5W(WXC8,E>Z,BAZ#840X(-&:*I%C_!EQ]$$<2;K"6!M7 M--%'WWWT7>6ZK6$/$+AIY I* $6/U-&G7,>OU 8#:_*Q@ PHI <\&96#-H MU4!6N=25V KRB@D]T99+0K2^XB=V7MR'9ATZ"5 M*_E?O@*\SW6JD\53T[-U1/E.[43MCR@'JH9C[8C.QC=QTAWA8?GVO-!@\,9? M]+VWH"\8TY\\IH;!8.MYH.\#6EJAP4*8H4&V8Z$V3 >M,[2]K-#ZU/KDT#VR MNDL./>5K*T:H^L2OHD4;>:D?[Q7YJ/M?^D38023"CBC?=+UQ7(1+)DIP\2<+ MV5-O0=VD5Q]22NEL5YE-V(S;[R%H'*ANU>&%#M3#V-8RQ^-*-U2Y#9,DWX.5F<'%0 MDT_+E"'5-0JP/BV0)[2S=/J1)$+B*/*Z5>U:(0,O!*?\+2R$YIJL%HZ2(E"7 M-HBKMLF$D+F9R$R'!W*VX\V/K]-;BI_X=-R9B)5<=?2L5N?TUW2E(3[,,"W7 ME_P]:1OW;](^@V'E)ILANKK,E8D+ M64>WE"1W/9J$_5S)Y&^PG%0I+HY+FTH\C$*BKAR#:#!_]$%M M5V:1^NIA1=1N[')8:5FV)T0&+F/5KU\?\W9A%N@L;)-D!5?FA]S0:U=]*[#IW^C/<> M6=V=\1[BF=UV4B?7&Q'?= C-A)?IOIR'LFQ;>0>?+#R,9.%QY0+Y1%2?B&H[ M"C#06)F/ C30@>'[E'W-]R1@^2-#?^;B(V%>9TWK')D,:5'K-:;2Z[Q>YVVL M=^W$""_P$X[%A+U%M/ C7* H">4'H"!=O1X\##VX(V(W NM2R*O*VA"@MM9) M?^ $J*Y=4[<>!/GJ"]=T[;T1Y8VH(S&B-&N9&*\:9Y#1VU80.>B,J5E[HASG M:9KV?!"C35OW/@BI#Z*.M6#=&_%CD"!QCTTP%R/P21V02?E1D.#P$2H-;L]#T81>[ZOHS5?Q"3&&T,T"43X5TNDG\8(^K=[/4N14W(8X/IUP M0?$_**17)*^LCUA_E!98V$Z\5J;@+E\M#]V_Y:=\,:M*]^PBE[D.H-V#[X?/ MXA0)?29I-I,9[TV'&RX D@7<=)AA,_S ']QT=A^,,W"6OY$V&-Z. M,E!VRPME8A&JNL(L"A-!=A/.E0,.#(2O:83;5OR\R_B(7,8^[V;(/B]+2"C=76VI)\[-G^:H M:4TUY_S,K6!6:0)T=RIW]% =FH?='<4=.UB'WH/N3N8.":M67*4=GM52)17;2G:MEEL+A%,0&*(+8>T2<P\ MIXJ+YV"=K#'S:>L:YT@7Q5!V/WID&0TC#6]F8PR!5= K.VQO,YGB/&0S";V[ M7]DAC+]V\>/RSQP_\:V>2\+3[#RD=,FWU*)6AX)R;5_;J.]1=X?X?,81UPQ6 MU+_\8*>E@NG:8XX6#(TH:75L.]#4FOWZ3C;.$J8%G*+ZU7G.,C+?"O2E[CV: M]!T8:^I=P:1K_XQMK)8KG&*ND\8?"(EE$DC=V"+Q7Y ,_=TF-F7@+AV:I:!J M:I'PN_#;9V[O4!PFA7*=+Q8)5W%T3&BZ661(2,O"2<7W!VXIZ%DYZ& UG6IE MZ&SMG$*!5I[!A73IGY&7V_,7DD9*>:IK[C/#?&98.YEA;3IT?+J8^^EB6F<9 M,7)1C1T.?>H8S+LX]A0HR+0 N\K'GML$!@,2PAA[]A($#'/=;>SKI<^LVX&N M$I]U6_.0>?O>0%< ;!<:HHHBN"* .H4,ZL#M3I19R [L%%'C@-#8U8?.486Y M6KI+BW9MAK86O7-%PL)V=;U#W)5-6LEI%2**0(PK<\08$U#$H8-MU68FN3%( M^EA&=[NC!;%NC$]%N- YHU(I=!OD:+DBC>M!0* IS*X(Z-HPU4EU=&41MC*W M:B2@.R75VYIY^HQ-5TQ%:*U&XV0L5V2^&>M0S#2BS-+QLY\#)LIQSDA27".+ MN+V9+8-X59TS$%\?*&A'LCY#MD=7=$;)-^=AUV=C3?,H7 MW/>BI?P<$KQ7%R1>H4>:AW1Y\M:02E7'+@C]'"Y_,"2QNDN7)[MJKE30*:Y& M4F H-[<(]Z&H.K#'>9VN_3.V(4EQ(4=E&XND*B_?D+2RD#*ZJJQP,]F0)"%9 MT=+G5_K\RG;R*^N*6I]+Z7XNI5K0$Z!P=04%?1Z08D-TQ<\HG0IU-6=7?(F& MP*CT=5?\7(:0:&Q!5U:0SZCT&94M7MM3;2HZMUB4^&@-I8%Z>>DFU:C\NAMO M+_@I0_/Z&A+NO;^]>7\-K4GPBVS@'#2<++V6L/D6TGC_YL+]LC55;6P> RYV M&^5!9F5;"[X>L1N>A7P[XMNE"+JOMCH:IM-B]IPMMTU6.T:!^F4Q@:Y3SDU> M;B,B>/TP"].;A1B"?2'I$^<5Q5]RU=W*?3T_^,&#W#W(/SH-\F\(3V?\Y^D3 MHN$4?>!#9Q=7 4ZXN>@#G<<3 MZ*RVPDF?(L\5*/4^?H7+PQ7WM78^ 7PHKF#AXUZ#CGLM"L66/Y]F_9X?@85X MK'G7NEM^'G%C5X]C!X9MOPB-9\&5/)1AP6SH.P"_!./"'J7\N4R/;-)K'/U@ MO(WO3#QVO(V]QP/-VHAF A,6X#0(HRB?Y\5!WX (OHORM!3-.(#X"07\U=:] M)*Z39P\MPZ,5=GS>QQY9@\G[:/AZ&V2#M#*Q>K[F:$WE%Y1]32E?8?@O5-03 M8)E@]P.?9)\XK0A?+XEM, [RRA^S#/A MKWD@MZ'B2H261K480]I[3:JCGZ ^/H9G,X;7%;';S;9\]U*"]QM:S=MI0#8H MIV5<01H;*I6/HQY/'!6V/1 C#<$Y;/1!(/WFZEQP$#IAZJC'SH41:X!5PRIT M+@Q0 S83$].Y->D#]CY@;QY0T.K_SJT3)1ZMN@>Z6U_##E)IC3.;(:.(I(PD M. [+I-+5QTQ<3QB%;!9,$O*-!7D:YC'F3>#QH)H#6PGV-*+51W)ZB^1=4KR>;C 6:FIKPO;GA.6;0K:PFC7 MC=(Q$S=\1^&2)IU^$G_O%'F&42_MWBK9GQ!C"(F[=;B,*IZT5[=[ETAM8PN1 MIHW=RQ[('>)".,()XFK%5L=X($6E$$I$@8SX;/F5B86Z@?>T//Y04:I[/R[5 MX:,LU.]LB[@BKI5&N-!)^>\)*@R9-#Z="YOHK^)S"4@F72W$R0MH;R:[<-^D M72RU#I_4/VR5.EAQJ_MMN%3$2;7]ZND-'3(E%,N-QHSJL%<]PB 9E>M_)EV' MQ9KRT@DPE\I1AL7PVL[;S10&\ZGJ/ 3FUA?XF,S0G3Y6RS,HS*>5%:A1[LT' M& 23A6NUO-WEE-MFTAT2TG5H+W"'P#K"4])_6 *E(')[LVV==[C?V^IKY-9P ME05\A=.06\N[%K"$2?@ -G5V.)4:L5-_H,$P78;2&[S;B@$&^&XKJ*SW;@$# M#8;I"L^5&;,5 PSPW9K[ NL/9(7IK8=2SL]A&PNDEJ[E[1))XXTH+&*CNM=B MVM_>)3A7A-ZA14ZC&=_*;R8[A:XEO.D[6MWY&UWN,PC*'\AI]&>.*>*KFJ_C M;"F*U61\"@FWT&(N/_\ '\ JGW?B$.K-A$NJ0E&\>,Y:C^$1*ZF$3=TY+&,TE M?\SA"(\Y=)@A.Y;DQP%FR XQ#;2IR>0*6@UP(""#S;D%IIQ6W6?EN#+Q.D5J M]RY XZP$5V9LUPB;).&YU K-JL:%@#!B6(JLAZ M!_+2)>@ H6W'RFEV@J VL-S=\=@,48;&#:$F^:Z[XI:CP:[9B9/NJE6.!L F MB8-@^'XZ0OB,,A+!2/[-621;.G\%1O+G8T,2?!8,#.%[9R'42D5]PCA.GSP.'0V?L0<@(IW=,\Z]^8IESU7OJA%? V8:.N6,: MP+$#:H/,GNY\VA:6<#MHUL__[%'\=2AL!1L90-TB<=<[.VBZ,J M>[.[ ,AP9)\A;/7/M;BBQK2#8^='O3MTS(YU[MJMQ="=H]=:'<$!O);:)0F- M_<&6ZNH- >/>+M@:I!9;[RR.*]E6YNSOEWNLS"IW)56J$3RMG3O9HCFHHIFD MI%U$/=LMFJD:>&A%,_6T^J*9>V2U4#2SI1)BA/'U^8&0F/&%?8_H$XX0NR=; M:;!?[DO;P4+]JI"F7'X(#79] 22.)/0KVPZ$= [L!4YR<0^E^N288>_!L5<$ MJ"XP$WM83K5GN1N.9I_]%:% ]O9:]T_^!TH8XWKY!,O>R$X+F]4"MAG&5UQW M$2D,.,TYE#>;G>D,30A%.P'ERV<^-[@&QE49NBST&*'HB.0'DB1"M4DSQ.>0 MH@I15T^T#^3&;-"78E*UMD7^05:XDGQIZQ'4?[ Y539J^PH]&<$'[09%M&:& M:]M;9$$[52I:6L5^E:I,7I)57<7:K).%$@WH":4Y6@O__1S$S3D48?;R?S&7 M,A(.&XQDX9S]7JZO< 8@Z=+7M+9 /BIVV@]Y5F?@-"7<6MZN>^ R8HB^YN%A+A%<+/;W0V=E-GK$L3,6*E7!3V4Y=)JRK\CA*W+XBAR^(H:F@MDB2I49(<>5K-Q*#M"1+$ M&#NX-G#4'\E";0%-6(QGH+G. MO!LG9,:U V[I!KA0 ()$: #MICX;/&=HF=#&I/O$Z#VR!I08O?,J2VV7J[TW M$WDBAZ*'S;0;!5F:Y">#GB/(E;-':EF&YQ#,56G:LD!/M'R@85I3,R5[?/)P8/V:4E36,OM($K&[KKFX2>]1 MQ%DHCA*VAF5;C_,)0Z;WZY3X\QE;\5;@5^Z8C.),?M0XS9VZ;\UGU_CL&I]= MX[-KY%6<_ TMM11^5^:)">/[P+>K@CN5KU$3:0-?ADUO94HR M%+P+:)D>&:0H"YC(70H>E\&"DCB/LB!,XX"5*8!!C+(0)QO9IW=3-GR %?]D M*S1[QV3[CLG#B584$7^90B82[:YH$3[@FT4A\3XC$3W8HZE.UQ:(U60B%YF# M=XA/VG0?1-/N-6]@EM"]71ZM+91=OCH8OK&O@=%LQ\_ _]KW,?"/?K\M";FA MJRSIBMFO:]8KH;L)W94B!-36PM7E)4F52UG9QA]M]=Y0[QY4ZKJ=26#O-W3? M;ZC=W8C1GC)V./0^1)@Z,'9/!61: /;M[GP)PX&AOB4R]DG29\QAH!/$QQS< M.=%K\\H#-6J-?0?6G90_!HFH;LO*'T%$6%;3&PD8R9[;$4R<]R_VYE^46D: MEP7R<8%?>I^6<5%,6A0"D!C%F^\'48Y.1ZV\H6VB]S+=17Z\N$U9W!)QBVC$ M)PF()?@P V/X#@E!LO[R ='Y21V&%<-8\"K-",T$#;II*6_H_7?>?]>._PZR MNWA'G?N..I_@YXWMFL:V3GMR;EXHT=!MVD[E/\$@D1H#8"SST/5:VQ[?FL&I#KO5CV MO5BU7A_(K]5@8O1I0YX^\><+1?"*%$[P"_28[:0]1U$^SQ/AT2]J/VYSI46" M=%DF2I[!T\K8-3/Y>D%GSG4A0;#8_$6]!YG3H.XP]AG>4OF29B"CNN[],W@6 MIG\\X#E_!0O"<,:4.77JQC9.X],%X8K#W@12\@#JTS\K5UPX_DO(QK/EYM>/ MF.L_-)HM/Z$GE%1L$O4Z6V3N.EWD&2LH.E&^)4"/8;#QSIB-=X-AX_/.+GPX M;RJUI49CV+C":JU://!G*U:0O*%MHL^YJ)H2BO\J=';E;(-W[)^ISR1%R\\A M_0-E5SFW)I2,J!M;(#Y/<80787)&M*0KFOHPC@_CM!/&J6=,^<#.\01V#%5" MTLK6[@IX"FV U-]N74%''S#3:5.NA(A@\P2BS;B"B'YNU+%574&G!:&LLX== M28&'+2V(0\H51-J=/)5>"%<"M$"YK#757 G"PO P\(RZLJ;Z2'\:^%KQZ4]F MJ0K-8E='=="HV[BGT[&@[6*-D;WK0;4O0]_' M"BOK+5Q655+LY9J:\#5'LV0#YC?-.145M\ M:?,89TF!9AWLMAD,L9HR^4CI$J?3 MPF,D8<6HKY5;6N:X#((61>W%C9Y3E$;R1#U #SMLD/0^(]$?RIC<:6%S,]LA0Q1F$P)E1I(842:$?+;44U_9;2 LJ>7/8<-AD:W1 M+?0=;%=Z .X#L$Z#849K>VK[!>^&PM2=.'5W,_G*4+%9@1B2]+' BK 85^8Q M>-'#.MEB!F 'R1M:)5J_*E1M+9%N-FN&-%UNU]$-K:F@:&FEBC>7)=GR-@E3 M4=E2: L+88+)%3I(%QLUOOE6BZ,,%0:Q=O+KFMM@( MQBN+UGRPX; H]$CSTZ!+&]_TN-X3GKX$EX^A\TTF4@?B7(%$#6K MN]FOYB$M5Y8/&".Y/]V59#PP%#K/2W?IP1;JOH%14<;E7A@:NM0&+ ML0(#PZ[H^P!^=V<((+G9E?EBC PTT]@5W=\,()/8L2MG!DS2J;Z0ZI52#C^&X8G, +YD!YFFX M8L0#^'WA9M%M?Q4>W>(=<)(@^I)18R(+LL< MYM4?^^G+JX]_/_^R?NPJ7?GPB\XK)UWZ:DXOJCG=4CP/Z?(.+41QOG1Z7TZN MRGLOFL*"MT[H0.+I^Y)L>5 M49QR&5I,%>'^%<%-DG#ZIM=IAK@*(2_:T?D3;HOZM= \*=FW3\U"U.SB9$)X0(F&G.4F%B!8\?#;#LC MH*W;.4ST1ZWU2H [@7G@1#'U+CH'T,&L,7![C!T,\-8C"QF,/6<##(")OWOL MH,"6",1;[,+ZT*LA1OZ9L4\.,T@,'(;NY#AU7_QF\ E,OOB-23)M8X=A=W+6 M0GH_##. )W_LHM80$ ._NG.R5HE,;^&[H69YI2@+F#@VW7EFE\F3!I?-94Y\ M7QEC[]*Z-E^T2L]O]Y)Z-E^T2L]MY<2>K9?]$K/ MPV\2>K9?]$K/UWL)/=LO?(9DSQF2A3ISQ7=E/$W/B]=QH+G/CC3; MXIID1)IOI5TGO5WFHO1=Y=N2?>T3"-U,(#S63!^?D/,J=*7 5:: *H]GD M 'LEQZXZ]IG\,E#ET2>_6$]^L15U#XJN*""3]4D?DK+@,628B<]VZ0G"- ZB MW?RY *W*6P6\:\!F'-:B:U0TC7&29RBN&Z7OGS*+47U;S#;( O!1P;;B7?V_ M?%A\S-:D[--)OR[0=XOHO:#Q3) H\=57MK5Y!G^?H(L252#YJ]8V&;A.(UK, MN#!9%=@4A+'3C&N;CWDFM) 'LL8:Q;?A4C0^I31,IT4_61RHO8'[!^4+RK9I M?Z=/?'V4Y.Z4(%T5;%--UIJC#)E=]?0V'L?NY=(^H-DML;\A<0T>BD^?^,XU M15]R8;G>3%;OOA0'-WDFG!Y"19=P8SB*S2DE(?6 1I70J#7&T02K+>A#/KCM M?G"[3P?4:'UPW@%5A48C)<^Y2:.$JL'6UIU[=[!'U$"F[MA3!HR/8K5J4G:7 M;V"E!'F[XDIBHG67HC!8S!I:(-WE-(Q&=DG\7#9C+UO+@-.U^;BP(MC.*@A0 M69$_3\,\QCNN#WT,I>D3K,1"VB$:%M.0>.E/XW_GK+PSZX%(+KAYJ6:#'5SFT2CR\.(1I<2X0YBQO)IJ0/.VB2IN,%DK8V#:E+WZ=\ ;K-1 MUL@U[F^!Q>HYK&8+TJ=_5G9T#B7YTG;]DWR!GW L!*F$U,WW-<5'2T&I0CB+ MR4M2I*G.JVQK.10!"3/8(U4F(=896\7MD-'R@5L?+(P*72^-B[^28NO^P($N MM'"*&5>6+G+*_^<:$R;Q_G5;>P#T^.3AP/HUY1M/<:_X1ZZ#<(+77-RD]RCB M+!37*;6&95N/ZQ_ VQ?71RHEJZJIC9.5+V_L4Y*N;FPA,@<,9QV:BS^,D>@? M!Q #W=NZ0(7<57U\#-J,:*[W:Z^]D_$!Z>O#ZQIB]P&4$GQPP:!-F=. ;(M2 MYX79J]R9%"TMD[UREU>[2P ]K!HUAWZ'-5GGA&6?438C()8D78&\C3R4"1*[ M1Y+Q4"/BK=<>G -%R;+TTOJC.*4$A4;COW+NZ!(4%P.WI'-Q;BA&$#-W[,?F MZT^@>N[ZL9^RKXV75C,=^_'[VL@ O.#.;5\#3/!;%"Y4_GR:#3&M0>N[ZVZ. M#!T9K8O!.2U'B8W^X[R7DH6Z1V)^US%"^)IQ/98RLS=U[-@4G8 M8H5"U\>;(-?JC2;W1/Z;7@A M^T+3HVM7K_._#"\UL:XZJU]H<>.CU\HG__?MZ[TZ(5,<7JR_N U*P,H/0H)TT]!-\G^?[KZ>N#8V MG4?+GF)7MTQ&9*?1["\322_]D3RM[-NE1\:/YJWG*0VE&\VC99K>-/X^FFN? MN/,9.:$7->A5Q-;5\'>>TV!?+5CPB)T'_JOP&_:PWBH''-M-^E7T5+O9MQ]B54X;]"B$3V>6_0+QJS!*K/,B;LJ MQ29V/1L;$X(-=T*1:&J.:MDS-@#ZH$ZCW]@^"W_V2O)B)6) MF$OM!/#9<="C,'[">!:+;_9%'"FZFH!N78VYG+RHD_CKV3-AM]0H^'?8DI< MC!B-#?*GIS__=G1NF2XQW<:82M014OUWOQVYY,4]\. M.S>H"#S2BQN/>*H;\U/TOW]ZEOMAK$^)@T;D)[JSIMCT/Y00_UA"#A77QP^( M_\[1_R*G2&[.W ]HAC6-BL\I:NHF:A[+NOD!45@YEGV*L.=:'X[./FKZ<_A< M37=F!J;/I!JZHV/@/P?:E MJ5U0B3DZ:S1DA0I?SL^[L%1O&CWPEM["TJ[H9\[1V3];>WT6&USP)'9YTK.N M;*PR1XG#1.UVY?9 [LM'*\_65Q[HF;K_\??[B_#Q@6X]/;>F4]UE1#A#4V/J M@XHN-0 Z<8X0HXI>VZ)JT=%/3=V@N+0].O4A;2$MZ<0IKXFC%HTSKWSBNIO. M'(7"_03;9)W(6QH<$(I1[=ZUU!^WV+ZQ[UVFTO^%#8\L?A70VUP5(.KU:):K M$56?8JJ=@Q?4A[@>75'%8?QHN8L>SYTLCR$B[ MU.ETI7ZOLQWI.TQ]N:2WULUQ3)S7RJ)5+_1G76,Q?'CM!5$-^D]&3#6/E:VD MN=U)&%=[,:YN%M-7\K@ZZU +Q]5;C\NK-:YN*V9<_D(Q'Q=[*0@.D[7:%NLF M_[W#-/8?ONA.XYMNZE-O^HU,'X@=CH0MMY[>D6=B>N3*MJ9LM8 ][M^Z.SGW M'->B3[JGY#MWQ/5LT[FU#%V=CXD]/5J:U4&WMS(XEB\[U3Q;PW.J+]HYK/\L MCP._[&\<_=AQS FVZ4"V6%L:K'M;2>.BA*I\X93=X$YW?GR:?R*F.IEB^P M5\#NG8Z!4WC]_P M'Y;]C1)!W.WMQ-9APV#=L0O%LK<02YBN8+HZ;&']32T&T[4T76\['_N:KE#Y M[#I9X7T*F2ZE-&&LY'2U2A-&T:LA+%6Q4"O8X$.[LPQ63O!% M-PSGTF&7.:LF/W3"OA+'(>1FQC+"] =?:9A#[HA)?F)CU;YWFG)+2;'OG8WM M.[U3W$K$9KFCBV");HQ?AI1RUV&K09QQ0\.P?OH%#GOG@A8%74IS^>4=,=@* MU2VVW?F8E1CY]PI8,L>&.Q\^V83S;&AJ7W6*.X<$4$WXL?-IOOP-O]>G+_>Q M'ES\TS5-9_]BX_+%I<^C+_T4X\UC1,PRGUMR)PN?JS]/'I5B"B4UP/\;D]3- MQ=FE=VKW-K*O">HH%(Q0(]V1&2OC>##(/7GB:-AO9K:E>:KKT ^Q&UQJT$NI@D"NA::<]P[2370^T4U\C.X)04?75&DB>7B, MF*Y'5W1X%M/=]"IWHCOTT6P&$38U]A$C:VHY+OV8&0DT-$T/&\B?9D0Y>46G M%,G-QN]^"40X01M-5ZO7ZO2['4QEHB4WVH]]TGB0>W)#Z\BJ1K#2[?:Z1V=7 MP_M/:&S-J'#UE:9$*=9MQ%?!T3>^+,71Z4B(.(SQNC-A\X8>V67/_+*)3O6[ MK4[F_D39K'+')@Z?2\_A4VD].,1^9KA!4^Y:(@V[6$(_)\1$^!GK!OM.XM,R MHX)A4YWR5W +W9QYC D6?QS7QL@EZL34_V0LI$\(V,&)72:,SSG]Q&+*F]H? MI%+)?*(W)\[IW_[VE8+ 0/(I^J=GL7JE@##Z>)5PKC)D/H<$.PS=B*TCN,P. M(LSM Z*?&3I^T U*,'&.P[LJI^AF?<@-5FZHA<.A/_3,I6D)1QE"3;5LVWJP MHE*JI6F+GM(Z1=_3[D&QD7J?54CQ=\O%23QA1;T@XM#WK%[RU.'%?E1+(%X3 M>SKA1<9,[37"HKSC%T<["KYF59"_'3GZ=&;P*H;5>_@/7'D(?^]0H?#?\MKA MTT![<4PG::^SX%K""XO"=SZW'BD\$7\JB2T4/K_^?;4@:OW'9^%'JW>?<0T> MOJ/"8;NLC.=L06'XN\5W$9G:TJ5L!(M'^-^$[\.'G*S,130W3&GSB?'7P,+[ M![)P%CR>KRB'MPB_"]^S6\3.=> V4>4CQ 3[%:;NV8*HZ$;!-]O.V8A:Y=G, MH.+\8+R>NZ5ZM5.=ZO2-YB^Z-W,NU^\8%!"?TN^R,D,4M*\P8P7 6S)C?8Q1 MRD2D,89$[0JXY>7J\"D:7YP^6[J4>W68>@T9\?/J]^S#"V):4^JDQ-QV4R6Q MK?@F]2BJ)\+J_K[5XA>GM];F*6< 2;FY#"#>8F'$&.YBHQ:,2QU;G9AX1URLFT2[Q+;)-LO5@GOQ@ZH3VX:JZDT] MON9ZXTY8OF4ZL\F$S=G, MFWL[+"*VEEB]8\"U/:O!63T )H.3>\#,!^?XH-@-3O4>G>JJ@@*<\;HP6K#U M\W+F1H=0II#U\W66[;AR "%)_9@%H44-F @A0B79!JY^(>OGY3 77';1&": MZ[V7,29LK@?'>M]!97OSP*F;7U'6]JP&A_P F R._ $S'P* @V(W! X%Y@BJ M @H(..K": $"E?+G1H=0IK <03>_7600DM2/61!:U(")$")4DFW@ZA>6(RB> MN>"RB\8P 5SOO8PQ81O@Q3,7 MW%)1&";WH:OAWML#]?/MY[09R\#3K!"SP-.L 1/!TZPDV\#3+*:K82G,!4]3 M-(8)57&1XQ@3CM %QWJ?2_1;MH//L=7/]JP&A_P F R._ $S'P* @V(W! X% M55Q4"100<-2%T0($*N7/C0ZA3%$G'^79 @E"DOHQ"T*+&C 10H1*L@U<_:). M/BJ!N>"RB\8P 5SOO8PQC#3:BT@#VIT4$51NV,XF9$B.0>5VK :'_ "8#([\ M 3,? H"#8C<$#@7F"*H""@@XZL)H 0*5\N=&AU"FL!Q!CBV0("2I'[,@M*@! M$R%$J"3;P-4O+$=0/'/!91>-80*XWGL98QAI]!:1!K2"*2*HW+#53\B0'(/* M[5@-#OD!,!D<^0-F/@0 !\5N"!P*S!%4!100<%2.T3JXZX6M@^?9 @G<[MHQ M"]SG&C 1W.!*L@W2#0P.[9[FDCOT9EJ M>:9KS^F<[ VS>?='6@^#AY0033<\EVK->Z)Z-G5NB'/YHAJ>1K0KVYHRR?7H M'- )N7D,[>8ML>\GV":?YO$W"#P(Q[5UU:U$G+7'B5AV/V)FI%YA>,QV?@!: M_8&V16^$'8 66:@+/']EH3S7/KW8VC:%)[O(:R>[W&'SB7!T?=--?>I-Q405 MLU 1J4=G[.T*O?OB>3AE&_!\Q]-9(I[_AV [ENG;.R0;,!V_5(OIR_36B.FW ME)^OF![<@K[,S/GU@YQN;4OS5/?&OB?VLZZ28)V8?R@N".*H7EX37B)_GY@H MYSRN.'<6V%@Y9S%.#P,;A=?0F_C\P$;A/>K,MG&H3:F?2:,,S.*0*T*<*YOH M3Q-W:/H+LE5CL#EQU=,-1W7 QA3X?IC6%_A^F.8:^%Y[^WYNF2JEW.8KCG>Z M\^/3_!,QU)B9=%74[Z M7"P-0 7@"M\:!#G(@)P M ;C@X_K /?<ZP?6-RP;\%T )H#\6W!=#6#[2U]VL!M/4$;?$^ MK?YF5S BOE7;%CJ8&H@3, M$E.RKK!N_PL;'ODTCUY^H;.&;74R_TK]:W]W9/3=M3GS7(=_(0=QR+7Y3!R7 MC2D*/[Y9)IE_HTX[<:\\4Q-4<8;83N8%F5F.[AX X)0B !<_K0>CX0!P=09"WH_:+VDT,U9AV$ZS'"%8S-)M84:3)?<^^_"X:Y#;L>_;E=R&52<3-^S\] M;),KRW)C>>K\^>CNBZ=WEF'HYM,7W3"<2X==)JAV>8/5/'^5.!@AV?]&.3!_ M"<+X!C=V*(I=OC2OJI<40=/5R90ZUY^8D7$FYY;A31]T7&%A2QN0\ *W(=>^ M$=>C,V^.R,]_$-LA\^KR*V$H=>$4-&4MB 5^S^HQ?AEZ[L2BPC_G\W]!/W1< MMGN'#TM,.5E$!7%C6$0&L8.I!9LX((>F]M6B0/P'C7@<35=946JU&?;&L&K! MNBN+M7XP:R%@<6,1GDE)VY\N]&;[#=B M\VUE*('CL-& ]NG3E[-G* .GO^%YNR8\7AT*<)=.R=![\ARW51,&OQI-O7C, M%^<[+,A7^F*=?1$0E5<"HLMF5U;$&F- 5'Y)EF:G(7?_RQO+WY&99ZL3[)!; MF\544[_FQ;:P-A_;%--B"V?R& ))?362O64B^*3FS:,[PL\ZNJ5"3@>!30=S M/]SY-%_^)M"P-E%=2]#2[L41!9L.R.]POCJJ"C&/G7F3+& W,V+ZY9VWP;>" M)@HV%K3$$>V39[D>DM-9[ YF=Q; !JQO0NULO@EU>6YRV#G=7]TY+>#<]$O> MH&M@S.< EL%\E4 .(P*'Q]0-%?*D7V(XR',&]5_"!#1#%$=P# MJUL-I0FIH")20>%LY^C%K_;<+RS&CQ=I1,7&*AM0/#I MRWTE^;^R R5].A(QL!<,^OGD<%;WZ2N(6 X^W8 \ *8"4Q4=,;FG7YTGPU:XLEQ]+ ROHQLR'>/ YG M,VP3(V@HZVR/U2&]7B-$\*U>;P/VC2DI :^K,RN(AFWE4U"WLGIW\],D-FNP M'P.H;:#(BC/-IR\6G27S2="U/+:"LS+>[9B]/[3%35YE5@9SA9'8RX8B JC( M9\LLT9[HRN\3>=H+WNDWL]38.N;>AU[E\Z1[. MQXT2JY\\1S>)X]S[PW*"HT/T*;:I-,PLVZ7.4?"EV+Q.'5+ [=2!'49B!SA? M'.?%RI( YXN5>7%2#L#Y8F6^O/7[1#L/C=XJ:ZB!=96UM,"ZRII*8%U];-V= MYS@Z'IK:[_@O_&/"5LC$]&XV:AB<-)A#-XO Y4.PH,#E0S"VP.7ZV.5SRW0L M0]?XKJMK.E-.V G+QDMA>5B)4Z/%"C\5&3?ZQ=ZEA&G8/9TM[ J)6/X$H!/0 M*:X?!.@$=(KKOP$Z 9WU\SLKLO)7./Q*7VZLA^,(\!(47O7P_ !>@L*K'JX; MP$M0>-74]ZK40K!HJ(-\(2#QD)%84X\.D%@Y)-;4^0,D5@Z)5?83#P%5!^Q\ M 7MK[=$ >VOM)@![ZV%[KUGGA&"$EX8^U4TL[L'VFS Y=4 ';8>!U0=CDX'5 M!V.?@=7UL]7)2S#?[T5DZ0:IL._WAV%[@765M:7 NLK:1F!=#6W=^;"BK#L? M'KJM ]95UM8!ZRIKZX!UE;5UMY<59=WMY:';.F!=96T=L*ZRM@Y85UE;]^7W MBK+NR^^';NN =96U=<"ZRMHZ8%UE;=WXWQ5EW?C?AV[K@'65M77 NLK:.F!= M96W=[W<59=WO=X=NZX!UE;5UP+K*VCI@765MW:5G6S,B;I%M"A/9U\OD'[KM M U;6QA8"*VMC&X&5M;&5-^Z$V%>63?0GDQ_5;.M$X%VD*9SE/1Q2AG/HIA0X M?2B6%CA]*(88.%UI.RW3)RO++^^]!X?\Z5'B+Y_I7^/YC' ^KWTN)H>CGNCQ M@UAL(HT=S1Y%F<_M9J*\BSY"AFS_N+&-UYMF/CBW[ MZ41I-ELG-OWZA%UWA+"MVND7!U>X2I8$'@W[CX4%M=57M@?Y./4*/MC7U?Z!VNW*GV59:*'S5CEYU MHE=="K"3M:$),-A6K]7I=SNXH31;-![DG-[2.K&H$*]UNK_MZL,U! M.+#FH!N]ZD6O^M&K0?!*;C:C5TKTJA6]:D>O.M&K;O2J%[V*[B=']Y/EZ%5T M9SFZLQS=68[N)T?WD_O1J^C.2G1G);ISQ%PY8JX<,5=6HCLKT9V5?AS#@T\< MR[-5XE#^L_<3@C4NFYK^?(;^AM!']H+^B]#__L\+;G[@GZU^^W&&''?.6/]( M!:?QB*>Z,3]%__NG9[D?QE2-.&A$?J([:XI-_\,/B%_IZ'^14R0W9^X'-,7V MDVZ>(OZ&25\#&]18G"*5L)WI'X[._.=_/)G1)^?^2#I!&$UL\OC;T?^X%I6I M+6\O(?ZQA!RJ2AY?/>SH;(P?#(*L1W3.E(OI.A]/\%D^@U$VF[_OH^OQY06Z M'P_'E_>%/OG^\OS[W?7X^O(>#4<7Z/+_SK\,1Y\OT?G-MV_7]_?7-Z,T[E$3$3+OX?W7ZY'G\_['APC( M#ZG\S_FQS@R;<8]9>\KR;15?+A[.KF[NOB%F'DS+''E3^G@5F9CY'QK13R\L MU9L&[L 1"FSG'9.DA #GZ$QN-O[)U?70?+(WZ-*X=WOR9V"YSDD-A<:T9FVQ76WMZN\.Y@ H!R5LL M_J='72QB&\&1-]086_84N[\=Z?1FU $]?; LXP$;AD7'^[(A&*@X*%U9_K . M",Z2CR>NQF9EKQ,0H.&?WX=WX\N[K_]!=Y>W-W=C=/O][O[[<#1&XQM$==B8 M*BI$K?G-'9([[[3WZ.8*C;]J]9OMX;WPU']]=ZPU:2T)5.U0S%.=6\I\F:_Y(O +%K_4LWE*TQ*C;:>'?Y@E67 MLY2%O#9YTATF!B["#G)F1&4+D1K23:2[#E(GW#-(\<$'@^/>KQ^6;5'SPP[4 M9[1ARV9JS8XQ,^:3VJ%6LVR[Y0O0M:E:-C57?,6'+]#[*^_SG=QPCB%HMBV5KT!^>K3N:KG++93T*R]%WU\=WQ_?'OL*]G,X,:\Z2#L+/ MM[XLGWS:[2=LZG_Q]^^%G>Y5\4 CZ_A]!1V]'=9R-UGQ9(]^0],,-;XO]-H/"JKMM_*"OECF$_J=_K5-Z)&S%0S&Q?SMF4UMBS[# M!B(O1/5<_9FYX51ELYO3KPR/.;KH+WU&AZ=%B]^BZ>A\)^@N"D+8PDM3'GQP M*%X-,IM8)D$F=_.69X__P'.J,S%F2D2+=UEV=WM*/-XE-0\R9 M9SL>"SQ="]$KN,LB*^\>WC,Y8:LSER\T_#2?"!JJ[NGVRZ$H+T6:?TS*UU:# M7S6"4;@3&G/SOV1&?/"E+Y@-?IM3*@)T%K$1?:M:AF6?(OOIX5U30NS_]Q]0 M<+]6_[C_:W0E?6!X$]YK/OJ"K3S%?V/K3Y.UKPKR8\>ZZR?D"58G2#6PXVSB M MN,QN: /9LC-EP;UKJ3\D-,,V>L:&1] OS>-F4V9+\8CZQME7KE;YXL\;8\[_ M-/E_'X+(W-< 9<]A(/6^T&\X@:,OX_,LDW-8L!U3'^)-Z(9.!E,4KR,.IC&V M"C=&P_N+X>L"&@YUQ$I:B(N^?CVOX+),GGFN:U-CBU0$/;\+1(3I^B=_!Y-L(,>=8/ZC=@PZ+D?O1U&" M'(^:#V=BL?1(F#QT:4"_1CSZB5>I9"3Z/P[&\%Y"V-30.\4?XP/%&OW^X0\Z M G8]OY3^B%$1W(?EO1U.!"<2.RX:-)&&Y\[Q6Q'VN6?;]-=^KIQI'1>[GK,A MMO]#G%? #BN$T,A"BZQYK;*E63#+64FY.-5=E_*=QK*J:ULF4\7&'!&JEN>( M'^N$5;X$<(%=[*=@UQ"]N,=RN'3GT2O;S0X#+0V>/;]T&-TWQAO#=WOD^J1$ M@"3.^V!A_\UD5S1.-LP @H"YW#&G.P@C@]Z/(*S2$)6=[4E9QWAE,R43^RFB M,]N(_<*94K#2I]BALJ 83J6WHXJ(T?Z$GFSKISL)OSZF*I9PVC3R MR,,,R^1K7_[BCOHAB43_>QHUA!=N<$DRD=&E3+N&ER>0'%U+_14N6]2A;2AQ MZQ#'I0"M'JL>BYQ8JWDL[]OS#N;Q:SS8-O&6?0\I(+E]W-X'Q4@Y5CK)ZW0+ MW;8-K:T6J\E88&C#3*72.^[LFRL\,J#/&&9AR%37-(/LER&;-^@ M=,L^I]/^9,5E6/P-?IPA:G#1YJ%/G"')$J4>AMRM_+)(T;OW3:9/Y"N[*;0< MO@%N/K)/GJ.;Q'$*VP&Q@29814F@#+9'23#5V_^P&L"\C'?.1%$961 9#NDS M']&Y/Z#":M0//IH]%)AV9Q8*49]WAEM'$IJIC@_FEK*:!7>RX-%#!MN8@ M5NFI:TD9TM8[')LA/898>#T6=B8T8@EYC]Y1CO*(U"]O?AWGT4E\?XS^0PE^ MR\ZP^Q8BS(LE#KFF;!VZZ$9UK>4-7Q+GAE_VP7C#% M(ZJ?7'+XBCM;PPJ8><77H.@WK]9$^0_X"OT]?]+-XD%'R*%&AO!PUS-UGXO\ MJB.*)56G#H?SV]'UZ&IU]QNE7;/O0WM'JWJ_%= M=+N8HC2T](BCJ)%!^//)8X,J=/_S]2_8\@2Z_3SZ_NUHN2L"OW+1%2%\M7@Q MB7; W0X_7S8^W5T.?V\,K\:7=Z<(&S_QW GS6J=LL8RLD/@!38@_6H4MO@19 M]##1B!ZP^H.:(,_4&JM?':&3UU/SY2)^:CB'=IR8\Z@577X[/K MT<7E_Q5+(Y^;Y;7PP:O0@Q'@KZ,OUJU?+6FO+WFO;W4;Y+G5S2<*!6OG_AO$ M%A*"EVB3I<7^L5+0RN+29/+P,6/Y%71/H1>P(2 MJ /!.K#\=J0DI>)_J#S<0_O MQN@:-=#5]6@X.K^FIH:ZSS=WWX9CWFP(GVW+NIARIK5"KW2V[F>/1"'7M*J+NS:&Q)1N;NK<<<;>VI1*-@:P<2+4K#"F(T?9/9?6#M#>] M$S](8U':S?C+Y=VN$5H5&">.#"]XA94:1UT;#NXK>:)>+[<)O):]!*,04GJF MM"MJ%E[-.MX,4\.*@NK-X3&'%5W1SRR[/$#A&B&JIK'\AH/[;B[U-;C'!N$1 M^>6?GN[.ES><,??VN\.SE(%&*PU]2HW 5]. ?!OL_8'C!BZI:] M!+JR -:J$#$,JWYOK5#;OO7A5?L_\6!:W^Q$>UK*MO5EY/;+\R^M4 MBR.SD!^]A+I\*Y5+9/> MAD7++PLOFUXKCBZYH/2-TNU2.OKR(^'^/;R[:'R]N?G]>O39/U7PV^5H?+]< MC5OZW!7X?*7'"1A/= >E%I2S_8&L'QVU2IZ![:AM2+!XB?99M;-H6.(WNJ73 M$#Z>QD<_L:TU#,OZ$6P5#"K0HM^PK8:\Z2-!4X+-8(]4N&E0D2\W;'\EL6- M\-3?W_B._2 D8OGJ\+'OC]&_)\1D.R/YGCJ7S;"_I=S?Q/738AL:+1O-)C9V MEH;T4Z<*U]!_$,H(FT_'Z]XNY&5&Z7_]NQW\QLZX]8*AZ(H9-GLM)FQM$IBBEN*.6LX3-O?(-M@GR*_39* MP6G/\]VY^WH'Z'A"'+)T \8+2@A]B2R/DT6'@H.&/#;B0WAD6^9,E=CLMI3] M4]8PVPKV5+*$FX0>/>;/L>VKA,TL(IA?3+\)MM>R/7@N>=*9H+*]KG32-$]U M_05OWXBQ J+%K:P(]OR2X"UO<<9%P^^)%ES\$.SHYY]-_8HC:\9 QK;DZ=$> MN5*42NE:[2H1/FL2R4[WP3^HOJ,BAYT00.R@/D293:S'8-)3[Z<%YZZQ-^$9 M&7[+/>KVT+M0(*4\A[^V*$2CVU %0I!'!V2[^ =!IH6L!SI3 N.0/%W4?-]U8FT2M&^8*;. E2QQS-TZHL%IPB0#-JN$YVP\I,^06+] M8LF,'XP4]4&C S7P3TZUBKU(HV.-TV3S(YJ=J)W:JC R3?" F:JDOU+9B.F$ M4@_4F\Y\4> _F^(YWW#^P&]G4%1H@1@]6\8S_5!W?OBBX)G!3;@VYS]6+<_0 M&&5L@E37PT8H46PR-?V1\@@Q14<=3-:)CA]WYN]I7U(-[.9+NH$]@A+!0**; MARYK;%NY-Z4_FS,XA5STF<+/\/:U/%.WH=YBCU[8T5OJ7J!K"849=K2'M9YA]>F#]*]C*$>+=O?@ADO(^MA8C.';FE@=O^+6ETR91!$$5. M,-NQ\/H)^G3&9-TR8R< Q!G$N>@AW"2*,0L0"#_A*-:Z!8[@S**&C(W/%UZ+ MKS!I-((QK%D4J$4/\$6<=]0A3_X^GC616(W%%\VIZ.<\4&(Q71!8!(LK3 3Y MFH;##O@!$0(1*D&$EG ;&ADN04O-\WDK-IT#V._%AJ9S:APT9JSPC'ZE%C&@@.2 Y10_A6\/\/=W!;,,!_3']V[9LW7'9P@96?_AK M'JJ?8/R);;ZDS$9A>0X/E.SIBH ]@'[)2SEL92#K;.,D;8(31:90!4[$_1H M6-2M6CK39DY8>I7G4B^HT?$;LA+S7/Q\($L,2D%F?(Z"(H$@J?F(52+Q MR,3364Y=-; ^#5RK19S"(OW%]MH@U\C2G6M91; ;( :E#V%HT'#;>YK0&-QF M8?GJ>G7H_OLU-QJ9$9Z-Y%; ]C.L$G/Y;69F@JNC,)U#W0_M%^'\THH B &( M@2A#N. +20T:0/.#(>,6L+@]H$CG=?D,R@X[=C"HMW.I&^/7A/E+4CR%XS 7 MB!^KR7.>4:SHCKE^K&V0EJ27QJ,3,(TRO+ET!B '$I0[A M?,(2$[S8Y6'.@E];\XO8"<_$LX# 8%UTF,8.'*4HNEU*HH![ X@69 A#<[' M'X2T>,HK7$(-;3I^B? ,Z]IRN8E?$F(3S5/)JK,". 8<%ZZ9^6J-.F>5Y'ZA M$RN71X^&QW+*RVK7L'ZR#-::MVT2E]?93V')$=!;AE_!G0JF@?$+"R$US^7[ M'X(U1,]<[*G25J_1?:W+=P2EN,T < !XB=$?.[^1[8AA61U_]]EBD2(FN O6 M.*+-FPOG&= +Z"VC\&9EHV6X_8@M:#\'#0=7Z^'("Z_9?";+96H+T(?[B'R% MK=';S26JRJ?^^N&,>R;N2L6W0S5W&%-&M%![P3_WMVJ";(!L%#Z$*ZP;?)_Q MX^I^9"H#3VR[3YCZ66PH9B?7S]RE6F=8" $ZK7R \=#)H#,F1K3+7 M)M+K@&W MB!#N.8UZPR=C^S<9][+@;H=#WPE>WU#RI-E,9";WB/;9<*K'&?\ M '"5..N;LZ(R=@9SJ%@';)?G5H=;J^8^BC4:[3F4[K!_#*'WC*])62C[0'4' M-8EA$Q4V?(=7_X)"!]"+,81A4!_NMR)B273L\$VW;*V%XW]Y]8.UD'NRB::' M_81,XOZT[!]+K@R]],G&4[Z=P]\\R%92@M9A_DZ^I77S2 86&W/5E6YRKYIG M91*2:+;]&0EZ#"Y/_2Z="^,Z)^;9['3G7J;-[Y[Y[FX*M ENU^RZ1I27_I.!=/HCFM_?AZY\KO7T(U='6E ;6 MOA:G@.<>;+CBO_#\=3.*NR'K"L@6QOM@]6&-!UNGZCHL'/.;E(;K_=^/[X]9 M(U,.W7/+MKV9BVZC)="AZ@*0 -06:K@9W6YQ50(D-^BPRPQ+T.(C:*BQZ&SP9 MU@.E.[(LT5K2HM/!H@?/8LDIK'I;[1 7_1B$%(2T!&L3^% 3PO=\.#.*8IUA MBO5!#5MSN_@EZ +L.!34X;D(BWB8[RY9E,RM;R5G@0.QGW5_/\FSKO&>.\N% M<@6MT(*X@+CD(BZ>R9'D+P6YW"[8*-SLS=IZ&@;Q>Q[ZC1+81'DV<*^!6O7!8GG0(5[-NSC M!J@+4UTQ9:>Z,._%=]QYTV:V\F/ZOH5K6P:OLV>-WVUM44_$3_C"]@.F&&[< MO!AD'A[NI32;2@#V5^TOXQO,!H71O.-9Z!7Q)F@@&R ;9>8!6*E07)(KKBR# M_L@OM_-FO*%'=/(3HH[/Q+0,ZVF.G+GCDBGH?,!UX4.XY]!C:T!LY3,\F._1 MMP2L!FC.HE#_S,:YCW,I.)*&M3&;ZHX?LFK8Q5 T![@690ALP2R0)_/CBBT=68Z^.X!.ORP?R;KF\S2#4Q6V/:OP/?1\!0_$9 @ MD*!2AW"A.W@VL]CICE00_HR.+0Z+>=FHPI%16_D3$5 MJT=L&(!L0'89MF$%B[JSFLA:\NR?^4DK?,'F(3P%S3]0-NK*M]@GQD-B?V7^ M9]A*'!J+ ,++1_BB#3WOPA VOF>?\?;)^C/AYYR#1(%$%;TVZG>T]]L4/\Q98 P:'VNN/Z MAW]3@(?8#UN8S&SFUB_@_H. M)XWS)'GR^?)\58]P)>9.UDZO7RXU8S%WU:9N_&WY6SMVI]0!X)S M=/;QX8PB0-=^.V+QE'R$7-UE3PS>!="@U]$YOQW>C=$U:J"KZ]%P='X]_(JN M1UJL"*2_6SBW/E$YU\F*F@GCBWMT?G-W>UPT=B@U MYS>C^YNOUQ>4+1?HT_ KY=,ENO]R>5D8AY:I>7?-7!?+_WC*;BN?;:QH=1$=?)@3&B_@K7T?$V/R]#@);!3!7HRX?7$>!ZA+@('L^" M0(Z&<"&5#UC]\62SCBL-U3(L^Q393P_OE$Y'0N%?[S^@M2@'^2$'NY\6:Q-R MV?).(XHB[D^'36?/_.U(2?6N\GI^C/OG,RB,XY \>T&.9>@:9T530NS_]]G# MRBWED"KMI8+0+ /; +!4A>GAW B+@8 M>76ZI! 0X4L2H/5$0G1!4'WWW<2>QC8%O=\K" MG8$'WWR=1@3I2,/(63KR2L+3Z'B?!601V(TO+_G,4$-):@^"*_/_>O# MDPIX'F5IFO"<'Y=O,72=T]JK%W_!N^HCJOK]Z\(1\1V:(##S%ZJ6EOU?UM:Q M@K*!<^Q,@C-TZ0ORIZ<_8\//=:S.9[BT]FM^K%NB=8G2)(862, O2<]6?EWU MU7CV,)X=LHX/S0U]L_E@NU#]QS;]IP2\2]L>&QE ME>*6_JIUA/S]*/01+^ZIZ4TUR]6(JD^Q<82"%\YO1XW6T=F@*?7Z@X\GJU2? M'3*B2B>@2I#NO(:T/&C(2J,EEP;IKM1L=42%M/ .[[96Z=IDQS=9MDX.V@ZE M$R"@Y':S&J.0X?,1<3,):%M2.F!R*D2 @.CM9;4[.Z.W*[6;;5'16YF8)USZ M>%E\$I7W+7T6YD,V,40WO).9NK)F4BQ;9B_\C[Q.;@D"ON/\;II.%4)O%#36 M-'74SVI,.6B''*O!:E]&DSKH*24K)8'0+Q8U((N%RN(@JVN0DRQVI$&K6PE9 MK%(LNN+RC"V7=2PJT=2#^[Z+^]YN9K67.XIG^^A,;C8E7IHGI@/WQW"G<7MQ;7#V/>!'/'7%<6^ELJ0=H[5>L^Q\E$#P%XL:$,9"A3%S M^49^PMA76I40QLI$G[LZ!7Y188E.0:MV>HB."&F6Q]I K@EGV7MCW\=/WU>GQ]>8^&HPMT/[XY__W+S=>+R[O[\%0(=/G/[]?C_]2^E5.U MNY+5Y_[UX8GP<8@(G>(,'3^P8^UT NWB*C*BJM^_+AP1WMW9MC'/4%4I]2X[ M!'/.3EX0),D$+;724Y6=S)5=(<-O?7[OLL>LWR\[1A$+/Z434"4 9R[IR@O M[:.S;A_*N0HT-+;':HBMZ53GYQW"MI6RK=O'1<.KG@R;$T)!N(O)O;!C08Z9:0KQUCQESXJJGYWBFNW00 M?Q$M%.9SRW&=7*1X(/7%7>4 BH!ZZU[S>P?UC);O2N[4OIP J;U9FA+I4R" M3+F ! @HR9G+%U:[1N4CPI("#6JJ1(" >,YRATDP7 M;&BNP6ZF+!N:N[L=0)1;QJS9+=O<"B0"8E$# EFH0.YV"E%N JDTR_87:M9E M8-T#6CV*"(+62CKYO_/JOJ/4DV;7GE-R2>FUA4QI 0"7@G+UO2NYP M[DBM;MGQ32TR=,EMN\.(9B[(K I(@( RFODDHE?MCI=\P\P]CYME=SJL$II* M)T! .&<^B6@_<(88I]P%6H&*16"!_T 7^'MYU[GL?(*-W"F[Y8% PB 6-2": MA8IFWB4[NX:I4J?;KH1H5C9D];-PD'VKIGN?N7AER9O/MJNN+[5E8;UY(* 2 MZ,UMLMJ=T2=FDEUU@4J09VZ+ _7_WC/^W&Q=5W>H]IP]:HMS&A=R2V M1L/[AFKHU$8W;.)8GJT2IW'N.'?!F\;$G1H-0S?)M4NFC6?EN<'&P&:L?MU@ M6?,:=TK89C]L:AR>E%O$5"G4T+N1Y1+4>P_]8;,]T9EA,WQBEOKD3X\& M:=#ONAHCJOK]Z\(1X7,%^]0S7)]$?X)-/+=VF/AVF)J1T"^;6(DN'?P&E_6. MSIK'378 8V!+^#_4D;;1,S8\\@%MO"@N=&#!\IFE\F;749C'--:I3]^-+KCL)9_S->U/-=QZ0OJ[\8: MA#U$0P4&S66'QX%1#A=OW?2%V'[F,H1(%+G!_Q<3D*00^2]B6QIV)NO1L>\> MM#^4$A_'S),P&#E<.&8N(Z@Y'(4/.;;M)<$60"QS&S,^V,R,#W(QXX/-S/B MF?%FGG9<:6YDQRE0_?8GO8'4EMOI-M=%]V3FDND#L5&K2<%!53RWQ!=$#3Z5 MV:?R0)"%20$)$&]5>Y#9=/NR][:B?*-07=1E;2"@$O#-;.IK#E_AH_ZMFQH& M21QLT%_J&OT:J7Y7,$%F7$ "A)-7:ELR[Y&*^']+V7]M!BWALIUZU95D<8M[ M@8!*(#G[]JB#07+MXLT[XF+=9(>.8-NDOX/RLRI);.90)V3[9<#UH:IZ4\_ M+M$NR*.NZEG[Z;8ZL$FW0@0(B.G,\<^>,"U3@R1N*\[Z144+KB'+[TUH36Q_@EBW0C MATX3?47]SH%0*Q_OA858Z02(B/%=#@XN#N.RI)2^G2<.Y96)JO;0?W=L$^QX M]CQ,^6&7(LEQ-\J)R9OEQ&29[^3J=*5^KY.0C!,U%P9;(>N\%3)5IV;>6Q6* MU(ZI$*4C#9IEJ\MD_!?L(8 @'JP@9MXF=E""6)E(?-<.)OZ.92=Y/X,HC '% M5'W%E**7Y,R9U^6].)<QVI M6?KB1LUZE>3C*2SU-N$K"J)Y#JW:*2LZ(J19WH-!UB7XEUHIJN1QIFFJS$GS MI:X70U/+26_)S9[4[)>=-!=(%,2B!@2S.,',G/G?CV#*?:D]*#OQOYDH^![% MB?M@:7/VCAVT<(;^AM#'$TU_]E_%;DC^^QI]?U\C;4$9)RR@@+U%=FVHZ/_ZS M$)+#IT:2M?)Z^>7$1B=QP_]R$3]\OR?#[H,?WYQ_U8-+1@*@Y9CXB=GLZ$Y^,)/MN4-4NOV M^H8__370F>DL07P]S MJ77#ZWDO7FM1,_QP-AJ.O]\-OZ(OE\.OXR]H?'WEW7!\32] [[Z/AM\OKNDU[TN@ M\=VUB=R)Y3DTEJ5W(2\JF;EH1FP_EXZH?L<%T[6)-@]D@+L&@;OVVQ$[/(YJ MC,#=B-X[,ZQ&[WW=0NT5%[EX0Y"77*]62/A^3B#'OF\32GA>BR>1PMMSSYHR MGD.G@]5X_';4?=L0[F6K_L;KBL6(+IDN/X19I0F]C9O^U9C:08*^T4\G#KJD MP-16"V4^GI#I6?!7V+-EC\R. K&E.06DU0)I(^J:51!H?NP)>CF#M"@@+>DB MP19F!80\H$50M+#B5$ +H 5T"Z#E('3+EL[7AK6'^QQ9L&S047XMM1OSB+C( MP08[;26%G_ON.UC,(^-ZZ/WRQO,'(K4_5)2UE+T6I.Q[C::\Q9;W9V)ZY,JV MIFS-F#WFW[H[.?<$;N@XA/ZO9=QM=2:W)5E)*$0JC^&%HPZ MG@7HG== EP<1T-E+@8#>DYI*PJ99 #H /17HW7B-+HNHT=L=J9U4YPU !Z"G M KT7K]%E$35Z9R#U>@/Q@5[!->&E MI')YK3(#O,^VY3AH9EN/NGL \9VHBB1=0R@Y1&2, 68KA-F$2H&MXI6=,-L^.FLI4D=N F:%?:1@F$U( M^F\5/>RJ9]MMJ==+V.PN$F8A];-%9' S(S9VV29T\C(CID.4I'-A M1<(O+"Z^%4/<$\/0S2<)/1&3V-C@#;VQ-M5-W7'96N,SB=8:#R"X@-HGI1U3 M^[1]J.+#ZK,/*JIJABN0NO01E;&DEFJ\BI9!@<#446!B2H&V#X[V)S!=J=4I M=_LZ" P(S++ Q-0A;1^.[4]@Y);4@UT;(#$"24Q,%=3V >#^)$9I2LJ@JCLX M(-&T106*?P*4]:H.!6+#@]!#,95M6\>&41%3H'&R+4$-I+X"-AID0QS9B.F MLW48F(]L, =6KJHY!N&HHW DU#]L%?+E(QRMEB0WRRV,!N$ X5@6CH3JBJVB MNWR$H]V7.I5=+(1LWQ:!W+6I6E."WAF6X[Q'C[8U#:,ZRSR$:$Y4A9*N*1(* M6;+%7SX$OE( 9,LK="M0 2 &B@X#N.]2D-M)*&')%AWMAESDT!FAKVB@E'S$ M?'D@?B\>F "_G82JB&P!3%[X[20=9PSH!?0NHS>A1"%;A)$7>ELB[E!^OT-$ M47YJ*)_3WX_.;MP)L9'.&2TAD[@E1("+P]+EU,/2"XY+=YK9:JUV%#OD-/V5 M4#&R7=S#,#VR3&M5C^V2]V[UA>B *Z:DB$D5R&\9\IM0O[)=]+<'^2WYN!.A M)45,JD!^RY#?A+J/[:+?_.6WVP3YK1A5(+]ER&]";30M62P6AJ==Z:9')>XF2C9_ MXHCPKQLS/%R^N#:F2D\WL3V_=LG4H5J'$6);O(+]FAWO2YR,_6>E9@?..!3W MD:*MG.?1^40P&5BLP/?:Y9900_Y('"E($X(\^J<()@1GT'Y%W$<*9@2Z>?1? M$0S_"R.@2-VV<(=(5#L-*T"X12,K=H3,L\Z:_:!W#\0DC[K[_@!BK6JM$>VE MHKR;1P^72!$%*SR?? AEJRN7!:L5C2TS%]<@@GSD*Q]YM&S)4SXZ)9_L!O)Q M>/*1ZO'FT:(E-P%I+WFK \&Z%B<(2LV7,0Y%1M)$)(^>+#F*R)DL6D/OC6T( MI-.VB.]&Q VS9WY*K>B0[A5;6R55%*P),24#:9;W8)!U*?Y%=/V33'J: LJC M&0M%TZ[; %OEUL"^K7;*PJ#H@ 9X. M2("U\4QKXZL.:'# U2?LZ.HA5#WM$.94.$)+"=!Z,56;;ZZ/WQ+[GOGJZX': M);9-*J].^#V'512P-3<,V*Y'5T=GS>,FK&V V B[L-&+*1Y\<[E\_W*S6.EH M'LNB5TL5OWP.LB."R8FI*WQS[;P8DR/81B\P.8Z(;G$@VBQ[KJI#25%%/>F5OT& +XD<0G&H*3JHQCZE+S"U^ MW$5R((($Z1&"]#3AB:E5S"V"W-7L0 P)@B.NV8FI6\PMALS+[!Q %%E^!C(I MN?IOPI!,M :F1.$GLE*#H@ 9X.2-BY M4JO\U?:USM.K!5,EMF!NU;9=>7)D(T2?A(+'G!;,;7W0:6P8%WK\0]_A'WG3 M!V+?//)KG9N%O[^:(MRJG7!3ZO8$:V$NDOR(215(=2E2W=_Z$-@2I5JTHX%$ MDA\QJ0*I+D>JMSX:MSRI[O3+S6$(+3]B4@5278Y4;WUDR5)3+K?S M63;YJ5Q>!:KSRLKV5DN)[:(#XA.(S]8GX(+U ?$!\0G%9^L#:,L1'Z'BR0SB MLQQ3TMQX=S?UZC^^QK!"WHYN4&$(15U9K.L#FGG$:FY=*GN183$MZ('E,\HT?= MQ*:J8X-22#^8TALXQP+-'(414@WL4,FY_?SI]Z-UF6@V?XU3*,$GT8J6&ZQ: MK-[O:GP7W7!9X07$H:6'A*L>RS>8/#9LZV>T'K+VE4H, ]U^'GW_EOJ,5Y*Y M(N)K4TWG)U /2(G$,92TE=?++R+^.'[M36[#WY\<_Y5-W]$S]!T M9V9@.BK=-'23-!X,2_VQ:FKXHY=6F#":V$Q5_X]KJ4CX?C[W? K^G(Y_#K^@L9WEZ.+>W1^C^^M_7:+K M$7U_B=Y]O;F_?X_>?1\-OU]6YU"?Q"F8@$TT>(![[AX$ MOA[?W\"T1."(1.^=&5:C][X^H3:*BUF\\L]+EM'R2((5]4!VEYR9O1]VWC5\A(47B\3O%R"B9+C^$6:()O8V;_M68VCZ"OM%/)PZZ MI,#4T#V942>-1B2HU90^GI#I6?!72H)B;S'#)N>U =*J@+01=<18:\&?M.:UPS@B,JW)_#@FJ$)">,T%,/1D:"% M!8=OJA:&(QVWU,(57.0M+[:X<2?^B9 SFTR(Z>C/9#76D)!)PP_K$;GXY;20 M@++TE8:]=X\1981U>PYPK&K/ 8Y5[3GUY%CEUB;WZ3-PWR#Z$^QLO;)L0@>' M5,^VB:G.D6MCTS$P]U>Q]H?GN*P6^ "6)D7=%)$6!K>:60X>7 \CN+-XONPK M^E%%@(WS !ICA@R?A*&IC1 MC!.D0W6?0;Y:S2P'#HHM7X*5_V0J\0?YJHM\93F64&CY$JPUW^;V"Q*/6Q0K MG2>7*1U"<'N8YZNFZ;&8VLBM0]T8%;:;J9=D171K#X<2UUQH4A>(8LZQVCIZ MS5EJEG=Y]&7!TC:;'$@,DE,3R4D1'#FAAF:KL#1O<]/N"I;1 6-S:"*39FSD MA&J;K4+-O1F;EJ3T!2L=V\380$?=2E '77KW5&W%8DC=-2%CKK047?_'77O M*9Y__W+S]>+R[I[.%/,?/J#+?WZ_'O]'@(ZZX["CKH0N7U0ROCLZ"G M<&XU6%6C^^^SS5AJ(Z^0'-[*JUYS"CRKWIP"SZHWI\"SZLTI\*QZL4-5]::>@?EAU2NM8NO 8!#*RLXI\*QZG,*/*O>G +/*C2G$'N>#35-9X56V(#0$V12@#D%F?3[0(,X@CB* M,Z? L^K-*? ,5H+V;J5%.;C9G>BFF"< IGQU:Y-'8MNL,,^UU!]Q)S4#6 L M_E?GUG1JF0>"E,-U_F^QKC6N36!N'9E[1URLF[5,\P-W5UNBU)G%8,=WL.-C MFV#'L^?UMN00@T(,6G>+4YE#Z/G6-V?_6N;M3H: "Y%P,9Q2_>$"+@ 7H"\ M%Z O !<9 U\\T]TB*D@ &-4"QB6V3@ MP/ $7 MV7 QMD1Q.W-?GET#!;R%M_F_W1"U&YYTL0_)"]I_M9J_)JN;/)3?&Z==?!I^ M'8[.+R5T0=2@@9K,&JC)@UC%L^\6RJ4^JBW4JKH[9PEZRV1M*8>87M[\PHEE4%_/\6^9U,([#LVLXSV N?1'"8;?=F;\^@6N^]#%B0WHN4*6 M%6G0&TAMN0TH!I4< ^G.7B"]DSY./_4JX1@% /*! [F;&*L/OW:##)^ M!8*ZWY7D9L+)R #L P=V+S.PPXK\,%-9I)JFB)83#HP"1!\ HM/.:NKTL^OJ M13O)I'.!BT/Y\F&"2E<8#_M]O8 N7HB8BNU!9FR'FR<*CQ*7<=SI=*5^+^%@ M3,#RX2KM;G-/P"Y /2L=:= $_7R0F$Z#M)P,Z4*\Y%Y':HKC-U1L1U9Y"=,1 M<9'!:_P@/;I_^4W=IQ@D:&)V*D)H62<0I"CQUIN'9;?VD5^D2L"/-UFU+Z06 M <6@R@ $.ZJR3AZJ;,N\'.@Q@'".$.[F >$=,G( 9X!SGJM>O3SPG"41MQ&0 M-UO^ZO2$*9JHV=J7>&!.PW(_%]V<3P8.]#1 &\(G $&.^JW7S$._;9VL DT& M(,[1X^S)&Z'X@)U'X3?VE9F;NM"?=8V8FL/X:6";:!+ZY2/;>!K ;R$=GS6.E^?&$77MVXK#*$DAP@5LC"F=J#H(4@U!2@BO2)%OZ M- O3 ]B>;42EI% M4OJP:>%0$)P&8)&27*"A =\00@$(\E9R_7(R7:#. ,EY.YS]/-)=]?,=8?]5 M2H[KRK()'1]2/=LFICI'KHU-AWIK#%M8^\-S7*;T8'\6^"K"<*;F($A6\(.2 MTE=)<5N@/,X#W3%FJL.G>FAJXX4B^8QUDU5/#&W=T3#0#N"8 @O&&4GV$!(0$B$%Y+2$G8@'2 =0DA' MVO+B0*1T8(D2LV&?-$68)L200X>P5 3.U!P$B9JSW2PGQPA>!8B&$**1XE6T MFWDD+<$;@)U_>69%OYM4UQKT9QIO3DF?P[*ASU@W\(-!&I3_#8>"@3Y%I5!Q M=5+'_.C&I[N*I6XV)ELDKRWNX-A#L5>UQUF*\1,LH;O0>U\L@P$R-(PWYGVD MZNKB#H+,U5CF0+<#SDK6[2+EHD&Q@\#57N!$S7&#\('PU5[XA,N=@]2!U-5" MZE)7SZN0D]^7)&ZV]-X7Y.C46!FM77*^[L(("PN LY)=+5FL:@+PLT#D:B%R M:7Z6O,\J!?"/WO:/8!-W2KG"I^'7X>C\4D+?L*U.4$NFXV^R_L.UJTD03;FD M&VKE]9FX^:1T=SO /,ZRLK/+H3JO_$<)AN#6OA"\TT'00KJ&@%\!\=O.C-^T MQ.MNZC?1+>,Z6%:D06\@4=(!Q8!B'\6=O:!X)Q63 M)\X'V(L53%D2[V UP'8IV!YDQG9Z/FR/$=\*CCM=J=\3K8$J8+D,+"O-/6&Y M (VL=*1!4Y@%#(!Q>3ZS(B>CN!#WMR=+_8$@*OO=BISR]P=Z,O#(D! V"=LP-T. M]CND_4 $#HL 44@81OL=B*0)5NX$?935TI:Y2S851)YI1,@(/03MJ)NJ?WS M23&")3@L B!XK";?2B= /#W:2MC>N9T>W3H%"!KSL @0$/@)>RS7@'^X;K#P M>R"3!A&=*L&?C!(@W*RX5"V4BK"@V2+9=#LA?^17Q->N"+9;::KG0EC,6N$.A*)T! U+?VA?H8B\@OG%"C M1VS'OV5%O=0*0:YT @3$?#LSYM,*)G93\XG>&]?ULB(->@.I+0N[/P (J +R M.WM!_DZJ/CUL:0'>*T. @'CO9L;[#@4Q.6&_WY7DI@+XKPP! N*_EQG_64H_ M\E+ZLM1L]@'XE2% P);3O7YVS9]/E4,^PK!HQ2Y++;%V!\-I+E62AT%F>4A/ M:>XQZEW&?J?3E?J]LG,8@/^JXK_?W!/^"]#\2D<:-$'U _0SQ0!].1GYA;CS MW8'4;PFEN2O9UV1]$"/B(IU[HX+,I'@$0!.Y:O*M= ($U.()W2]ZBXJDP3Y2 MME3+^"$O*U"";&WM"0"564V^E4Z @"HSH47"=BISR[PGZ,O#(D! V"?T ]@. M]CND/T$$#HL 44@8?/[=B*0)0.Z$?;35TO$72H! JJ _82=WENJ_WQRH& * M#HL B!ZKR;?2"1!/CPX2M@-OIT>WSAV"QCPL @0$?L+>US7@'[ ?7-D]JA?Z MLZX14W/87!O8)IJ$?OGHS+ 94M!PB-K07QH37:,7GOJ0Z,CRT5GSF.UF9=>> MG3BLO$<09HA' #A!U>1;Z00(: M*RCI&BFI+#VA1,P6N4.4( +U93;Z53H" M>K.,U",HS0,D0$#LEYU_!#DX0 ($W'(P*"T+^:8$I*Z\*)+2%VKM!78;"(;Z M--"+E'X$2W" !$ 864V^E4Z <,JTTRPG!PEJ\P )$,^![C3SR$36TQ>N[*[% M*\LF]-E(]6R;F.HKI,=YC[0_/<9DB*_A0=9!3<&_J3H!X[HU<4G8Q M*:0,=--YH)K&3#/Y5 ]-;;S04V&_]OJ=OE A.)=. "CB:O*M= ($5,1EI"M! M"]< RZ43(* PE9W_!,&J :Y+)T! P2HMGPH250- ETZ @!(E4K*V1"%+70)N M#^ ,@NH0 %%Y-?E6.@'B:6>EG.PO.#LU0'/I! @H3GEDD\%)J>]NV=V.'3XZ M6YSKBPS*8DH(2VD_8]W #P9I4%XV',I82D9XR&^Q'(+#K,O04$4=9BVD RH0 MY,2B!@2@N-/<.XI@=0;[.@!>X I+%OV MQ*(&-$&1FD#42A70"F7+H5C4@%8H4BL(5V8#ZJ!L 12+&E '>0\U;1>F4H4B MH7VIB T/:!564Q3<.@641(V5!"RJ58H:$( "G>:66+5:X#&7+7UB40.ZH$B/ MN;7/2C/P=%,]WBYYK&EZ3EG5RO7H M2C0W102)$8N:HC#]"XAN:U^B&^/*\ LGU%LAMN/?LMKQA0BB(A8U8'B+E=YV M9NE-J]O9S>HF!A#<],J*-.@-I+;HD,M)@/M=26X*LG8G@MB(10T(<6%"W,LLQ%D*VG*2 MWH'4ZO1!>,6D!H0WUV&FYM7ZV4UP/N5G^0CT(IW6+[UM0[(DE5,Z=D@B?4BK M6:ER/<@LU^D5,WM: M_NR_FL75C?U]C;Z_KY&VH(P3%E# 7BZ!D*%@B:!9RO/06P]\/1?^,T- +CX( MP<4^V^SA>0YVI)L$3>D/)@XBID:T5U5O\J X:M9&'_(1(0*J!'0KJ1]T< ML_='Z]!M-G^-F?BL:.;DZ71.S$ W4#DFAN',L$HQS9U:]C[ .'_OZPOVDDJ6 M#V*!"R:3S$[5[[]L5U3*/6+GI]+>VJS#R8G9JE/U.06>56].@6?5FU/@6?7F M%'A6O3D%GE5H3JF[3+UN\[?^P+/JW1]X5KW[ \\@]LPU]HQV M64#H"3(IP)R"3)[Q6FL01Q!'<>84>%:].06>P4K0WJUTMR0KO7'+P;*->PPT26%.$QK4)'#\8CH=[Z8'E M!\/RE0W7!\=W< VRNP;A[L #= X@_"V"D1 3"V>O*J.W_&8"AZ*/ !<;)R.G M5'^X@ O !>@+P 7H"\!%QK#9;Q4*P !@K (C;$,)R !DK"*#G04&J !4@.,) MN #'$W"1#1=C2Q2W<\/EV69;0DJK7\:)CD%CIU;SUV3&Y0&C-YIR12="7A U M:(TE\]98_5@6[J&36H$= DONGAN384UIKM>/.2A1[C=DI=&2X:#$#>96%%CM M>YQE]:'<$LXQAP?F ^?Z'1YX(&"NECJ..3YO0_P>Z/%Y!X+B"JODF"/E/M=M2NR4#H@\6 MT6E'?O1CSN/:5%>+^4L'Z73% 7M11S[(8Y,B8;MF#.I-L2V$&=2=9LM MJ:64<^1K_;%<8:4]B#FG*1=@%W!.4VL@]=KEG(0*F!;7M1[$G%T40KJ8N&\@ M];M">LD5V-M27L)T1%QD\&HI2(_N7WY3MX$%"9J8C6 06M8)!"E*?"VIJ#$E M/F@T9?I_\+*UC_PB50)^O,GJ)B&U""@&508@V%&5=?)095OFY4"/ 81SA' W M#PCOD)$#. .<\USUZN6!YRR)N(V O-GRERP-%&'*)FJV^B4>G-/0W,]%.^>3 M@P--#="& I D)]^ZS:;>>BWK=-5H,D Q/GYG-VFO!&*#]I]%'YS7YGYJ: I MLL/T%](=QV,=4R%55:IE4@K(4JR4")D35SU=,65^L= =\1$!>_L TSMBNN#, MVVM$_PL;'KEY3 V.&" ZTRX;N\[#0.*&@!=)*"+S"N"E@90%Q,FEY5JY @? M:G]XCLMNZXRMA)NL2,%0I8^WDX&?ONNUVQ4%^)"_*5&1%YZ-!&T.R"X$V2)D M)@'L /9"P#[8?YHJEQ SO;>,HK#=@H!J0#5'M5QL\G5'99WJ;G?: &N =0#K M7;*Q^P1IJ]<3$:2P1,%,[4' 0IYJ&D[8>1)MDR&EV4 M]4!86OJC0)\!"$339V7L001E!CC.&\=E;T0$3 .F\TYYRZ7M1GP3S:E+%8K4 M:T$"^U 0G 9@$=)\H*$!WQ!" 0CVI>24*)+/6#?9SO:AK3NZ^73AV?3O6SHEEC8B[LWC&+] MF2;(!BA( ,&."K*,?!AH1Q ,X06C[ 0;" D(B?!"4EK"#J0#I$-XZ1 I&UBB MP*2O?W8&(# ')3 0D0((4K1FNYST(C@4(!K"BT8>Z4IP!&"_7UZYT.\F5;,& M_9F&GB@L',12H,]8-_"#01J4]0V'XH ^1*4H<752QZ0HY:VM$3N:&7GV@AS+ MT#4.C*:$V/_OA5,T&Y,MDK\VPQH[!7J9Z(.Q5+7'68K=$RR+NU![7RR# 3*T MB3?F?:3JZN((@LS56.9 MP/.2M;M(B6@0;&#P-5>X$1-;(/P@?#57OB$2YB# MU('4U5[JJI"(WY<@IC=>+Z?''LAAC>40UA0 9^7J^XY8)03@8H'(U5[D]EF: M *Y1+C4*A[E?^]/PZW!T?BFA;]A6)Z@ET_%3/-:P$D$TO9*N,-9.C-7W4+R3"DZ/*^#L'5>9BQG26?G!.+60.KU% #Q(8$XK2%DIY]=(^>3 M'LX'V(NFIX.>,+XR="8O$]F#S,C>XB36?..]!8IEJ=-O2CU9&'\#L%PBEKO- M/6&Y 'U,/0ZEV0$8'PB,TU L)Z.XF BN(_4[PD 1-EUOF- <$1?IW)^$'";T MJQ&%,S4'08H:3]B@P@G".$$W:W;@?A';)K &> G=]EV\QV7O?F1E0X64C[G#!74;:$?0W0+Q B)>=E@2X ]P+A'MI:4O .>"\0)R+ ME-8$Z /T=/OE)')WT=VIR;2N MU.T+T]\ D%TFLO/([AX43F$78DK&-S@N&*G!><'(71P1C+#VA^>X3#W6\<17 M\>0>RM, !&EQ:K^D)&F)9XU#U1O(!BA( ,&&"K*,%"1H1Q ,X06C[,0E" D( MB?!"4EJZ$Z0#I$,(Z4A=>10I2UJBQ&S6(%"115L'!:F!L!1 4(9C,2@G&PE> M!8B&$**1YE4,\LAG@C>PKZSH8>Z#79Q4B@P*"_H MNYGQOD-U0$[8[WNX_>R:/Y\<>3["L%B^E25Y4,[6LH3I+R*A#?*0ESP,,LM#AH[?^42]2YLJ M*?9;4KO=!_P#_C/A7V[N"?\%:/YV1^KWRSEB%Z!?#>BG(5].1GXA[GQO(+4Z M0GDNRQP4?G=\TB!&Q.5;U@691_$(*$L4Q2LL'N\MZA*&NPC M84MUC!_PLB(ER-76G@!0F=7D6^D$"*@R$S9E;Z1@NBI'@( R45*N=$4B_H4-CX0"<6XY[C?B3BQM2U\.)*/"! @H M&>U]I\3 5(B+Q]()$% @RL@1@YT @07B[)SR" B0(#@(E):BAED P@07#9$ M2CZ#N ! HA+:JIEL/\D8UZ!>7J7JE:_)EJ%9^+-B:O& MN7!WQ /YLM+J7"J&VA^>X[+;.F,KX28KDO-J*7BKONUM6 4&.^ ,%2& /&$H5UL(GV/_M.9TI+:LE!]W\4&8^D$""@-NR32]XGMGC20A<7=?@\=0 S:43(*#'T_E_[+UI<^)*LC#\_?T5%9XY,=U/@)L=T]WC"+QU M>X[;]C7T.<]]OTP44F$T+21&BVW.KW\RJTH+( 1FDX"Z<:>/$:*6W#,K*W,3 M][:5I7)K$XHF)0]=LP+4-)W/_&6^0)R*'WS M=&2M1&_>"3CS!>20@_)Z3JVX*>_$G/D" M%F>E%^W([5TDM8#<,)9RM/=\ ?F3R(U\'4 KJR;O))SY G+(0]L\=%;6R'[= MC#XY)U]'&S^Y%M H>O8((!)[(#8BGIV<7[3OVO>7UP7282./2V%2+0$,@ 2_ M?AK!PK:/PUU*CY[MZ,P)85 =O1'=]GLFXS0 &\?__QB^QX%7AI=?,_UJ(7E<./X2,#: M#JE^EPRV+>K\^Q%Q6W5;W)9@0_ 7!V F,,<50^ZC/7RM*CY3?);/_:3Q M66-E/ELC:6-#/'?6*)1+F<:0%-\IOEN-[YHK\]TJZ1T;8KA*M5!O9-KV03&< M8KCY^TF[L] M"CWO-Q- B;-9K=XJE%HEQ6I*Y>5N/VE\URQMB>]VH-PJV$NIK%A.L5SN]I/& M<>7Y'+>;D$AEKSPTD6?SR>O9^A@_82F$<_+_$?+UDVZ\B+\2TUS^,;7&?TPM M+UH=7YQ,\\$_8Q2'JXHM:+3M^300K\P13PQ+AT^?6QPD'<8(U<"/&%%K## D MENW!;)Z-Q,2)#WT/TCPIR@#*BF=0%6GS\=O'[R32U ME4J_)7&E?,+9GS\ZX<--C7?3?0H'C$L-N3@2FT3^?F* 0;_HV*_!-]-?:.W^Y\_4N>8H?D)YID"- .; M[SY4!?7F*=G'=1O!"[3RY11//^(/1\6=3$ M_L(_^(N"_I>15V01(\Y37Y)'IN&^>ZD%>J]W?M_N_GQJWY'OU^V[[G?2?;J^ MO^J0RX>G1Y!#O?,=K^;RX;[S<'=[U>Y>7Y%.%_[SX_J^VR$/-^2RW?E.;NX> M_NR0#S_OVS^O;N&=CQFL\<.M1;R![;O@B[H[7L R EN2.=>\TN[ACC(*!:G1 MP\_NB&KA9R$^0"5QKDJ6]9MB71+?"3#$6RAVO@K3(6#B367LAC)M&YF[,0,H MBWD '(!(\+(:BW7=3LSPR,*>L,+GICAOF$?G7W=*^>H>="+Y 0\'+KD&NM0G MDZ'E!2G^3Y 1O459*2"7K#*YS9U)@ZL)]E:6EX)B!O?-T\,/\O!X_=3NWMY_(^W+[NT? MM]W;Z\[GG> ZVCR'B;&]L_GF7="\9QXH$,RV(!],VW4_SH-F M-I=&LUW(WQ>MH9*["\W-A&I'E5*Q5!87FO'/Q>->&^%9&M[MJ-TY'A@Z M#.A-,TQ&K&EUB5_C0XVZ ^*[3(>OB3UB#O7PS!&)X877>5!V^F'M\-#F.4R, M[;.='J5ZR \3!S;E,[[E*S8"Z610KB2II1,ZM&'1?_$'.=!!N;%TEEM(_@SZ MLX0J7^\VZ.-4 G^;3':^:<>(924[OUJ:DTZX#\A6"]D#\I]3H.M=QOYVR+\& MIO^\!/:\(7OOK/_WZL%[,-#1!#<9=1EA;R-FN2R7J,CU0G(H "IKZ#]KX&F? M[YCK,B8)Y [IXUJ0QVHU"0KE5BZ]_3VCM-PL)(0AHAK=^F;Y/D+9K&^X5V_:::/ MB[KN]YGFN0]]V105OAA0ZWDUV=!J*F5X0 O)X7'/V9Q^8LMKPRP8(SH>FE/# M2AT-[>/1T'32/,_2XD3BXL$/!;/+$[YU-_U[MQXO&$B$YE &M MK:A!46-04$N;$\MZHJ!54;KP@!:2P[A7:TY[OS65X688X;Q<:#1SJ0K7B6SM MGP\HM*#2?GO%]6E,GY#NM"GMA\?!Z_%]+5[!L[(GJ4]J(7O*"@F)/YO2?^NS MPD1D9#\8X>!=PK:FP2X\%WXWQOI)N<1"KA>20RF0D NU 848D,JCH)35&C>4 M]B0I2BTDQ[2?Z@(FY 1M0 5N@/CCE=Q+\]H%*4=PI[K/\1D62QH.#=<%'"A_ M<%]$0)H$2$A^>E]68"+[(ZET@.?=RXA<5NS0IW3@ 2TDCSJPL6[ZWU8Y(%*$ M9X7&62[/!/8[UV_%B*A4A_(BF-*%!R$*MI,A(Z7!792PN9X@J+?. MX-)W@929$\B#M9MJEFKUW$N#7--A;A:2/X8X*VTG4V:+#%$MU,[RSQ '[RNV MA^*\<,!,7K>/_4E-4V72'(A46">59D[@Z)*.# ^V^!?3 ^EP:;O>QJ1"N9'_ M"%*NZ3 W"\DC0ZR34),)0Y0+]5+^8RD'[T4^A.5L176MV-7F'.!""8:U!<,Z M.39S!$-(,[SZT%IQI8FLTT).\TZ5BCP(3E@GX6;[G#"I&ZNM@\N[V3\7\C96 MADOEG1Z2*%@G\V;A04M8BHAM*@NO49[3H3Y'TB#7-)B;A>21&=9)PE',<*1N MX\0-?>4T'IA(V$XR3OQZ\N:\QIKR&14C;(L1MI.1LS%&F+BI6%6GCGM5C1+5 MJQ?^CRO6I!*4=[;U7/28,\2RT/#<>&&I-2>W@-LL1,FR?;GS(5MD.=$5^HJG M29_M) ,%B6.7]A 3J&E:AY2_F&/KU!U,WPT!J(/XJWW)@\29Z%$^BXD,B%?Q MR_;X)4U=E[>3+/0>AEDR&Z":;2[ +/B3>.E0G-J@[/-;](33\]2S !I3_J_H MH[VP!V@VIA9P"?ZO/+OHS(S_]:"]9W)LMWM.E7V;J"X$E'X)A/[HV"^&SO2+ M\4\70WCA,5<[)/=UCWKKU;RX[?-9*",?7O&TXFG)TYLHD[1-GIZ(S)\5FK6\ M9'0MR=0J'A$W!Q6U+OP[(?;7B/[6\ M9%DH_RPW1*T8>8J1UVE?N"M&/BOO%R/OG4^VM3"S8;TP5X69E?,#63/:AF3Q%F&]N[]OWERK" M?&CQRD.>YS QMK=.64*2[FS$8V3)YR9_><^'*SD!S>7:EL(AEV=39( M#4JV"O6&ZC"9TTAD-Y=+Q2R.*V91V42R:R#;'OHA<:\D MS!J%LWI>KMZI.&-NZ%?Q[!3/;B*9=5,\6RDT<]/=2)V+OO-OQDM%*HEO;L3MV1 M!EA.SJ_[?:9Y>/C WK0!M9X9<:B'.>L6-W4*PN#!C/47( GL8X 9[ YS/?$P3CYNHHBDXX:%_+?G@"=C@P4*)B?^[CAC@*:1]_*)M MZ9,/8F^NY!#6RGGISI!#_LKGJA379V,5;:)>:$[8/C*?:A5U=7EG&1D31VX8 MWM%EK1V,[N3=_E''U)L]IMY$K=&U!,_M&^ MN[[O=DC[_HH\77>Z3[>7W>LK(M[J,?BAA2<[>'F?TU'>C##E[AR>NY,F3J>2 M20TA0\N58K6\11FZ6E9=JU"KY/]<1X4Q%%]GSM?54@)?G^63K\O5.I@X^;_X M=D#71G9I]#!+SXFY4SU8L0@[([KM]TPV+2/^?I B58F[B#^LIJM M4RY42SG+X,L3^^1S58JI=\_4E40')I=,72Y5"ZU67BX&O8=_]BZZD^4U_\[/ MQ\>[ZQ]@$;7OR-5MY_+NH?,3S"+R<$,>NM^OGTA8"(#-;A.V-130 U'V'#D6F/&2/T ME3HZ3&$Q[Q@:>"4T8LK<+$M84YKIM(DZK?R2-)((T\M[V67K6!MJ'0#];J(\ MZ3+TFVK4GQ4J9]GF.RQ%P7MGP4]X*DO:YQ.YYU+#$ MK;HP$QV55M3ARN1Y6:K#<^)",A<([Z^.4]U$ 4].2P_]GRYK(R$]2#*ZM8+D MCAO;"1O,W"$%!6UNQZM>UZWD)2R03TK,S4+VD24V40%SURQ1+Y3J>4E97D") M<=4*?_=L?2R^@@^T9S+^X>LGW7@1?R5Z;_^86N0_IM87+8^O3BX(_XP1&_9/ M9LZ7N'IL3=@#HR->00=]5$VSAR-JC5'U6S9>2?-L9 Y^ODXQ\UK>OJ M\'(,ISF"') 1T4PP3:18HE7Y+:H JGX3A>4\:;Y/CW72?3I+B M/7)Q)#9)8/S%!QCTBX[]&IJ%4U]IS#3)X[?[GS]2YYAAQ F.G@(UP$=* U(/ MV3'@M(F_XW\.'/(I:?O?KY*W+\)=ZV^^^W!Y9UB_PCETPQV9%'9E6"9(TV+/ M!&=D4GWPJ6.&-B4#!T7TW\!O.9D@QEG+>19&'L:)+5#G /%\_T?-E4;-(2I)%K)8:V9J%[.[E$FCJWOE]N_OS MJ7U'OE^W[[K?2??I^OZJ0RX?GAY!TO3.=[V:A^YU!V@3%G#?>;B[O6IC\H8L M3@RK['3AP0^>X/'AYWW[Y]4M?/]QMPN=%8NP\ !WL84@^7#R$M]-T92P)N[] M('N; ^BD^[,/"%R>L' M')\%(GA[T)/2 V#UE0WCLR#K#V <_+8,1,>&$IJ< M-*_Y4=7C]1,_F.H4R$6[<\O/KQZ?KCMXL(7/>;I/1#/P)(Z*K6]KD:;"2O71##+SPTKU0V':;!AT-6\_!)VU2MB M_63F:+A./L8IZ<2FX5+$L4T33,?>F,\IYR(X#*:]N7QL#;9:(*_P# 5(@0\> MK.Z_/D5'":G(-/HL6"7V]]-]#3;F V"=B0W=?^^2;Z;=HV;X=L^!,4]W2/[9 MDU@W K< 0^N+2UX'@(YQT7[%R%^<),B OC#$.J^KQYWJ"P]->!H0VXWV"X'F_%B-__!&L*INR@WP O M75*+ZA3_.X9]DUO7!/S \Q_LS=!L3@"/S/&_D&\.@U\XY'( OD?2X-]M6,KO M\ _ CAJON /X,7_]"^G8/DQ.78^T72/QYQW8"046 _K[0<'>Y*]U!]3 !?&A M_C"8!YI.#@93P8J^D']1 .P7Y /8$S;L N$19(&]Q;W\((S"/XL]I8_#MMBS0:Y7JYBR9 MKQ2),FXM*8492C/?HJ#//'YF 3+!&"Z.3@BQUF/,0D$V CW##SPPUN'H_.1> M<%E('/ :Z$UC9,).GID%G OR$K]G(S'QK#1#C$GQQP]0@L5%ZS$L$=M#+8ZL MS^?$<0S+!?KB\3L>;;F!U])T>[G$57OQ?_@P3SYXDTN\G?)*J2QL!=C"$WOV M3;'&3MI/_J\PB4&B@G "0O5-KT TYF#0 XV-#SXP2G(>/Y[>V18N"WX)1"W%-+" MDIH(G:U"I2C6$'RP<$+U__BNQY\7 E4EKT4*P '0-=]QN!4V\RZH!IC$8AH8 M4M09!1/&PQ)BRTJ0WV&=:)>'>YADCPZ2&#_S%;9-<$",U?\-,&'0'>E< M7W[$*5-F YO* 8.K52"HGX7@R$2+R(/P2(\%QR?2L-BZ@D]8S"X @>+!Z(\W M;5-=A@0/E)!J255W:$E-;/8QT@DBX!HM.(##KH"?I3V5M(:82;58HY MWXJ(:7B!2 BN(#ODGE-CW_TM2$C?JR7>;^"7N?W<"\?6-V<\.'0TPDM5^ M,]SBY7TLE0.FF$GE6$",8;Y&8]E\C2:::S/)&@*9@#*3FU)_3]MI=?V=)B6M M;'RG==CIZ6RZY^16J9=*0%=@\ ][S"'5,MJ,TLS]R/T_\/5 H0N?! @$% MZ M:-P-DM%I$D2G06*@'T?H:&1RIP%!:HFH(,:HP28-"-!PP3"';3LB2(VOH&]@ MTE?N2@"4:,\T7(S$H;)!Z8=!.(\)1"%53\;\8"$,G!2=>\?XM="6,$\XY3(V M,XI1P41"S5ELRNG /W2'OM)0[\9VJU1AOE7A-76PUA$6S.H,P!M.M:'KF6@[ M+,YX:X%IQLB'.]MU/V)$GHCV;X0O.H\*\!WY&-/I$/%LB)DTDXFT:FY ?_H_ M)#%!G :W<_D%7?)_/L&+L?3Q^#?86\WT>4R H5@0P#8YL$< [* ]*0*;< $" MUO*09VWC8?NSD ,\MX7I13"1'0H^.DAHE*"Q]J;X>S#:?0]/&_B)H.X[P>]% M2*8@8TFQB(F.:\-P"PM+EL?[I<9+= H)F/ #X)(B]@%G$Q4\Q>^YY.V;(DP# MHC_ST^G@8,4; M@&J*VRL#FAJ#"6-48T =R'P;G)J_&,QM\(B7.$1U45_H,B3%>]C GT[4@E9@ M9I&PWM3MM83L*3)%U\+.6XJPDVCZ,)FT.W'LR?-6P2\V36 7/-B3(<#AR/=" MXNU1%Q0#NK'Z\AP>,%X08)413_CQ!VX>V[XK3DG9&X:V^0#BE^#_TH^?#YB, MUE:X'6W =-]D#_UIU8NG;AK8OU(4\QR]:45\5FY>URO5+% M=:55O&A<7%XW2E?U>JT99DYR$@L2)/N&Q=>4G,VZJ>3$20SR6@<$\S+=$<56 M)?\\*8G/,O.;?Q8U*O#/\Z\BM7MCEZ>V?<-Y%^/#M@%ZUC]/L/W=HJ3>K5QV M6[I:VF[2*>KNC@&:+P2$L%>7XQ]Y_@9O+ ) XLEQ0';H-A4-_FC L461T"6:-8H)T<@ZB M:-Q]H9[M?,P%22L:R1&-=$2,[L,5LVQ^OJVH1%')#)5@!)Y3"FGSZ*:B$$4A MDQ2")S5*TR@*49I&4<\M3[/N.]GU\A9&\C:\PDK?Q%4;R-K["2-[&/Q2,[,%I0G;&Z_V, MV4I?L!X#YL3PBG11#N+ -L&;94F6V^I\HL MT( X-<%X5CM ?]<6Z<>=&.ZYJ[-2&1O_4#"B3D[G6JR3=KXL M,GH_OP#+(9Z:+IM>FZ\0T-++3DG8C1I&\T3=W;N:Y6,*AA\ZG:7$7N9T1G_G M2>FMI3F\<"$U902=QR+;'HBHGN^)V'H0CV'Z(QWCRVW'P3+4PXD"A>\)4S9K M^3@Y>A^S[*>J3C8^-DSDBV0B7TV"1-Q#H:/DF]*CBL[VB\Y2].BJ0:C]VM._C*XSD;7R%D;R- MKS"2M_$51O(V_J%@1!U2;?1Z'QF9?E1,'YQF@)0KFLD?W@G6<65YI@1(*@FI MSUN\1RB]JKVZ27C4]U&6IK%\QPY7XXV$!.C-75>4K#!S.V"UBP'E0JU24^RA M]$A6O%+9XBW&::VA[C$JQL@58Z1=HZE4=WHO<@T+*P\W(]]YM>9@^.6H[:R$ M9*?-7;_)I'+(3WE2+W;1^ M?XN*!:\:P0N8*]:<3S:[HQ%-J(9WV0=Y,ZNNK].D=4>D97J=[<_PE49-ZK?G:*1-6E$=2%25+*G78@4A>2(0E2_.T4A2M,H M*CE(39/[:W"JWYU*FU?C*XSD?WR%D;R-KS"2M_$51O(V_J%@9 ].$_;I0MQ1 MW'O+47Y<:HYH+2'M#2\5E//6[ZZ5S66#(TD$S5O^Z[Z8&7$[;(FE:5D;),#[Q:0B]'S,@OY[8' M7J70;+3R0>('=ZEKOXR5.>T;YY-N%L9*C5]U+Y5+>2%99:P1M?821OXRN,Y&U\A9&\C7\H M&%%'K*HQ7@J<#KW1BFKHH^AL%W26$GM)J*:VPIEJ1HWQSG)254TU]-G8E'EJ MZ*/DVY[(-Z5'%9UEK$<31M? M821OXRN,Y&U\A9&\C7\H&%&'5*HQGLKR7/-*2CTA'WJ+%P[7:8R7T97#HVY( M<D9NYEZCZHMW .RAU$C *W-Z2&[D9N.Z??&RN=NH&.-H&"/M%DTC MH6/D%N]*;J0O7HYN2Z;?K#D8?CEJ.VM.Y\C-7,G1PVWD2NTIQ@L5%F*[BU\,#;L'67 MO Z813"8")-A<6.'C6P'Z*5 O $CKU+^%JD0P,3B$AAO=L9/RUUB1T*8L#?- M]'5X& ]($O9?WW@!"K0\E_281GV7X12&@R%-T\>H)'FU?5.';PD%-!6#NZ.G MI.T2U]<&!6+-S\DGGNW!KF'^^9QV5E^N ^6_VS!_,'TGO+EZ+3:FWSCV$*RT MD>]Q0GKHSUR$'B&;!H2KJ198NZY(*GL%T?S,TY.>5' MWL!A3/R,HS1E>,.2+P)?8TM QEL"IOQBLET@0;07"!\"MC-B&L+8')_N3!C. M2E^ M!180:]1W7@).HT^?KOI/J56QH^U'@V:E4Z,,.@7'?LU_&KZ.VP@2AZ_ MW?_\L;C^?EPM3NC7*>A\B69+0XU,2H/U3/T;@\AT,]DXM-: 4Q* =@.8%'@T M!&4'>.+ "! :^S#Q]R \J'QL?[LN7CQ=MW\OMF^ZUT^?"35?Z=@-3,3/J+O8 M!!R^D %7KY])!>U^>;[YMQ+_/_C=S-&G_.J$?$HDU>]7R2@0Y\&;(-3NP^6= M8?T*9]$-=V32,4(1-"\K]DP0LI,FN.2ZB" I 7$#HO=O()!/)IC]54+# .EL M4#- +KXQ_?"%.@:U9M^=1PC+6Z GY[RU,%HXEZB\P%SY^HF^BRPF.&A&R 3R M9^:=K4N^KP;R,^]9\76"K9>+\DY'KU[;FH::#G3?HV-;\*;$3;MS00S7]4']MSL_TWZ/O^2_*Z:\5*Z*7L+ M*N MW:D8=#,L)6UZ=!M,I#Q.'?Y(IQY0O6%M% P8.V"\[!-6>T(N,-!",X:"DBW+ M!U0%08<> ^F$3A.A?7@IE4BO0&AS(BUCNE>I4I&$BL,RZIAC8!-[))Q/%V<8 M&AZPID [.FK4&N,WX, ]W@8@SHZB@7#PR"& MQ2\H4>3WB(_A-4^@-DOG)7>ZHNT_^R##@'3.5A8H9^_3%B!FR1^ 41:7\LCY M^.UB+7$F&W:#EK@R7 U$.0Q!P/,>LE?;^84B98 WOMQ O,;>>L*@EB,Y'&D^ M>3&G?#5=I*YG'R@)[ W4%B '$2GP#D@)^$.*?" YYG@4^%./9G+B,P%E]G&B M%S[1,)K(/16S((SA/[O@QU!Q+,6/X5$3" D*NT:BI^:902#*]5XP'DP=,*SD53#HP,$S7 M%H(B7#.()E@&F*<8KK^X_K^Y_773[V=ALQZ M(>9V.R\&#SD.P>;GFA-%]+'&"]M@%#@2'*!7 UL"1!C/)D#A)"T?;IS8/1B- M"@O*AX$<82YP-HC;)*B,1SS*YI$7&W0A&A>@J[@K3H4BAI79%I,Q,C!LOMOP MP]_AGX( #0I=%^9RP;<"/?\HAW.I&>8W)"Q6O"5>< ?&:,3#?& 2&)X)7U,> M)@2!C& 8,0Z+P/J9GB-F%^%H0ZK# +[C^E3(="J_)O3985+2#ZB':W@Q],#\ MAV<[>!^4!^J![H$.Q+S!N$8P3,A! M\8'&2 ^, @-P,] 9!_R QX[(HJ#'R5<7=A! O^@RK6B\%0>&#K#Z'.3U-<&S MK7W]A&^>$YV.N7A8YH=G)^#+-#\,RAOYP)HGFT8]R:*R!IRTR=]SOX?H[2!)/ K&/S$$K M/$R<*5:6S)RI )1G,F9^XZ">O_WF)3*(4^+S[\L^[X;!-Y*?GIK6:[[[ D=GN*BFH72:[:P,Y6Y52%%99)M*' M,>U8DOY1?WMMRA8&GJ\F0.X;?0A7!W>$> Z,M9L3%HC)!!$GZP6C_=1@C M][:7"B!Y3(:@Q,QB!#'ZVI9 $'PZ+OT>5\\#4.2Q\)@,BW!0N8'!QS4N_,-3 M;Y%"7WBZ9. !H#7 XWC"A,41N3VM3UC*J//[OMDW3).;Q'@07IBP"0)*QV^X MO9:\ *,_QS/I,1B!R2$$N_K":81+]J2K6D^6ORAL0MDZB"9]F#=4SN" MN<(<3+04(_OGDN\ 8&!K!I_W%<0&GUR8PM,_Y4D!H3 GUR\((&X,.& *BV!N MN.,PELM]A6C[\O"7O<@ 4?C;8$^7 5SY*\*0DIY*^.[$RG#5L#J7F0BF0FA1 MBU.L(?S"A1_RB"]:89;+CNRD] \P%FW?E?%R:68B$A'*H_!QT;XO%+]"8@>=H M(U$X%0E:IDMI>)Q"Q1$+*/;+@D@2B?1N,)+(9?>M($ 3^(7B M=4ZZO@438%1%GPTD">ZR7 />1N(.U4",Q+GLFG)D0XDJI:QP) TL'@L>) KH MZ3>DZ[4HHV[2MO)2 R ))AG_E4 ^GFV%<-=]?AQ(K6B-(&_^GF8,)W1^1?N^ M^9YR,4DV\%T 6,D93Z$^6NUVQ%FY4BB59GT="04A8452!&QY64H)*$3:J7MG M,F8I^@R7/C\[3$1W$>A*!HZY2>1.:/@PZ N:EB<5\3"L#29RD(I'X5=T" :> MBV> 8$D)(0*+^,5XW%C\59#9"*$Y? DV&.IV^>+K -UZ$+%B#;PHF(7%OQRT M_QS;?Q[P_-4BAG71*<5X 6U#I+70^H-HDSDR7==@_*/O]._Z*\!AM\GIXF; M)^%>XK-8S\%A)D\12+V"9#BZR!(94<=#&#HO1A"]!:Y=SI4KER+&#(0Q/U7E MJ\Z$/Y?(^CG:&TA-=>-&W;@YW!LWZ6HB.@X+8P,HJP);!05O( 31)*48 C%- M^]4E'[BE ZXEO.-^_)PS4;9>ID0'3#'=-]E#_QK<36_\)PC_VTANQX*NUV\@ ME\#L"@.N%V-Y$NNV+;TC0.+B!@P;YA<<(,669"D&R*^DD< MJJ2$M0P(YO]LL5-"8ML215'[ M2%'W8*_L!4'M00WJK.B_HN@_G2"P)L]T/J< MBLO3I2WWAM;KA69U-OE5T;JB]5(YH6!R4O+^OM!ZK5RH5+-I]:)H/>^T/J=D M\709W7VA]7JC4*WGI);XWL5]LW-RVI,IW7V&0_8=GD# #ZOYYVN&91/$-8/A&X+=MZ;Q.1I[$2*50+6?3._!(-.9^T7US#>=GK^B^ M7*@USA3=*[H7=#\G=7\I1VBOZ+Y6.*LK#TG1O:3[A.(%2SM%>T;WS7(N([ZY M/Q[*TENZ YQ_EDF]LN+" ;I&2Y^IYDNR++WLN3W;0 )5YM0/6>K2W#(%).+U M(U;SD,HYB;+,.6L^\':?1\4,"<5B$MRO#)FAW&PJ9E#,L!-FF)-TD-HV?:?, MT"CGY%Q5,!8BGG M;>=G _5"K9E-$H3B%L4MP"USTBZ6\NYVGGC8*C2;V7AZJW"+GWAI MDEBUFZF..7DH_K+[%5R)XL]+-"\.6X/%BY;)'HPZ[R309XQ@(UD-6SK(9B)3 M-7K#CG!8HM6Q+4,C']B?U#29]S$HCNR2 3-%+R=9U'*B2PG62_5-V>HMK- X M4S$7TRNGRO<&]%'3H1GT^,F>IU(* MA9XMYWC_>P* 3X;[ZV)\P2QM@'7X> :&#-IQ@KYG,CT]Z6?=\4CD;'QC]K-# M1P-#FWEK<4,&$)3PQD/_!_V/[?S@Q0#=.15(L1\'JI%7T(XNLZ9U"!:JG](? MQ 5V-,,*C+$>,R'7DP'58U6^GH'GO>"EU&J&O\EF,^#]#Y2 M E0!R\I.7!M!JX #;\O%JYW^8H$)P.OM8\%7\7&B\!_?!DQOZK+;(P!'!P"X M03?UN=T>(WI"N$2='@64#[G6/E?2[7CW,&Z=_4"[:@1H?8SUGGN(>L\=:[>^ MQ)J347\S8=D&PC-5< SI6!C1L@D$&08@G]/N[Y3<8*L0WM8VAJ_"9&<#T5J8 MA2:N*UKQPH^2AYWN &8*FUDTZN7M 653"JR*'G3^"F:+6KGI#-NXH9":^]-8 MLS'1)Y _$UT_A+0 4!LOAA[KB":$F %XI5%#NIVR8X8%P1^Y[L3&9-=O(Z8; MHICKT?-=C.J"7BA2=F,=;L,5[0EY/TI@+9\W$^@QC?JNJ+)-0=MXQE^"^F43 M\==(:?">2"F,:PN-]6^CS>=B=8EEYRKFMG9HE.W6:JD M#/M5RO+E8>1 -UP-3 0P9 'D/=OWL$L!E>U*YS9-14$S); I]KLT8/FRR2%O M&6,RZQF^2^\WGDP,&5H+1UO^_$R5/U?ES[]D5?Y\^;[K9!'WSSMND"<-T]C9 M=??UCC\"&Q4M3VI>4!/%:V? F'<5">/D,N&57'9@K\H.[!?MN_;]Y37I?+^^ M[I++AQ^/#_?7]]W.4;1DGZ.@L;,U2#U+M+(+M&Y/()VXB'4TIOR@S]Z!5]7G M4;*HI'X[[%449X/+$&9<$"6S0C6U8GY4D'ZF5OU,+?N,B^N'HE0V7)5S6PF4G4\EZWC.2?*&F6F;A.!B\M[*O+)-_E<,4U23QFI9Z8F;#ZH M1V0I+"]$E[P-O-7-24W3+&5;-?:2NH,"T>!?PO[K&R_4#/ON@D'J@:9'EQZ_ M_[P;K.= /,SU)0]OCX&8E9R;5+CMD))ER["MIT/NJ,YYQ>9 M3%M )5>55:I3MU>-Y3L YI7*U10*=1*-N<,PT?.GON(F^G&HLA7NK.=*8"R]@32Y4EM' M%UY')-/V+JGCC,&E_@.[TZ]6M.&L4#TK9RMQDN("1ZPZ%8\ C]37T;T;YI$S MK H\I^K5'O#(7GJ:Q\'K^67B=.YLK*/!VI:^!29ME0K->157\F4ZYX6F%!U7 MF^MHF2W1<:, VF\?Z%BY@&NZ@$^3!S+* SP:Z_9L5?T9D0R*GGM;I'5;WFI7 MU\MSJE?N@5&K6.- 6:.UJDK>'&O43LZKA6HKXSBL\O@.DLG7KO*2:Y9?J=Y+ MK;2..SEE@T^* ;#1)Q_$WES-/"\7JJ4YQ9&RD@Q+U'U1''5<'%5>Q['=,4>U M"K5*SJ*K[^ HY06_*S_QUGH!2K$=@[DJ ?% 4MD.>Z)#Q=I>.@EY"M_=8&FU M =/)LVWK1Y*_<0!I7;6$M*[EO(U =XT#S']#Q*]D]%0+9[4YY;OS%>171)Q/ M(D[((5K.P-\@$3<*Y=J[9:1F*M4*EG;&^KY K%'^G\44](5WJG.ER5/QJ%6BGC8X,=IDH< MM9-Z[Y037-\IH<5OE76Q(&*M;VTY?,4:!,=IASF^8YU'$=) MAW#>7']W_29>)+@ME)=LW\51OEHMIU+>'/_C=0#VD'C?7.RHRV8]"R>4W!)XN&E:NQ22E0X#T"V:QON&YEVO< MQVW5\G;NDVM*4M1;7[E*TA:HMURHU/>BW*9RX=94=']2AV%+$P,[CQM!3#-4 M>UAKG/(6=HR>VI8>)7()>KH65M1J\?)JQA))5;A0 MO#+-*^\N.K4;7FG65R?(LR)@Y?I/4@K<&;1GF(9GL#5-]N99 MSIA>I5LH9IEBEI4K0FV662J%:M;IAZI,Q:YR+ZY8G_%^Z0X#"\MG*NOB0,[O M#WNB0\7:7MKW>0K9_;3<@3$:@4 ;.;;N:QZ/TOD6B#C&AK''+[:O#9BC,C-R M9$:EFD>-A%)?@2_Q[T>!U0>GPYP70V/M-\,MAK0@O_W!.X(N* L&,^#D?QK> MX-)W@=:8$]A5X_5?E1^P W0Y,/$QW9?TQMXA]3 MZX^6SU3A'1##8=WI+TR7,VT7=]A;A?&N#!M[=>)(-9RHUFO M5FHGA %!C3"7P/'9R6Z !OS3.__*AO%9/A/# NO2P&]KIU\_L>$YN6G?/I$_ MVG<_K\F/ZW;GY]/UC^O[;N?K)_BU!.\.UCJ)SRPHJNT2NT]2 $8Z;.1QNYQ4 M040A97 (%GBC67[VS_]@4>\F^+5F^CHC8-.32WLXHM88=HJRZHO+;_FXWE"^ M2(8@MC1C1$TQE.V,;(=Z#,1,SX,-:K[#T^T*9&A;;(Q\_8MYI \6+3S#GW@ M"WA[9+N&YYZ2;C0GTK=K@-1U"35-,@ 9;XZ):]H ^K*:TP#^L+@MRX@P^B#L6UY M\,ECP#X>X1MV#/<7\6S28S, /96\?#4)$Z*9U'5A-)S"G44#=6!4?(#99V)D MJFG@#.#5*JQ."^#'!XZ.05*Z8/ M J?:EW;G4ORI?_F8!J]JI500X/IJ\.Y- ?R+8F<()FP!YHV!Z()-@I [/R5 MIJZO#0IQD@*D _R&A@6[,;P9PIHB(#)@)H#)6X76!?C=@>W#$(B?";C3%VJ8 MJ"N* -.B"\#G.T'H:]1Q^%M L2 XR0M*3@%H3)@!UOP+F[Y0H O^&Q"H+B]I M DR 2()M@*[6?@UL$\DX8"*.96\LB%VS@8* 4*?W:\"0^G] UTMDTR&,:?PE M< ?OCQPV-/RAF%@':8[H=I%.) /P\7&4^ ^-D+OYZOCE/'P"!L4I>9JWHP+" MZ94!$U(W(GOQLP*'%!@4=LK(N-$(@IPQ8UO% 7J$<:08:D)R[%@=\"?^#92O&L#[S*Q@Z&M,],EO@>VTE_XI1S9[F'Y M43Z*88U\X-(LY7CVFH33HNQ9CS3#J0GPE*@$^B!I+ S\ZG@Q:2[997*)P0JM ML,DO<29[JYH0X:HAB'O,$_0<)_" ]F?>V3T;QJWCWIC$O0:P MOMFS[8QG%M: >&WHWM8/&MR*U(CEG4$V,6Y"L/!$ M1)')W<_))TW11<%Z0"'E Q! ,4#MUC]/RJ7%BCG+8^N0EJJ_S<\]VHA,DUM. MQ>-J7\T)2L3_V<6%PN3SZ2S91E%H3BCTBFF20,M(H.76_A#H'N90YEX_[IC/ M8EITFN>\ 490D[*9\!R+\(,LF/G5]4/.FT*J9X^^ILC_::@_O.TQZ[=F5(_LQ MDT:W(SSO10!A1TS(0PYD0S&'8[B^NDIYF;-<78IOI5T^#;.J+\;AG]\-YE!' M&XPYL?!;<^%WMSSAC']1%I?F_AV=&'?'(W')CK/Z#\[I-\CHRUROFSXQQ<3, MZ-2T+5(!F8YVYP5UC=7:&-4;A7I-E6I2O+0J+Z7T"-@?7M(T?^CS6NOC3K+QAP$^O2MWD,]A=S;)VZ@RG>XJDB\!>GK$JI7/NBV$RQV8ILEG)-,\=L M%K'8),,I5:5X:/<\E')E,\<\M!6SKUPN-.H95R]1O+3'O)12OG]_>$F9?8K- M\LQFY5)I+]ELHV;?_JBJO4]@RRX4CH.$-\>7C:.JX/4F@M>5(PI>+SMGSK1 M0C7T33C_E?E:X():OW /5Y(E\^&X-$[.ZX52:2]*J^>$DA7WE-**?N\-]RA7 M)6]4KCBKE%!B=)'BFO>SS4)V0>;\.GWSIKCA7X+]5I-L4^NY\P9 M^Z05N-X;]E'F7-ZH7'%6*2''8 \X:[/!YKU12"KO>O6\Z[#.Z52A1I5^K2+8 M2K5L0[4DI ML.5(0,OF%G:?$FTJA7-H+_9(3.E:\4T[( =@WWE'N3MYH7/%5 M.:W%>E[Y:J/.CM)%BF?>R3-I?=GSRC-;L>.JZB9"SN?,&>K>'7.MA*J2K^G.+/+56* MV&/CM]XH-,\R/GA3C'J4C)IF_5:V5&SBT*S?B!A9*U"I)5MWWL M'#PE6O-7$&SYM:>IA92B%SGP@!IGA>I9-5^BNGK<'M"1\E"J0Y12WR*OSDGN M0_/5(_%-CI2?TM@II>U&AFX#UT5EI8L4[V2]]C3>2:EZD0-[[JQ2J%9S%M%6 M/'2,/)1JSZ44N,BK/9?_8+,RZ Z:H=+X*:6A1H8&'2JC"=.V1H9&4 M!9Q52@6^!A(UHB4_&'5]A_$ >T$ F[E(D(8[ )!2TL=W7_B[@^"4B7@#ZA&' M_=K1 7@?,(C00$ 5"+9V,',-&B?"7 M',+@!U7$L_ETE LFCVD#R_BO#Z_ ##I^.10KCB_,L/@ ?=LT[5?@4**!VGZ& MP9G[60!J1^23P$F 'GF]((4T/@N\_ ^((=BDA!S 1X-EP>90V+T$$'51:(+$ MACF0; AU77P(STR#]@R3R]C3?=AV16[[89IHBCV*R)8$ 3OSK1AA!72"-$B! M$#3;<>P>/[S426\<)[R] $-5@N%GVB93?F_9HD7]TH!(4C+;%ZR3DORK;KR< M<_TGGHMUX4/^U\0")^P170:8RO#_$[&F26/DC@%;L(<12"P/),(=" WF=F&0 M"]/6?IT(BZ?<:-:KZ(4SL$A&>-/)\=G)SC1-+TU=U*6ZZ.%[I^3NNMVY[O"/ MN].%.U:^"?S3!;%^:0]'U!H3D^.0I-BNU;2J.AT/^ +UW#=F/SMT-$#IR7,? MOO\>,VS;FL-F+%MP_1[Z=Z"T0MNUM*3M>GM_*C02ZDD3][\^LG:? 9.B M[NSW0> 3=T0UKM*^VZ#)?L=_4%NF;3NMZ,G\;3^!N@36^&Z8IGOMXFNSZ1X= MOL0;V_8V#9-:H;4"3.2:"5\TD:LND$N@(IC:,JA0CB YM?!^);S4[Y]*,7-K MI8E2\B_?8@2A5R"<_[P8_0%X&1"GSFV-Q(4$R^64RE="07F#TX![HWC#$ 8* MYBZZ3"L:;\6!H0/%?PYP63DY[X.R!]L.WCTG8T8=E[P:W@!L,8\Y0V+9K["4 MD>'@]$;Z=CILY'&4PIZJI0 &?&?7_3X39D4Z/,PQ*1?F@61HZT;?D"#!U2$( M./A-8',P)&-$/ $;,!M]$P6S6!)N(X6^I\Z] Q70C%0 _W-)#G_T(PZW!I[V M^9$Y>!7TH7]K ?/#\FZM'S#=P!QSM8%1U Y]@<5&KFNQLB2ME\&ZFR7SWP!R M? ()#@VF(*Z80T $69[*;SGAN? [\94W<&S_>; 4'5<>Q)8R%@GY%CZ[[F,=PK.2V%1A$3R#%1>X@2$6 M?4JZ7 )/03@ *8=O\#L"YAYW)5TRH"^!D%I6?M[;+X'XK-2E_$M[_X;U'-C. M&-\OR_Z;3'^K#O 6 W*)WAHR*FYY*=C0#&Y=?%;5[!B@!_8I1T@"2-' MFF<#+\#"_O\!6 #N )?#=S+Y,T08 D+:.2G,X@T,1Q?.[H@Z&.C@"JOOFWVP MPQ"U?)VZX7J.T?,Y==C"!T0)@*$4TPQ,% .K/UA4PE(&5T[3IK\'Z(C988B8 M&A1%CEI?W'>L':C9?H9U&IH; P#^17&94O53=T+=ZC9+G2,,!0A9![_DAPX8 M-J,:D)08[14$+E 58@F -P3Y(^'Q @#D43-"/<"%:2K9 Q@9C@#MEL=-VYBY MAH2'T$Q%N<,DP2S0 I814!8W#$%#<4]C.=N^6A(&.A\@9CZD1-Y*> 09OOW* M'$YJ(H#JD@\\H H4@BS^\7.>B& #@2%ITGE4]:UQ<7TY%B_@:#,MG>MO#D%*]7KJI-:Z*E6JC7*R5 MK^K%5JW<*E;.FLWJV46I=-:\"?+WO_*#'WEJQ_6(QDQ3GC*%GU&ZAY]-ZH(B MZ1L67_W)]&E7J?1;PDG+J@=@<720$C\1#DZPX@=8>U+X:6?9_/,G HB@5__/ MDT:(N1W75EKV2+>HK8 M#H'8[D$O[R6M[6%EOCSQ3$7Q3#ICA/9FW@A?$4Q>"4:Z'(I@%,$H":,(YG@D MS!X7 :AG7 0@3."18>7C**^;D%.\,-N\E:L*[HWFPB/[Q3<$)[.W,&:W6BWU MYE[44E>$G$M"/ILEY'(K)&3\$7"_G[2*X(N3](>16LD2>.2[9 2&7"Y66 M(F5%RBN2I9R5ASOLJM+95Y*.4K>/PY7;9FFCS*7/ M2J6-FO4->';K29U:+>/27ZJ@GF*2="9I;,#!6_.*TB6*33)?>QJ;S$F>>)>_MRZ;-&O[JTWVO6SD[E=P2=T!0-S0"2^_ M,P1?F%]MUDQ?YR7E1+&3J.HAKS(TE648KZ1'7JE+_IY"Y+6$H,::J6Z/=,P+ M,JY6:*-:FU-J R\%I^XDP3]:,]=IO9W4ZJWDG;SO[G7\2K6DT/??JUYT@SO, M/BZ0>/6.PF*H)PC)-1-S9J#>6%9BUD%BGLX>.A)@7!/7O7 S"5E&:Z9FK+F9 M6>$O2"#8D22EA721?$-_!^0DIE 582:J,KSR,BI,+](7H)5G+"@VI(85BG!1 M*DW6 M%0"1!>"\YAO*([%L28$?J45WA8N>3"5!&%O%5-D&4*:,2QJE1!7H/E MP>V+LWJVMR_^7(K+L%H(+U/X\2@"ZTO/6=J,6)C0L4H(Y$,())GG M9RD%DN=4P%M*1EQ) G@"_,MJJN\OE8I7M1+,]:SEQ6^K1V3B-E>>;$'VQL,A MP;IUXR4PUQZ_W72?4B\:Q^RWR,:*C3#H%QW[-1)^4]^AF4@>O]W__+'X.O-< MPW *7%_BHC:ERX+TO$),!M7FISY,_!TU/IF"T_>K9#AQ-&P$2MV'RSO#^A7. M E)V9-(Q;HDW".EAW;))Z2+KMD?0H&3@($?_S;.UDPG2$QX4#F9X!C4#D.,; MTP]?J&-0:_;=]>UV<.:X7P%^UR6*)=[EF[X+19S1)@@Z3N$!\<^\LWL^;+MD MB'4#,=[H.X'3J=M+U7,<.?:+H3.L)VX,1Z:A&4+93E9CYBU21"E'340WJ8D^ MFR.ZHH@?R- 9=X=A+4'!8OR9Z_=<0S = MK!F)7P9Y-D.87Q,A5AWG I=;9^@P8$DE?''D,!>_%3UT?]B7&2U,A897W=1L90M" YL%' 4LF)?(R:5K8J'*Y_=P]#=5V:^ M,%%G=-6*"EFGN:BK"]L1#Q4E'G(L'JK;%@]H+W1?[16E0JEUD%)!&0U5)15R M+!52>IYM4"I@AMN*%RSVHOJ2LA7>*Q5J2BKD6"JD].S;G%2XL?W5X@N51L87 MHI6IL(V[SP/F,-KWF+-ST;!:1>W\EU[8O5C91.V%LY3.B,G2)];[<([HZ=H7 M[)$:>AOI:RWA4RY4ZGD3/P==X#LO]1B"P\WLI5,U*^FTS7N#VE864[ODE)(29\QV\;W^,5!4''L6&K''(W!]"%-")UM M10C]M()T::9?OV%3WC:_I?I^B53#>C*SMR-S)H^$U?11&4RKBZ+'Y$RY6.+7 M<8@E92G-"JG6JD)JCGA:T3"J-G)6;5)56=CB"FZPMH)I$@IZSA,)C#AR/!>9 MF4SSTEN8A]G-GDT)Q\A3$]9Q;;KL0N?O,97?>4M('B< * Q+C 5[( )MK MMW4 MJ@5QD+AL1'F6-I!3!H9EVYK!+TF_&MZ 0W5Z(DP1IL0%()IL^KLP;3N)6S)G%KQG<H26XMCUK/!EH;=_9K$4@69A3D2S[ ,)52 M6?OR[?:N>RL^Z%\^BC(Z+K_U8=H@0;F 0,GMH.KEHPN(H4#%3S]/.Z<@_1R0 MD2^&X[ND;>@%\L1,@_5%991K8#)[",S681K/N(\FOVP_77>BR=LP++,H5RJP M@C3@_*".-B"5I@#,*>&@07SR(?E(0_H+X--S;)"4V@ @@0K$YHN^154H+?-(:&J% A=(ABMEJ1.?/4\,*/0%947P/"J$+4T>/I, MT?C@5\DXY^NLSQP'B1FP)NRZ4]*-K8$"FXW_@A?0<')MW]$8WUQTJ4S*75[) M);@]I@NC!#8#(S@,A*:#SO O9H[QFU39,&ES J#_8B%=]8")^H:X: 7/#"?: M0+#X#<%^P VH-!@F@ Y96V..!R^@,&= (^0_(#-=W>#^EBOD,>S?QEO9 -%9 M42' GS3QJP$_Z&&)#]W7<,>>X"_0'OQ*&% Q?1;7^7HHOU_PBB#@VET1_!*# MB1N-UL(1I /< 6A\96*CLHS;W'V(39"^[X$!%M?=_!XE:C E,E8@VU3$2O4% M=@$,@@3.14"?Z4B+R5I+]_FU4& Y :(^J#KXUDC7[FW_V0<.P34*S1ZJ1M0X M8J24&F654DK.[K]# [[M>P,;#9+VF^$6K^ A&%+:);I4SO@'!]6R\178["6N M#YCVE3KZ:I7,JJ>-!97,,"Z89 W$M>9BP_(*M*V@@S+20;D5PMCN]]&SA;'B MDID[HFO.T8B;:#$1R2G(];@//$,_ ND%&_RF!#T??,7"91R?'8SA/-24. Z4/%@'Z[3QV M.&7V3EF1E(QLQY/R$XT_<$,=M')\/*?S'*/'SW\#0@8!A\%#%PV?Y=6ASL!R MTF%IA@5VDQ#,8/A@/0VD]=Z8SPR44!0B+U:'X91@L%4(P;@AXSLC>R; R(T? M676&JU:@8L/6\:S,1 .*QR1=_A.+,<%V.'.PNXD"$&AS^R,>914U)8(5A_L8 MBEB@RP0 @=\MA@>:U!F#H2D]OS]_V3V7AW<6*;IRLQ! 4H[-:\&B+9/("X%'(FT@X6@1W<"B+!8 F,4Q@M# M)U4Z*04IFJ3:!71X)E_Y$E+# /Q@$,T*S6=$*Y*SY3(@-EC+I'2*HXCQG((% M**B7?A-3H>"4 B\FRN,%L9_5EJK^,MBE56 M1;%44:Q,#UFB8* ^6X6J;YA2U7*S+@S]_+1XE)R[:+"42Y@&!+=ET )?Z;^8 MXS(Q9)>]4:$= HLY,7B&FL4)HLQI(6K;=[R!8)K_^M3Q1,V7!9'V0A#UBMEJ M:"[9GM$W E/4\/A#-S@ZYR?*/I@K2T3.T8N>C)RC51EJR9DSC0YS7@R-B7B@ MF 3G!AU# QD/GHH==$Y88OKFLG7-SZ8B_,+"#0Q:L5=4.;BH A ^E;R+, U M,,27.GPI6 =H+/ X18%W( $P^8621[!@J%%ZA[)J5MR3F.>L8EA5GKS;)M;Z M$8OJ,7R-UUZ+HB322#0L;AI87GR[*>N_EQ8 U?_C"_O:%1%W;@B!E8HPTH61 M"C#"X.QD1/U=;HDK7%F>;##M8,1 QCDF/(TQ\!PQU8P!'-=/Y4ER3G(!&AGD M @!*AH; 8=O2+[E7]LPL#2AN479 .9?9 W.T\7^&I$6FUW\R:DFSRDQZ[_1<&H=L;D3,16"S*XFJ %TQ(+ M7B4;LS>F^3P] :0.2'/@3U[!#^F0QWXIB%5@;'S#%>?K*.ZX245D6 T5K)ZH M5B M>O##[XR:X#]U'>XZ78)C?8IH0RV>GAUU;\OP9)KP^2Q/K(O:2S'EO1(HS*H< M;@'2?M QJN,6_73RXI-VRS*N0$_#+I:0'UEH?]X);LQ'+P#:^:+!DQ>T>D=#1 M^H+GAIP L2ZHX0X!D 4R'Z[RE3#-!':#I2H%#7-W?.2P_X#)H#&Y!/B5>!N4 M)7SQ+(\N"7>FI'6%81-+IUAM=-'N;UC/$=NO36Q_!K3 MWAN02\/1?"/@*7BIS5]:O( VJ%Z3M!9,[GK&2,9M)'QQGR^VZ5L>KE["$58% M4P\$P<+T!51P,E=%F!9#Z@&<5*L9TKF^1*L*X,,C.TCB/%([\GLF& 8B"&(\ MTY"8PR*WKP/F(8CQ'Q8SXUX,VY2&E33L@S!/3$B;]-45[6HX2@0)@=SE&)(_ MFV&IV.^!"3X!YE&5R)7JH=$QE87!#VI\C!!KMK![H^1/L7_DJ""LS".&.EB, MMG0>^.T5OB1,%<"XLK"$81[;?&%Q%^U TB3+67'Z* MDQQ_"&/ B&ZR^-2P>600U ].$,?+Y/IN.H-WHO!V@6VL[\$&83P :VG]58-KUA-76(#96\E M7[7-[OKD%0.C'6,O MY/?3QF_KR_Z=(?.)Y\M(X;\0H]G M+Q4 :)LUE8_*V]"U^].#XA"/VD(W\-J M.+/65Y965100#=V796I0<*-Q4TM=O@+-)F<]@+8GE49SJ:[S_PZ=,W$-(O@D M3&JF!T10+N%ODK*JP23C%EG2Z:AM\?A4Y #*=R_!#\>Z@F%>=6G)O.K;^YN3 M\])I)6]%<7)=)51 0S//60QE_L MB2/N8DT\"Q#V%L\&07S)HB#5 &*[- V#U?&U\/^59Q>82:!R(\#=MVK@N]UT MFK*O;T39"]*N*D-X*PQW/,M24B ;*=#8A10X8*M_ URU55MR0Q9,6BZ*,&[* M9Q/V8!9[C5OPF]IXEKB;S&_8&28KP59CUU@P3NSLFDJOV)NC8.B?%$U.GB-7Q/C M]XLUKC]AW:! PSIVLA(@^+*,WPMV6% ",_%BW(5-'1V_O3(\YU M=HX$)T0"%D!Z=N@PO86$X\HJF;R@\,OB=B'_\LVQ=,G*=;%^7N0IK01QM3Q; M@KA<+Y::Q'&R7FY?CIKT9*P(K2=OJ5* MPI8::&J4*QEMJ7ERWBPE;&FB3O)IG$UYW2]1^#6L5"G*Y(B/TR5I$^DN*F6* M=0_ QRC:5G' B[;@A6)1N" 0I4.J\SI?V&_+T64/ BP/BKW 8E5DITH[X! . M>_9E)8A8KQCRY)NIEXW+I9ZH<)/VSEE8WQ.W>/TFFMQ@<511;PV7A_^)ES_F MA6\C%HTQGBCRL'0W #*6# 2#]A@Z=#4BF%V<'L:5L3;2G%;4^]/S7?]E418&$(@*3E[=%I8'$,!P-G#EQ*386GXLY>4L4 MF2HWYI4%2S/%XBP[13I @AJ+%W,)B1,&\$?PRN)V&=6$#J/E5K%4+Y8;_^91 MF%G)CR<8%]A;:]QU?-=;YL!BFVKQ;)$*"=JFS3.; =VBC@_.R9YME-+S^!V+ M;2+ +"9 R:O_( *F2K5CT4G]Q7"#ZI_?F.V _/G]E C(%7B!:8'C*<.<<[OH M5J096,KIU1+2@,M.[,$C66<^5FNE%*P^,5Y!ZI$Z'B 0)+$LG7,QCG\CSZG$ M"F=0_.A'H3S>42$6QWMD#D;RZ3-[Z%^$V^!?/?B>Z\'V ,(AJHN5)7%=.3F? M#4_\)EN7B4KW=C3^'&07R*OMF^AD82C=&(FZF,)=FB?BO0&(A.%Q0 M*5/V%KUU'/9B"U.!\PSY@#.>R#'XHY./O#2W+,G-9P3#E1<%=60-).!YK+8D M9&,D-#B!N -C%/:Q)Q]A M?(K0DURL)2!(F,>. VJ.$6;B 4P7G73?&7,2Y6^X;6&2KGCNTBA7 M"LW*O.XW$=OS;BQQ+N9AP5I\.HUW*PX5-TE:5A]D'+K:Z@C7Z4:412SW!:USN M"#K9OGUB0VI@J#4R=*-WUC%Y*^4$P@D#X8O;:?Q=A)W#>HS!+^?*R#7.&GC% M=WD4LOCW4^,5Y4%\;N4;)%O![K_W!, M_,-/VYZ8J&;/R]\#DG=\WI<#D3'G,$3V 1LRYLG2TVZLJ# 9,',AT8K2Y/'T^;T#EFN+(ZH?DUL+(T_( (\FJ,X/"^2 6)KV)1H'?R:> MZE\^RN9Y)E:B7M"T(>I,D[@2X= NM1.^<'X0)1JSX!9 !HE\@+ KJ)B$BNZJ MD5]NA+,*46:/I.N.)BQ#8D$8%#89?$#T@,P560D\F4JXO:+8 MMFL Q6(S8+Z.8D^8;F(U\XY[&3CL]I@A/0?]+,2Z@B_">*C+Z]5[*-B##^@X M8R%_T5L! ZMH(T\&CT[)SQ'O79.BX=):RR+D[T&M\4"/0&.(1?P.<303[$DT M*?G#"P0*+HV![8(+:3L.!C@PM^-B'+TBT[?:"+U[?O+ST)=F:*@V5S-$*X5Z MJ50HE1(.C=\3??L0:R04=2Z23D;0LE[#Q@=##+YJS/VX]&&5; 0!.LSUD<9Q M"D%&G.9Y<_@5FQ6GD4%SK\@@T/HWMO,-H;(:-90+%?"]ZF?5N=0PQ\Y '/&@ M8>16+BW)_PI2:'>E])>3 M0NO5UK^W96?>R*F9B%T).'7G%]NO'7VQ_1P42]AA$KLJ%[YNO0[!6KDO%ZY( M)G;K9CXV__30K7AY/B6//)!.12EIU,6WTM;=T;6.I;&\QQ='FZ $LBPL&*I+ MCF>F26=1I@0L5VMPSZ_>Y:9LP_O*J9W5$Y-TRA5,TN&.H=1L>Z 6@\BLA;2G/#D5W/86_5FH7%6V;>B; ?",X=0[/HL(=RY M(@.E7.'> 1O]R5UVIK=!D=%GQJ-@J+)OJ.'P ^G5.*QY6JWM WOM82VX[#3^ M)$S+9WPQ?W RVKFR7\V,W\9"]JR^T^IV_X;AD6XQ&O>K) M4*N:>!*0<3V(9&[Y>.BFQAX:%DMVT=@#&V.2G;9F:-3SQFR'$F;(36@AZ2 Z M:W-CJ7(A.S WYA?'V1=[8[7R/@F7*_?#R-A( */1J!5*K=E,S9Q9&5DQB3(U MEC$U6BE)R?M@7VP_AE'9B[X-&ZH$==!9RFU-\X>^2-OF=,3S(APV (+$I,X[ MV]UMI:+LX3(GG43<%75E9980:"([59L F@E ([TQ?VI;F+D8I-6F5>TP@IHE M0_AFL.B^19AV**##;ZA25R:]N.0#O]UC^RZU=/?C866C=+0!TWV3/?1CU,N) M=X)V;_G= R3@E,24NDI,R3YR&U;]J_RV^U*#Y;0Y]R7Y8&(S:5TB;0=L HM< M^H[#+ WOB5/+%=?M23O,M,XP%V$IM"A26)\4?EH.@[7C;=]OU+! 9:"HQ$QZ M)(4@';L(%%/L@(U(;KE1.11IHXH\#H(\LDYRZ^+%ZZQSW!:A=P\CE),*-;MH MY04U,;6M<*1)4*LE=%1W'PQ).\%LU5(R.CI8OA!U@@A*7 8.C^@Y$S//8W9& M9&8L7<=(WN 4DZQ2:9Q@V47XB]])JN4O>G'P!XZ'P0IIV8%+L\(]\R+;*[*J MT A#"RP3ILA;Q%QQQ)YP1%JZW](<,2]VDY%^:.0O0^_C6A9ISD(\FVJ+]9 0 M>A4%1_:MG=S1-&GYYC]'P> M^^[:C]1AL9O_[^GK4\U)5Y^<\F1.EZ5$13:B8LG,QETZ&%D(#;P^KV3&GBU+ MR8QL9,9R#3%WXX)E8F$TRWLI+?;\,&%3KEMX,)"4PIPE%JN'*US7Z76ZEX)U M_H930EK54EKVYWZ<=]1B\:RS5CY:$J>RV$Z#O8KI%=//,'U"]\5,'*]-A[,S MO@.FF#^?O*"8/\[\"7U*=^M!;9KKSUI[Q_?K7-9(?)9UHCM6&3WGZQ?/Q4*# M4IKK9\'/ZZEW9;B::;N^,R?CO9&8\;Z#RR:]M$S UJFX^_!T?=?N7E^1Q_93 M]W])]ZE]WVE?=F\?[CM?/_6.JWY^-]:MQG"QL2ZBFM>KAMG&U(0/[6>'<>G$ MJY3?&1I('MEJ338"D_7M.YK!L$YV@=R=WIU>GF(S2* /ZA+3&!IXD<4T: _[ MT8IK*S!I@7P(JM5??.]$)>JQ-8S#:[_CC1;8M=\'TL.^$+@&EXH2LQ0[6>B^ MYA&08R;3!3R?&(@Z!\DB1TIISL M1VFX$?0 M:?DIRQPBV064M0';"@ZY'U]/TZV&N7O\![&(SK&$0!KCJ3(7M!T MA,J>02,8&:&$%Z<AN*;'8>)$] &^'-"7"P^&RBGR;H:L\ :^*%F7) WH+"(1;SX#>_ MHH>GI.-K [DM(^@!F-++IEJJ)\=DFU,QV3G4)NZ3"BB&;-VV=,G4@N#>0ZJ MEV5L#SGE]1O>05WQ1FBYEESS'Y&3"K(Y#06;D[VB#A)DK620+7%3$(B935X5 M%,VW5^A9(*3R@F9J(E^;=SAP&+8,Q[X$YKBP&+U+GE(<('H;*W)$N93,$>7# MYXAF?66.F+D[NPI#+-58< XOB&X[,6LM;;&VN%\' XB6=ER1!OV_>&]"J<6B MNO.A5BZ$G6 C1;ULYQ./.4/#XK>64SJI".LQ=?UB^; /H*I3TK:$F<#7(EOQ M1(MC_;X TH*6N;!]P$(<$\ "O"<3CH=+#^S!:.R@76'4D/(KWL$*9BFZ3"L: M;\6!H8-=_3G@L/K)>1_6\_43OGM.QHPZO(70XO6)RRN5NNPX1?NPK*"'KX >2X6-?7 ,(\47&9E39.SFTK6&@1%\H!@=TV M31A&8@#)[1F&M-#6809/BA2N O6(R2BVS%SL;7)#>+%-O$T!$S.>@W8T5W3L M=B79P@#W?,,G$P*S.2%C$)*?==_1Z1BBRO\^@MO,"-I"HQ)PQ&W M8.43^)]5U/@U68]#?2=]9?"DR.B/\UL%(6R?ZM@:&N8(R\L!H$>TR1+52R2Q M#XQ1(!/PIVW J,Z 3+^!+3X"1_3N,O(P@R\C-S--2:C$+KN^TDX6/MBGS @:SG7 P8OW3G:DE,R:$QP2W2763/JDDN& M:5W)PZ'<_1:;"E2)&W1[I;P')KZ1:H7,Z>&:-P G62)SEL3W[3[T8\]6-%,* MY20K11?]B[=@NL=U3]A0/F0FZL!( /)J JC?@R0L5F0]?[=- M##C,GG7%>2' U0_#LAU>RP@$+'.]<"E1P.1B/)4DM'1PI'QR7IO%TV^H),52 M2;#60J##P?89V*"SBP*B\&9BHZ 1K-70N3%V.7#@5]U3.:2PSC 0\6KT65I# MN&HE[=!A4SA9*EJ5-39^.+'HGY5.R-44H%TBAS.'FSYA-ST\CQ4)&0/#$9"1 M8$R#<<:0JLR!%!B,?K"?="D#>Q52AD/C5)Y A$(#M,)PY(%Q.J+&9+/WP-D* M7! >7H.=C404T<4P'K>*]%/RC1N=$L& M++:DN_C)XA,#8/O,O0'4Q:?\$S8=_]UJ2JV60'*3/BT%]VK\EVR>:U$>J@U, MY5BO=(Z#$(N 6YT)MY.!;&7<-P%72;-]$X/Y''MX"@6F(WDQ;%F()O)[GWT0 MM-B CY?#ZC Q20KIUTJR\:!<6XJ]LDM>Y9 BGUT2O M\5C+/:R8!F^:+'*J8-38!G+5IW-;!3)D<8S9GI43!;SXHDAB!C -DAA$\998 M:G LN>$AO5OV#SHF9=$LNS7;+)OP.BWFC,T9.JM8)4_J@'=>F.)^OI "8PYD0'9B[?9N!@("?W MB_"\&!S'C1SC!3N9Q3C;Q< 3"#/1X$RRVGRE6ZTE.YOU8KD9_S/-V12KY(M< M[(5S@HCH ?S29X<.GU#NG]!S[%^I;"\'[']^*Z0U\7R#:B?AB) "!\4NYZ;E# M7]C4T7$Q@8?ADG3M(H108\*'[:91I#N'!",%N\2$@=/\_]K[UN:V<2S1[_LK M6)Y.35(E*Y(LOSII5SF.T^WIQ,[8SO3NIUN4!%F<4*2&(/V87W_/ P!!B;+E M.!8I"UNS:5DB@0/@O%]07(]"N$HJ<0=UG\+3M*.>M0\HX<5_,A#LRI]]HSKI M>CZWTK5BV^IE5%4?/@B*RT]$I,@G7RV;/G"N69BR5XT468L\[Z.@$K7U9U)0 M:?_B2U16LN2N$= &TF1(T+ M)(KP3N/T7EFUU\P;LE63:K6^EZ9ON4O3B M9,[S,KAO-<(KO;- M@*$[1@>+X=">8MFYHZ;VKKRE\;%$7 ?BA@\6&!>EPS.6YX?&/*;WZ&L2#X,4*X,QJ*>055[&1Q89 ME^O >_?>6E+U522S=Z-,W9V27ZMRH*XK^6D]+)_END>K'G@9XYNK!';J?95 M]?<'W'>U &9:>5\XR>J8DJP**=_*R56X>F!9-PXXC%I%C#K%)(950"BJI'8< MM0S_:WXY2_7X;RK#JD9BAQ6UP@I5]>2PPF&%XQ4.*U:!5RRH!BW88?,%W])U MJIU[OS[KD2V=9N?&OE=]1:L^OCN1NHWO3J1NX[^4$UD!9T15DK>HY'%6QMQ@ M:ZEH?NZKT*JZ 6UVWOWEWWMV3]KH]IS;?:9;/9GFD1\RB45,4@=Y*'%4G;4Y M:O7C8I5B5 V&<2-,2T,0L1#L2.4Z'-^JQ(%#O-%9BL&E?_MC=W)L-3K[Q+*J1-#M-';;>XX( M'!',$L'.@DWK5IX(MG<:^[MS[DJNE@CJ[^RT6X)/=7$OI!"Q'40YVLO8UQPL M"ZAE4OV/ /#9Z1HX77["3=%;.PO>2C*? M\3"2'$:#'$5JXY/I8K^K2NVU0@+:VK@JUYB>%KRR9C7I">5[MYI0EZ.G]:2G M.:D4BQN)-:>G'>Q(Z^C)T=.2Z.GANS%6G)YV5H>>:A^5J[+LX#+&QA^FL\A+ M-#L?I/"';NBN(5.:#_)]7&E.FLSN=.N,.G"8=K?1+NE#6@63V5HGH>VH15'+ M[IQ\FBD;LR;4LMMH=>9<-^^HQ5'+\U/+G-23F;9,=:"6[G:CNUMI*-%1RWI3 MRYSTE'8=9G\II='$ON[ MKL;?D409292D_)6E*+TTDMAIM"K*]'2*,G:*\LR>FDDL=O8;E43O7&9 M1C_3/%/M!5Z<*5:WC,;[F4A)JN+/M+X>74+WL[A$>\MIDFN%Y*_OP_*2U+>? M:5!5A>6>A-V%3R 4]VOC2WA3/?J];$R_!]'W2K+6?J:95!D[WW'2;/8S#9]JD+QKU7CZP;*P MGZYM;M>D_^*<&VA>F :ZUB16TK_J62VWNI#87C45EH[$UH_$YB1@/)O-6!<2 MV]IU).9(;"DD-B>AX]DLUKJ06%5MZAY)8RYR]V"/@("+'::J'! EO(2"P3[6 M0$F%H"_0T*T;8[K?#SPG7>9IENE2O&"8&%E1.SGG[:TA)L_);,=4+JK49[I^V0VB'U MUOZ1'6OFW2Q+A@K1556!XQN32)<GP@?__%\+)P* MP_A&>J^#R$M'<2;]:"#?_%KE6J9WLW#&BXFX(@E>]$=BD(7B;&A=5@5$)I+( M#_5%5?(P39.@EZ5B B[=PD0? CC_O<-YA?M MG=WMK2W0:P50Y 2F3I-,;##\WGNN2>N'O@0:' ;1)?Z],4UAK=:K$EKY4:*S M]Q5H#,C)ZXLPE!._#X3VVT:+_U:$1W\SS\2/P "8V&KM%5KR)1ZP;-@]X)T[ MYNALF=87R)5KX3)]3J)5RX0C%6-[DE^](!K!,.G]/UV.$B&\+_#M2'K'@)X# M[T),4DIQ\;9:C?=OQ?A _?.,]U;-*<-U&+5Z&'4:1*N!4"O@9Z\*_SL._^]' M%N]IW-5:TZN.[$ZG;^.Y$ZC;^2SF1%7!25-G](<#&#]3N<#T2_VH4 MTKTW]Z%=$JDM:_PPOU/EMXO[P[A6Y ACN C#7T$ZTM&CX]M^F*'F>RBE@/\- M+OW;'ZLDJ6=7&(?BE:-X2<5\61N(^J/X]G9-,N00N:Q*Q"DB^TZIE6]':NQBK-&*._,@?N/MNJ^8")87LCS-8 MC@YKP@6VG*!S6*VPNJ0N_7$V2EVP>JM=DQ*Y^J#:^F)U29GYX\R2NF#U]E9- MZFGJ@VKKB]4EM#5,P!2NJP'V>#?#VN M!P?8VJZE'\)A=058W2DI@WZ<#5(7K-[>W0>J"U?O;78?5 M#JL9J^?$M!>W0>J"U>W&?CT3-UPLY!XKY(\XNO+^A'_>R\S ,+5V&.)=&$1B M6>^XR?*XR9ST@<7MF3_^K DW:3=<6,4A MMD'L.2D#BYLTM4'LK<;V;FWNE:@+MJTO8L^)@B]NU=0%L;=V&IUZ*H .L:M M[#F!\,4-F[H@=G>OT:WGE;LNOG)?EMD[BP".2O.J U1A@Z=12L#FLK@*KYP3#'Y'D51.L[C3:VR[- MR^$UX_76G'#X(]*\ZH/7];2P:Q]BT5UY 'B]&/BX<7#I!S=^M(P=G / \LK% M?@2 YR;D.3#=1\Q/+G.__*L>Q+R[6TUNRTHB8N4 U) 2GEP-7Q=*J*H)_THB M8N4 U) 2GEPT7Q=*Z#0Z.TXJK X -:2%)]?6UX(6ND@+6Q6Y7!? !!=YN2?R M0:^[H@]7XMO7D. MJ:M ZB>7V-<"J5%QZ[A(N<-JA=5/+K&O!5:C:;Y72UY=^\A+E8;(>29EX'M^ M-/#^]/_K?Q_)%(,]SB2IE"4\N>:>C_4P&N2'^H5N.ZL!IP#YU]YW\L\A.R-[ M]\FE^'5&=A2+75?+[)!=(?N3*_1KCNP[KJ.Q0W:-[$\NW*\[LN_4$ME=Y.4> M@^[?K^D,Z_%;X_>32_/KA=[O1:M<2PUV YAY[Y2P=B00/6< J 2@MZ?7B(PN#?1^[>7(/ $*33XPE1QI)ZL1].MO5:(]E=\VOB\A= M9XIZ%+7]Y*X+]:8H M+$EH5]-DY$#-+X%-#Z(LUXHIHF\-I<* M+P[R?7QIL082]> P[6ZCW:F'(KRU3F+;48NFEL6:3-2$6G8;K4X]'#&.6M:2 M6A9K1%$/:NEN-[J[]5!@';6L);4LUJJB'M2RO=_8W:VT3=&CJ(7-O;=I+Q[< MX5\^',V!]S^>Y^DEG&:P/4%??5EJ>?U]"MZ_3X&:0TJ JE89^-%"1H20_PZB M 9CYOW9V"]!.% 2CQ.N'OH3M'B6;?3J^#0V4C=LTGKJ(B"U?9;_^K47_![@Y M8]J:G_3Q;+_2*/RK!WLAK#X?D]3SLS2F#[2OWMOE[!'0RI.N8'HOQC: OWI! M- (0<.#V^[=B?,!7-'GO@X.+K(?9QFG@A^&=!_]X\="+L\0SMT%Y"=.5]/Q$ M "DDP;48>$.@,B\="3*3\9U)$@^R?BKA2S]5CX;P: (/PQZ.R5DC 1*/NK$W MO0LA/#AYH.[^NY,4(+X/ZL,FP>V=!_*[]PDH+DXDOSQXAV.FHT "H),X2:G& M#[["18QCF<+7?4 V[S"*,C#MS_DAX#^?@.#OG;1%OOGR[/2ZD$%R^2'.%;K5<;:H#""*/A9A+?F)^F M?^L+P(VOOY]^^W+O+#,LJ\#[IC;I73[;O0?1Y&/>_%U4#A6WY"?C>*$'9^K'D^[?^H]"" M)%Z!B&RJ,D17?*9,3,[Q3S[$!>;I4TJ5FCZ=:=&(!W] :^+O&3J]NO<%,!>S M/HH:% H#\9\,=O;X&K?W$M[_@(BSPV=W>POK& 6H31/$Y203&TMCB[U[ M!5M;B8B+;Q\NCO_Y[?CTTCO^%_S[_FUOF(@*#8_V#67YA]A/!DA?'P,0FBAC4?4-?93AOO>?S$^ QX.:T/?ER .T"V!: M>OZ7^W3[DA1#0, VX&+'_CB%?)=W$T&QGZGORZ(^7T5R,0(HI_'Y*!Z/X^@" MV-GWCPI:J9_]J!9F3(#6@B; R>FGC8-6LZ2S"2H5PN^//(D3X+[T"0 X"H M%)(452U4X)O>)6RWV<&; #AX3X!Z?\<<;M$3W.4C5"<8\T2C.!R@J@7SPRG& M>*(+CM=6XS5Y0(*1MLFG0T7%"D#$"!T.[D=WWC!+LR1?B<2I:/5R9OEZD: = MDMX8A_B>[">"!H?'\6LXL@D,S+K=_CM9@I/-*HEKFKS75RG;_C&ES"E(ZZ$@ MW:^J5*,^_3QVH3TPUC?D?]EJ-[?SK\CY9C^#P>>'&,VF&H,5'I]$:0#V<6?# M2X,4H5=_*5R$Y^"0R8+N-+TOAZ=@[GP!O4>ST OOX\G%T;>+BY.S4^_P]"/\ M_^'G_[LXN?#./GF?3DX/3X].#C][1V>G'T\N]3/GQQ??/E_2(V=?C\\/\8<+ M6Y-:)NO=U[NACW-Y8-"T'S()'$)*[^Q:)->!N%DZ!,M?>(GH^TN06\<'[0[% M2D1*@1^"$$?!O"F!RX)J0UJ"V$31+Y*^0!T !7K30STN& 0^INZ00IC$80B* M9>_.RZ2';WL34%MHR#Y,U/!NX#O<]P:-J7U%H(:&07J'7"X,AL)X@8P#"LQR MT&50F="OG/YQZ?T>QCT_-$_W$ABSZ9UEB7<#"E-XMQG?1 "-M*$<^=>T7M3O MX--D="?1$0=3"2DB6!QYG@2PI3",;W#QL*/?12I_I:\/B1WZ /_-* "U$!8M M YE*K>M\ P$ 4U+:$SQTY$?^P,?_WL'1>2@O&;OO-\3 M 6\D[$@K&]SX[N#XZ583>ID>?^=12U[AR]0[E$'IZQ>P$G\2XQ%\\4%&TF.7 M(S] @&BH?P4B!55;#<;]?=]Y__#AI-]Y)Z#BPE_X'!<'-3U$G5#&'OP!NB3M M6VE#+MB6),ZN1N2\$P#%%>6#@0( L_@>B&C8?8E$")L/!XY:9])<'BD^FSQ9 ME 8/^8#$)&6-?:NEC;@; ?]+D-XB) -$QI[F6WI7M[<:6ZV61F?EDFTPB2H_ M[7:WL;7;PC<$/ &@CJ3G7S'V[>PUP*#C/?"].^$G^!.=+J$/DIVOAC6TQY/E MOEI"_3LF+5# ^FA:IB"N$2'C2&@R]L@UQPRX!&&.<:!M.A54\&-M1(8!ZR5 JW1+IC2 M)'@'-YQ0%0Q5VG+MYJ;E(;0P7"3(/"3( /8D"P@".1'(K7!(8GXQK8-Y&.!* M!N#X3*HD1(LM/ MO6& S@?M66EZ'T3?SZ30 @(W0L^E*^.8A2(^-?1GBM'(+ 1LZ@,/!:P-@*#[ MN))(7/E(?[ ',:!7+ /U%TC=(8=1#*J9VKLL24"ZP0,AX&*F)R.Y#N@,I--O MP% @A$D8XO>&TR#W"1C;?7*0TSINXB0$87L":U *'H_1L( HD$ M+:08"#CT;Y@^$G&5A1H.V$'@5C W?)4T[-_@Q%T3^Y2F(T MP<#"@T'\7D!*"T 6]VA"X HP 2*,YGBP$N BZG")JQ(70<=*&@P#6)<&%K Z M51Z>?!(PP)"1AV!<]@4!@-H:;/UWA![=-Z1U!5%&LL&7S"LES"<9%0*, X& M"9X((86:IXFA,F^8)52B&43L)D.G#8#L)[0[,AX;M.6]!.L[[@=T'D0YBALR MY%"DS1&)^&I0L"P?=B<&Q#$X4'P-5>,BKX0CZ!$:N7_;]"2.>!LO0;X$YY"0+&$/B@^;W MB6NHX*N',"H_&+X=7].BS18UFTV]O(:9[FSN- !S3Q#B#V @B13O#X>">$+O M3H=$BT1,QP7JO &$4]0[Z*#,1,40+ U<@3#FCP_3-RYG*PM[%3ZW/@N"7QR M[@&[#@$0]%Z44;TU]3II>[R-(^#-/2$BI7T0"0NI]!.CTP![ @P"9,JIRCI) M9#)X#L16M!8.LL(RU*8XYC@>B+!P_LPYM825.B]@D92 0OP_'Y!$2B@%*5(V MK]4I I4E)UPJC1EH5$Q\VBW\!>2ZA^PVO2.%NWPC$P%,.D3E-D5.:8WZ%U)E M& C2#0&02 3$4IEOPMB60$G$?[( S>WI@P$Z$9$49EA+=QW$( 52)S[=T;-Z]J=%CVFAV1I#NCAQH(B@:,V^A%@22[5<#((P6%$!D@4U? M,$[-6PON4![ ,6+FWM60,GLME#*E!O8--=BC2W@)3QZ7*_PA:94GD66&Y,+X MWH$(OU%,$$'Y\'&8<5[-%S\!;*.P$S)N,IC0\8M$EJHYZ-F!('V3W-&G_P=O M>, Q0_SY]2^=YK[^ZXTY_K$/.G[!?$6 MV$V$\Q5HL1\D_6R,^-57W,2_8L5P(FC<08-EIXE@*#Y962DC%OL1JJ0+'P'AXRX&3 *@5>*!5#;6UZ>FLC5-!IG )YO! M^HU/OT<^'>^.5R@KPZ MJMG>>2@DF'_,X[=/#-\^]I@IPR2 M&;T3F%04HZL'%1G PLV!CSE,H JBNXN3J9%8UO(&/7A-VYBC9(,=HJ8S0(2)"8)L)6]@39?QJER_)'LLB(;<2LUWT M3X,NY8V$'Z8C3A8J618H[N@P8GB]_@BV3_E@ IFO#W8M8+>FUC+N:+X4'R>5 M #@_2:L))3+UP\FV11:^.A0;XG#&B\TV!Z:;DH,&7IO!*2^B0&C>+YD8,S5_^THQL&&@1HE*#_[$JY4$<^ M4CX 'M$N(4=@MYARE..A%]V^OC1VC0KF@!!#-1]L:[3NV18#$W"2@34$JC); ME(INC*M-;0]AR%^B 2?X71A7*05\!"F>P&R ;'SRP&*FX8 YC^9O9%$C$0AT M\O!C,I,3RKXT7F?+>Y#'CXQS.?8'8!O>P$_ZJS1A59*)AXY$6\AWFQ+,,!FC MEDRZ.?O=-VFH@WB2R>,TLO\5CS1DRC-I#V##F@J)<:FT? MU9H$:" GEMQ0IOR#"?I93%ZB0*]T7^C(@AS%\YC!A? Z8I2T2% MEO/)9#&LB=P,WISDD<;I4 $%'=CAAOZ@G.Y)81XJYYW6S-D!"F(BQ%?X!/X- M+$2B/:")>(I7 #H#O$*Q3SP!Y $WB,YH F>1<;[CR^S^A?,B!LON(#0,HZN0 MM]T:V=X\7\V/;'>!;:*<660/+ 8,O2KR,">%I'F5!0,3G$BR4&R._>^4#7L( M;(C\;7,Q9I"190.6*CK%D%X!WWN --XA'$GHM8T.H&P;, M(E0R0)X%P?QQ)*;@U=O&3 ,FHE,U"*A"IN3$BC(:"+ER<@4RZ[^6>5O8HP&Z M@U,3'&&WK0%7N1L&(G= JH&07>C-ITCBM?8*G+"D WS56$(YY'I,$E[ -B(Z MD!Q.T%"%3 ,E]?H^Z07X;&[<(_J&,2HU$0HRG%H]AV#BLQ@TP-\U9$/BP!2\ M%*" I,&<$Z 0]A3"FM $P(E^QZGSX4EGB%,-9[ VCW90N$BD2'F X+XZKT91 M.Q/1=9#$3&NXQ0K+M(C+-9 \5&Z<6=.A%)#CH A'8()<:9\Z L.Q,G)> 53B MU@J"4?;3;PM9'W.@^@E!W0FP8[>?2Z<=E6?H!6A4KCLDJQB4"Z M;^)T[.RGX2P?J'8X9M(DG.&"!_5U[27"/^[47YB( L?B /.XO71V;]. M/FZV]]\0IQD&"<8+\[0".)6_LI$/B&:B7\4!I"G!">]X'R2@M3_0.F\>NZ?D MA.C.2I*:3@-A/A#K.$*[K4I8\(&_\ 'O#Z;A,XL1YV5(TVLSZ_:]*\KP!"D$ MVS8.^KP,\SNIJ8-Y**:BZ&TERU"?IE+%M/2;.ET+ MO4@.A&)*$^?\+Q50U'@.D)LXK(D+6PDXEO(%NW5EG"R@)(LA"(>T',MX(V0? MAM0*MM\W)H[&=85"G/VDQS#KY:"#PA_%N87R 1%L9@?]@3])"P8J\UG"2A7D ML/$^O%,:GJ6X$?JQ!RN/$(A>'W,8MTW3=AYLX@T FF4J.(K^ #ON%=[,Z!V5<)KS5H('Z M;&YJ_5RG:K'8HL1D_:B=/$E;1B>H$I19V[1#FY1&.7_\&-,V!:U3;:\I69Q) MHJ(3+%LG86))TA6A;!X:0U7'HC)@Y:CPP$+N0#G"-,"@+TV"NS2ZL[T:@IGA M+ [,)U RC!6>S"1EE)$9R:$XZI LZUR_HO.N"SB[HO'I!9^VHSO5"8XR(B%49#.,,A]($*T#G M'9"TG&28-=L3Z0TZDF8* /,:/=8DT$=F:4VVJF0%JC#J \U#$!W)+MYA!)% MB]0_/\R,A:1MK+L,'0"YVPNMDRR)[$&,#C G!5?'@CAN0#%33.RC(?$5/94V M]K!81 07.CRDQ&B+V,?D MLD"&J)Z(OVMS&/0E*7U. / ]4YPK!:CK:&2$_LV\;'[30.V?IL/+K'+RSV+. M_SP@S^>00T,IGGF]"AQ[=,6.$GY&V[@D=5@6&F))0#7@>=B#I\BW@VJNT$C91%?')M4:<=W5?)M3N0:LPB!T?>(Z MJ69,#VW5PSZP%6SF,A_""FJILC$LFU%#@V-LTAAZ3SB!OJS;JX-UK6^FE/=4Y&D M'9_\#OE68TPS((\=)>OIRM"4_?MRA$GKHQ@>1W\XZTM-.*/I<3"2?!7! E5N MN,K*R$-CFGV2PHD=8D@58,E: H%6\JRZ2LE5%[@.51=UI]VL?3\!/I>H&@D5 MDI4SCZFQN2Q#92BKSB%55,B4R1,^\XR$!Z)RIUE(Q ML>I 8GTJJG@YY^6H*3('O;2-:@ANBIUQ;07@("=$/;BB&%V^L#/4?X_13/GQ M[4D'8BB21.&A!8'RM;&^CJO1[ZIAUTAO.D)-$L^0B-NT7 ':'W-2GQT5TY:1 MB9P%R6"37<16\BW2L\9GQ!%&F,2/)!44<]S&A-GL1@*%S@?D?--X4!*8:RC% M'!0/SB\$ ?R=&VBPA6KE%2;Q':>.-'*L-?$@S)'0KV /P($&R^*/.D:9$P.Y ML*515B3H&*#L7!,6)8#*V$R0ZET0R6+.MRQN-CD-.4 BS-YRDJK$V F7NEE? M!!$UZ @H+5RJ#&-,60'[/W]QG;"7.V]24T>NRV/Q8TPD.^2,7)I**%4; G*M M<;8!I7]:^3CJT288;N3;SS@)%;Y3Q54A.B8,>F"NLA]@-$1\I_R\'!K5@\'J MQ6&"LB;K743<=JI1["O @5C*V5?1=-,&HU$067F^+P=" BP,O(DV2457H440 M)A1$\?L)JMNH)5R9&^UTRQEN7,/VO 4QU:I1M/#^HF)* 8T%YX%/_,)& ,WH M?,HRMPOZA]CZ9?5;F;DSF^[9S9AB5>&5\PRT5(*\]8$4_A@C@,9ZGAU/4!!1 MYCV"=+\5A"#*=QXS'NF8U*P:@[M^)1P4I5.OO?8@V;[;$![J!KI"EB MF?"+:)QQ-0 :+0F5TJVSM_FIV# M):I)P_))T RF62>E]TZX>Q'Z4CBKD%*[4-= #:4G/%,85+8=;YJKP F6KW,? M^_W1E(M)LK&-VC9G:^HZ1L[S5^4!!78]B0,J-3B:4MV-WR6E6V_-B5+5 Y50 ME R#CVGMFS&"G<5-[T/)PZ1S2RF,RPR?QE"*"56I9>7^]BEDI_3_W,>4/Y<7 M =QBKI!IZ&>5/[ :269B09.$*4R D]]6,@M$EIW$"U2HBR]-U5Q<'*MAP:8; MIDC=J\(6K"PS9V2EKR&@1C1&9"H;@L*=L_F8'/A%H@+L"51FGII\RA+0H*F, M+M/\ FU[_SN&F;'_3\BQ@]"J&.53!8,EAWD*$0&A5-JG9BVV2T'U%M%]C#AI M3,^6C\DM6Q20"RV*]D0G>ZHZTWS!%,@P9*#*Z[!T=T8;4=Z @9U*/8UC^="D M!#!1Z&"T*9++YU-CCX*)5-6[5!:!_@H+3

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end